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ABSTRACT  
  
Rapid advancements in genomic technologies have increased our understanding of rare 
human disease. Generation of multiple types of biological data including genetic variation from 
genome or exome, expression from transcriptome, methylation patterns from epigenome, protein 
complexity from proteome and metabolite information from metabolome is feasible. "Omics" tools 
provide comprehensive view into biological mechanisms that impact disease trait and risk. In 
spite of available data types and ability to collect them simultaneously from patients, researchers 
still rely on their independent analysis. Combining information from multiple biological data can 
reduce missing information, increase confidence in single data findings, and provide a more 
complete view of genotype-phenotype correlations. Although rare disease genetics has been 
greatly improved by exome sequencing, a substantial portion of clinical patients remain 
undiagnosed. Multiple frameworks for integrative analysis of genomic and transcriptomic data are 
presented with focus on identifying functional genetic variations in patients with undiagnosed, rare 
childhood conditions. Direct quantitation of X inactivation ratio was developed from genomic and 
transcriptomic data using allele specific expression and segregation analysis to determine 
magnitude and inheritance mode of X inactivation. This approach was applied in two families 
revealing non-random X inactivation in female patients. Expression based analysis of X 
inactivation showed high correlation with standard clinical assay. These findings improved 
understanding of molecular mechanisms underlying X-linked disorders. In addition multivariate 
outlier analysis of gene and exon level data from RNA-seq using Mahalanobis distance, and its 
integration of distance scores with genomic data found genotype-phenotype correlations in 
variant prioritization process in 25 families. Mahalanobis distance scores revealed variants with 
large transcriptional impact in patients. In this dataset, frameshift variants were more likely result 
in outlier expression signatures than other types of functional variants. Integration of outlier 
estimates with genetic variants corroborated previously identified, presumed causal variants and 
highlighted new candidate in previously un-diagnosed case. Integrative genomic approaches in 
easily attainable tissue will facilitate the search for biomarkers that impact disease trait, uncover 
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pharmacogenomics targets, provide novel insight into molecular underpinnings of un-
characterized conditions, and help improve analytical approaches that use large datasets. 
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PREFACE  
This dissertation is the culmination of several years of work as a group member in Dr. 
David Craig laboratory in the Neurogenomics Division of TGen. The author started his work as 
microarray based technology and whole genome association studies in common diseases 
including Autism Spectrum Disorder, Bipolar disorder, Alzheimer’s disease, Parkinson’s disease 
became the focus of several investigators in the division. From the start, the author found himself 
in a nurturing environment with projects that pushed the envelope on current technologies, to find 
faster, cheaper, more informative ways to study human disease. In 2007, TGen stepped into the 
next-generation era of high-throughput sequencing and the author and his group was responsible 
to develop new high-throughput, multiplexed method in next-generation sequencing that allowed 
the implementation of gene focused sequencing studies on large number of patients. In addition 
the author was responsible for the wet lab work and manuscript composition in one of the first 
whole genome sequencing studies at TGen that focused on the identification of causal variant in 
a rare childhood disorder.  
The chapters in this dissertation are original works with some already published by the 
author. The author conceived Chapter 2 with the guidance from Drs. David Craig, Matt 
Huentelman and Vinodh Narayanan. The author was responsible for conceptual design, wet lab, 
data collection and analysis.  
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published as Characterization of X Chromosome Inactivation Using Integrated Analysis of Whole-
Exome and mRNA Sequencing(Szelinger et al. 2014). The author was responsible for all major 
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analysis, and the majority of the manuscript preparation. Drs. David Craig, Matt Huentelman, and 
Vinodh Narayanan helped conceive the conceptual design, Ivana Malenica and Jason 
Corneveaux aided with data analysis concepts and computer programming. 
Chapter 4 is an original work by the author with contribution from multiple individuals. The 
author was responsible for study design, wet lab, data collection, data analysis, and manuscript 
composition. The author received guidance in conceptual design from Dr. David Craig, in data 
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management from Dr. David Craig and Jason Corneveaux, in bioinformatics analysis from Dr. 
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received guidance in statistical analysis from Ivana Malenica and Dr. Isabelle Schrauwen. 
Sample preparation and wet lab support was provided by Ashley Siniard, Rebecca Reiman, Lori 
Cuyugen, and Jon Adkins. Clinical phenotyping and patient related inquires was supported by 
Vinodh Narayanan and Keri Ramsey. 
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CHAPTER 1 
CLINICAL DIAGNOSIS OF RARE HUMAN DISEASE IN THE ERA OF NEXT-GENERATION 
SEQUENCING 
Introduction 
There are approximately 7,000 rare diseases, and they are defined by a prevalence of 
less than 200,000 affected for any given rare condition in the United States alone. Although much 
effort has taken place, only in about half of described, rare diseases the molecular etiology of the 
condition has been identified (Boycott et al. 2013). A substantial portion of already described 
disorders are monogenic and associated with rare, pathogenic variants within a single gene 
(Bamshad et al. 2011). Rare variants can run in families and follow Mendelian inheritance such 
as autosomal recessive, autosomal dominant, or X-linked inheritance. Therefore, Mendelian 
inheritance models can provide a basis for the identification of causal variants in disease-
associated genes in rare conditions (Bamshad et al. 2011).  
Historically over the past two decades disease gene identification for a disorder of 
unknown genetic etiology relied on focused, candidate gene sequencing or genome mapping 
strategies. Candidate gene sequencing typically requires a prior knowledge of disease biology, or 
familiarity with suspected disease locus harboring the candidate gene. Due to a continued 
reliance on Sanger sequencing, candidate gene sequencing has and continues to be labor and 
cost intensive, which resulted in a limited number of published studies and limits its future 
potential for gene identification (Thomasson et al. 1991).  
In some cases, mapping strategies have been possible using linkage analysis (including 
homozygosity mapping) to uncover disease-associated loci by tracking co-segregation of genetic 
variants with phenotype. Usually, mapping or linkage approaches require multiple affected 
patients, ideally together with family members. In linkage analysis, the family members, and their 
affected relatives are evaluated for regions defined by genetic markers informative towards 
chromosomal position that may or may not segregate with disease status. The main principle is 
that disease-associated markers are not necessarily causal, but they are inherited together in a 
region that did not recombine during sexual reproduction. Across generations, these regions 
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become smaller and can be powerful when large pedigrees are available. Given a genetic 
interval, candidate gene, Sanger sequencing typically follows linkage mapping to help identify 
causal gene and potential pathogenic mutations. One of the first successful application of 
genome mapping strategy in rare disease was the identification of the gene associated with 
Cystic Fibrosis, cystic fibrosis transmembrane conductance regulator gene (CFTR), using 
restriction fragment length polymorphism (RFLP) in combination with Sanger sequencing (Kerem 
et al. 1989).  
More recently homozygosity mapping utilized microarray technology to find loss-of-
heterozygosity (LOH) regions for recessive traits or structural variations indicative of deletions. In 
mapping of LOH, this approach takes advantage of multiple affected individuals within a founder 
population to identify regions of homozygosity that overlap among the patients. As is the case 
with linkage studies, LOH analysis is followed up by Sanger sequencing across the minimal 
region to identify potentially pathogenic variants (Chiang et al. 2006). Similarly, the quantitative 
nature of these arrays can lead to identification of the genetic basis of disease by mapping 
deletions within individuals with a common phenotype (Craig et al. 2008). 
However, candidate gene, gene mapping, and microarray studies provide information on 
a limited scale when compared to the complexity of the whole genome or all of the coding regions 
of the genome. In addition, they are usually resource intensive, low-throughput with substantial 
costs. In gene mapping the region of interest may be substantially large due to small number of 
available pedigrees in very rare conditions. Therefore, further reduction to single, disease-
associated locus requires multiple mapping steps and additional families, which may be 
unattainable in very rare diseases and in heterogeneous conditions. Locus heterogeneity, multi-
genic causes, can also result in false discovery. Thus, these studies are most informative in 
highly distinct diseases where a single gene with high penetrance is predicted as causal.  
The emergence of high-throughput, next-generation sequencing methods, approximately 
2007-2010, combined with the additional ability to capture DNA or partition DNA at defined 
regions opened up exhaustive single step approaches instead of the two step process of map to 
candidates and sequence candidates through Sanger sequencing. To date, whole genome 
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sequencing (WGS), and whole exome sequencing (WES) have had a remarkable impact on the 
clinical diagnosis of rare, Mendelian disorders that have only been impeded by the ability to 
identify the one or two causal genetic variants from the 3 to 4 million of genetic variants 
differentiating any two individuals. Sequencing the entire genome of a patient by WGS allows for 
a global view of all genetic variations including single nucleotide polymorphisms (SNP), short 
insertions and deletions (indel), translocations, large chromosomal rearrangements, and copy 
number variations (Gilissen et al. 2014). A number of clinical WGS studies have successfully 
applied the comprehensive sequencing approach in the identification of causal alleles in single 
patient studies where disease gene identification was confounded by heterogeneous phenotype 
(Lupski et al. 2010; Bainbridge et al. 2011; Welch et al. 2011).  Conversely, sequencing the high 
impact, protein-coding regions of the genome by WES helped expedite genetic diagnosis in a 
number of single-gene Mendelian diseases with simple inheritance patterns and well defined 
phenotype (S. B. Ng et al. 2009; Bamshad et al. 2011; S. B. Ng et al. 2010). WES focuses 
sequencing resources to approximately 1% of the genome by targeting genetic variations in 
coding or exonic regions for about 20,000 protein coding genes.  
As a result, in a short period of time, discovery of new clinically actionable variations 
causing disease, or genetic diagnosis by WGS and WES shows a tremendous potential to impact 
the ability to diagnose, treat, and manage care for rare childhood disorders. The reduced costs, 
fast turnaround time, and availability of a range of exome targeting assays make WES an 
intriguing tool for identifying the genetic basis of disorders with unknown genetic etiology. 
However, WES still yields tens of thousands of variants, of which many variants remain plausible 
candidate causal variants, as their impact on gene function is not ascertained by WES or WGS. 
Thus, improvements in interpretation of genetic variants to their functional impact can further 
reduce the number of candidate variants and identify those that have greatest impact on gene 
function. 
Currently, in silico predictions of a variant’s functional impact are based on how the 
variant is predicted to alter transcription and translation of the DNA sequence. The first step in the 
generation of protein product from the genetic code defining a gene is the creation of intermediary 
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RNA copy of the gene. This messenger RNA (mRNA) goes through transcriptional modification 
that removes intronic sequences and leaves only exonic and un-translated regions (UTR). 
Genetic variants can influence how introns are spliced out, which exons are included in what 
combination. This can result in multiple mRNA species, or transcripts that can be translated into 
protein products with divergent properties. Functional predictions utilize this information to classify 
genetic variants into functional classes based on how they impact the mRNA transcript. The most 
common functional classes are loss-of-function, missense, or synonymous (McCarthy et al. 
2014). Loss-of-function variants can subject a transcript to nonsense-mediated decay or loss-of-
function of the translated protein. SNP and indel variants can cause a frameshift in the open 
reading frame of the mRNA sequence during translation and can result in altered amino acid 
sequence, thus categorized as frameshift variants. In addition frameshift variants can be further 
classified as stop-gain, stop-loss and splice donor and splice acceptor variants. Missense 
variants result in the change in the mRNA codon sequence, and consequently the amino acid 
they code for. Synonymous SNPs or indels do not change the amino acid sequence and 
assumed silent to function. Previously, population scale sequencing predicted that 95% of rare 
protein coding variants with a population frequency of <1% may have a functional impact and an 
individual may carry up to 500 rare functional variants (Tennessen et al. 2012). However, not all 
functional variants are disease causing, thus additional information is necessary to associate a 
variant’s predicated impact to phenotype and further reduce plausible candidates. 
To further narrow to the most plausible candidate variants a variety of additional filters 
are applied during standard WES studies that include predictions about the variants’ 
pathogenicity, their observed frequency in the general population, presumed inheritance of the 
condition, and available clinical information about the patient (Gilissen et al. 2012) (Figure 1). 
However, even after best practice, a few hundred candidate variants may still remain as 
potentially causal for any disease, thus variant prioritization approaches can greatly impact 
genetic diagnosis (Richards et al. 2015).  
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Figure 1. Variant Prioritization in clinical sequencing studies. This figure shows standard workflow 
in a clinical sequencing study. It starts by data generation and alignment to a reference genome 
the millions of sequenced reads. This is followed by variant identification and variant annotation. 
Annotation is performed to understand the variant’s properties in terms of evolutionary 
conservation, population frequency, clinical and disease relevance, gene function, etc. On this 
figure under “Variant Annotation” the various acronyms refer to databases that contain 
information about variant properties. Post annotation, variants are filtered based on quality and 
based on genomic position to select the most informative variants, like coding variants. This step 
is followed by variant prioritization, which is a multi-tiered data reduction process utilizing accrued 
information about the likelihood of the variant to be pathogenic and its potential association with 
observed phenotype. Candidates are further evaluated by a board of clinical staff until consensus 
is found based on the combined evidence. The selected variant is validated and reported. 
Reports can be focused, or expanded, that provides information only on the most likely 
pathogenic variant, or provides additional variants that are incidental or with unknown 
significance. 
 
Sequence data generation|processing (Hiseq) 
Read Mapping (BWA)  
Variant Calling (GATK) 
Variant Annotation (dbSNP, CLINVAR, HGMD, 
RefSeq, SIFT, phyloP, CADD) 
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Clinical Info Inheritance Population 
Frequency 
Predicted 
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Predicted 
Pathogenicity 
Variant Selection (Review Board) 
Variant Confirmation (Sanger) 
Reporting (Focused, Expanded) 
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 As described in Figure 1, variant prioritization is a multi-tiered approach and in the 
following we will describe the most common information used to reduce plausible candidates and 
the approaches that utilize them. 
One of the cornerstones of variant prioritization is the assumption made about the 
inheritance of the patient’s disease. This information is then utilized as a filter mechanism to 
eliminate those genomic variants from candidate list that do not adhere to assumed inheritance 
model. Inheritance based reduction of variants can be used in single patient, in most Mendelian 
disorders, the inclusion of genotype data from multiple affected individuals or from family 
members can greatly expedite candidate variant reduction. For diseases that are expected to 
follow autosomal dominant inheritance, a number of affected patients with overlapping phenotype 
are usually needed; ideally with parents that are unaffected in order to identify heterozygous, and 
often de novo, variants (S. B. Ng et al. 2009). In disorders that are expected to follow autosomal 
recessive inheritance, biological parents needed  to find homozygous or compound heterozygous 
variants (Becker et al. 2011). In cases, where causality may be due to de novo mutation, 
sequencing the family trio may be sufficient in some cases (Vissers et al. 2010). In families where 
consanguinity is suspected, homozygosity mapping in a single patient may be sufficient to identify 
a homozygous causal variant although family segregation in family trio WES data can provide 
additional support (Bilguvar et al. 2010).  
The most widely used strategy to prioritize variants in rare disease sequencing studies is 
based on family inheritance by sequencing the patients and their biological parents or family trio 
(Farwell et al. 2014). Parents being the first order relatives of patients, nearly all of the identified 
genetic variants will be present in the parents, and application of Mendelian inheritance patterns, 
de novo filtering, and clinical phenotyping can reduce a substantial portion of genetic variants 
suspected to be associated with the patient’s condition. The power of family based sequencing 
can be seen in 30% success rate in diseases where well characterized, phenotypically 
homogeneous group of patients are difficult to obtain (Farwell et al. 2014). Interestingly, recent 
clinical studies of hundreds of singleton patients achieved an approximately equal 25% diagnostic 
yield irrespective of variant prioritization or patient selection strategy. This suggests limited utility 
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of WES alone in clinical diagnosis highlighting the need for novel approaches to improve 
diagnostic rate (Y. Yang et al. 2013; Y. Yang et al. 2014). As new publications emerge, revisiting 
cases can yield a diagnosis, suggesting that in many cases the causal variant does lie within the 
primary few hundred candidate variants and can be better captured by alternative filtering 
strategies. 
Variant annotations can provide further evidence for or against a variant’s causality. After 
sequencing and data processing, high quality variants are annotated with population frequency, in 
silico prediction for pathogenicity, variant type, predicted impact of variant to protein structure and 
function, and biochemical properties (Gargis et al. 2015). Population frequency information is 
usually obtained from large databases of thousands of sequenced from the 1000 Genomes 
Project (Consortium et al. 2012), or Exome Aggregate Consortium (Exome Aggregation 
Consortium). Annotations for pathogenicity, biochemical properties can be obtained from 
aggregate tools like dbNSFP (X. Liu, Jian, and Boerwinkle 2013). dbNSFP is a variant-level 
collection of predictions from a wide range of in silico tools (e.g. SIFT, MutationTaster, CADD, 
PolyPhen, etc.) in a single tabulated format across millions of variant loci. There are multiple 
variant effect predictors that annotate variants for variant type and their impact on protein function 
(eg. missense, non-sense, silent) including SnpEff, ANNOVAR, Variant Effect Predictor, VAAST 
(Cingolani et al. 2012; K. Wang, Li, and Hakonarson 2010; McLaren et al. 2010; Hu et al. 2013). 
Annotations are often enhanced by medical information obtained from genome-wide clinical 
databases that contain genotype-phenotype descriptions like ClinVar (Landrum et al. 2014), or 
information about known disease causing genes, or variants and their associated conditions from 
OMIM (OMIM), CGD (Solomon, Nguyen, and Bear 2013), and HGMD (Stenson et al. 2003). 
There are two main approaches to prioritization that utilize clinical information, variant 
predictions based on annotation and inheritance models; a probabilistic model, and a heuristic 
model. Heuristic model is based on some assumptions (e.g. variant is rare and deleterious to 
protein function) that guide variant filtration process. In general, it starts by filtering out known 
variants, commonly from dbSNP, making up about 90-95% of candidates. For rare diseases, 
variants are further filtered by applying a population allele frequency cutoff of 1% (M. X. Li et al. 
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2012). This is usually followed by further reduction by filtering variants that may be present in in-
house sequenced cohort. The remaining 100-500 private variants are then evaluated for 
pathogenicity using in silico prediction algorithms for deleteriousness to protein function (obtained 
from the variant annotations). Application of inheritance models and genotype segregation are 
also part of heuristic models, however, they can be applied at various steps of prioritization 
depending on researcher and assumptions made about the patient’s clinical information. 
Probabilistic models assess sequence variants for their likelihood to be associated with disease 
when variants from affected patients are compared to variants obtained from control genomes 
(Hu et al. 2013). Filtering variants for inheritance, population frequency, or predictions for 
functional impact prior to comparative analysis can extend this model. In some cases heuristic 
and probabilistic models are combined to obtain higher confidence candidate lists (Coonrod et al. 
2013). 
 Still, there are several factors that may impede diagnosis and yielding the approximately 
30% rate for identification of the genetic basis of disease. Technological difficulties related to 
sequencing can impact diagnostic yield, for example. With the advent of Sanger sequencing, it 
became known that genomic complexity of an organism greatly influences the sequence 
coverage that can be achieved, and extreme GC or AT rich genomes are hard to sequence to 
even coverage (Ajay et al. 2011; Lam et al. 2011). This GC bias mainly manifests itself with 
coverage gaps. GC content bias in Mendelian disease discovery is especially problematic, 
because most causal variations lie in the protein coding regions of the genome which are known 
to have higher GC content than surrounding inter-genic regions, especially in first exons (Lander 
et al. 2001; Majewski 2002). Both WES and WGS are prone to coverage bias which can impact 
variant discovery and produce false negatives in clinical diagnosis (Ross et al. 2013). WES is 
also poorly powered to study copy-number variations, triplicate expansions, and large insertions 
deletions that may overlap exon-intron boundaries or those that are situated in non-coding, 
regulatory regions. There are a number of target enrichment assays available for WES each of 
which has its own advantage or disadvantage in terms of completeness of targeted genomic 
regions, capture efficiency, design strategy for exon-intron boundaries, and accuracy for SNP and 
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indel detection (Meienberg et al. 2015; Chilamakuri et al. 2014). The non-uniform performance of 
these exome assays is a critical consideration prior in a WES study design.  
In addition to technological challenges variant prioritization approach and available 
annotations can greatly impact diagnostic yield. Filtering out known variants may remove true 
causal mutations, as dbSNP contains rare, disease causing variants. The choice between 
autosomal recessive or dominant inheritance models can be influenced by the accuracy of clinical 
phenotyping. In addition, the annotation tool used can impact our interpretation of a variant’s 
predicted pathogenicity. These factors can result in the exclusion of potentially deleterious 
variants. Alas, there are many types of annotations are available, and variant prediction 
approaches differ between laboratories and in many times between exome sequencing projects 
within the same laboratory. This may confound disease gene identification for patients with similar 
clinical symptoms studied at different times. In addition, continually updated annotations warrant 
the continued re-analysis of previously studied exomes, and may alter previously obtained 
results. Effort is taken by multiple groups to standardize analytical processes associated with 
clinical exome sequencing to provide a best-practices framework that aims to maximize the utility 
of current scientific knowledge to improve diagnostic yield (Gargis et al. 2015). 
In addition to best-practice models there is a community effort by American College of 
Medical Genetics (ACMG) underway to standardize interpretation techniques for WES (Richards 
et al. 2015). One of the main confounding factors of variant interpretations for diagnosis is our 
ability to define a variant as pathogenic, which is mostly based on in silico predictions and 
available annotations as described above. As noted, there are a multitude of tools available to 
predict a variant’s likelihood to impact gene function and thus impacting its rank on the ranked 
candidate variant lists. However, a systematic evaluation of prediction algorithms has shown that 
the concordance between prediction tools is approximately 60-65% and is dependent on the data 
source that the algorithm is trained on (eq. Ensembl, RefSeq) (McCarthy et al. 2014). This can 
result in discordant classification of a candidate variant in terms of pathogenicity and predicted 
functional impact. Since variant prioritization assumes that most likely pathogenic candidates will 
have a large functional impact on gene function, incorrect predictions can result in the enrichment 
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of false positive variants among the top ranked candidates. Thus ACMG recommendations aim to 
standardize nomenclature to describe variants identified as potentially causal as “pathogenic,” 
“likely pathogenic,” “uncertain significance,” “likely benign,” and “benign”. It also suggests the 
combination of multiple annotation tools prior interpretation to improve confidence. Finally, the 
ACMG group acknowledges that functional studies using RNA sequencing (RNA-seq) or protein-
based assays can greatly support variant predictions to gene function obtained through 
computational methods. Ideally, these assays would be most informative and provide stronger 
evidence if performed in patient derived tissue (Richards et al. 2015). 
Our understanding of the genetic basis of disease-associated traits has greatly improved 
with the advent of high-throughput “omics” methods (Figure 2). We are now able to routinely 
generate comprehensive data from multiple biological systems including, genome, epigenome, 
transcriptome, proteome, and metabolome, with methods collectively referred to as “omics”. In 
addition to studying genetic variations by WGS or WES, researchers have been working on 
analytical methods to study the comprehensive expression profile of genes by Transcriptome 
sequencing, the regulation of gene expression by Chip-seq or Methylation sequencing, the 
diversity and structure of proteins and metabolites by Mass-spectrometry. These “omics” methods 
have been successfully applied to various tissues including whole blood, and recently garnered 
attention in single cell studies (Shapiro, Biezuner, and Linnarsson 2013). Historically, 
measurements from each type of omics analysis have been analyzed individually to look for 
associations between the biological system studied and the phenotype observed and to find 
predictor markers in the biological system studied to the observed phenotype. The study of 
individual biological systems allowed us to uncover pieces of the puzzle, but as described above 
in the diagnostic yield of WES studies, studying single biological systems can explain only in part 
the genetic etiology of human disease. Therefore additional information is necessary from other 
biological systems to gather evidence for causality of genetic variants in disease diagnosis.  
Recently systems biology approaches have been developed that integrate multiple 
“omics” data types (Ritchie et al. 2015). Combination of multiple data can reduce unreliable data, 
improve confidence, and gather additional evidence that may reduce false positive findings from 
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single source. In addition the complete biological background of disease-associated traits can 
only be deciphered by connecting the cause-and-effect relationships when considering all 
biological systems simultaneously.  
 
Figure 2. Multi-omics for the study of biological systems. This plot shows biological systems, 
genome, epigenome, transcriptome, proteome and metabolome as they related to each other and 
the various “omics” tools that enable us to study them (i.e. Exome-sequencing, Chip-seq, mRNA-
seq, mass-spectrometry, liquid chromatography or LC). For each biological system on the right 
face of the pyramid, the various features are listed that the “omics” tools are able to interrogate 
(i.e. SNPs, histone modifications, small RNA, post-translational modification, metabolites). Arrows 
on the left indicate the flow of genetic information from the genome level to the final manifestation 
in the phenotype on top.  
 
There are two main integration approaches: multi-staged analysis, which involves 
integrating information using a stepwise, hierarchical analysis approach, and meta-dimensional 
analysis, which refers to the concept of integrating multiple different data types into a multivariate 
model associated with given outcome (Ritchie et al. 2015).  
Multi-stage approach divides analysis into steps with an initial association test between 
data types followed by association analysis of the combined data with phenotype. Many times, 
multi-staged integration studies use two types of data; genomic and transcriptomic (Huang et al. 
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2007; Lappalainen et al. 2014). Integration starts by reducing genomic data to those variants that 
are associated with observed phenotype based on association analysis or in silico predictions 
about the deleteriousness of the variants, and additional criteria about population frequency and 
inheritance. This reduced genomic variant list is then associated with other data types, to find 
those variants that are associated with transcription or epigenetic modifications, for example. This 
step can identify variants that are expression quantitative trait loci (eQTL), predictors for 
nonsense-mediated decay, alternative splicing, associated with DNA methylation metabolite, 
protein, miRNA levels, depending on the data type used. This step is followed by an additional 
step that performs either an association test of the combined data with the phenotype of interest 
or further filters genetic variants based on the variant’s functional effect. This approach has been 
applied in the identification of eQTLs that are associated with drug response (Huang et al. 2007). 
In Autism Spectrum Disorder (ASD), integration of genomic and transcriptomic data from whole 
blood sequencing was able to identify potentially causal variants in monogenic forms of ASD that 
were missed by WES alone (Codina-Solà et al. 2015). In population scale integrative studies, 
utilizing heterozygous alleles from genomic data and their impact on transcript expression (i.e. 
allele-specific expression) have identified common genomic variations that are eQTLs 
(Lappalainen et al. 2014). 
Meta-dimensional analysis takes an approach where multiple data-types are combined 
and analyzed simultaneously. This approach essentially combines data matrices from as many 
data types as possible into a single matrix. The combined data matrix is then used for multiple 
analytical approaches for association testing with outcome that include Bayesian modeling by 
Fridley et al. (2012), to Cox regression by Mankoo et al. (2011). This approach has been used to 
develop comprehensive analytical tool, ATHENA, that incorporates, copy-number variation, 
methylation, miRNA, and gene expression to study association with complex traits in cancer 
(Holzinger et al. 2014). The advantage of this approach is that it allows the study of interaction 
between the data types simultaneously that may be missed in a step-wise process. However, the 
combination of data types that was analyzed by different methods and may be at different scale 
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can be challenging for integrations into a single matrix and may require data transformation that 
can reduce correlation between the data types. 
Currently, most integration approaches have been trained on common disorders, like 
cancers and cardiovascular disease, with a relatively large number of affected and non-affected 
control populations. This allows for building models that can perform association analysis for 
expected outcome. However, in rare disease, many time only a few affected patients available, 
and phenotype is not well characterized, thus integrative association test would lack power. 
As an alternative, in this dissertation we set out to develop an integrative approach 
whereby simultaneous analysis of next-generation sequencing data obtained from whole blood 
DNA and RNA of patients with rare childhood disorders will provide information on the functional 
impact of rare, coding variants, and enable us to rank them based on their functional impact. In 
many cases, it is easy to acquire RNA from tissues of childhood patients enrolling into a clinical 
sequencing study, particularly whole blood or even skin fibroblast, recognizing that many 
metabolic disorders are transcriptionally active in multiple tissues. Rare variants associated with 
dysregulation of gene expression at the RNA level is consistent, though does not prove, that the 
variant has a functional role, and could be prioritized differently with respect to other private 
variants with completely unknown functional impact. Thus integration of data from multiple 
biological systems in the same patient can improve standard variant prioritization procedures and 
unmask variants whose functional impact is not well supported by DNA sequencing alone. We 
hope that integration will improve our understanding of the functional impact rare variants have on 
cellular phenotype and disease trait that may be clinically actionable, will unveil molecular targets 
for pharmacogenomics, and will improve patient specific care.  
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CHAPTER 2 
SHARED DE NOVO MUTATION IN THE WD REPEAT DOMAIN 45 PROTEIN IN A SIBLING 
PAIR WITH BETA-PROPELLER PROTEIN-ASSOCIATED NEURODEGENERATION 
Introduction 
 In this chapter we set out to take advantage of the wide spectrum of genomic and 
functional information we can obtain from simultaneous sequencing of DNA and RNA in a sibling 
pair diagnosed with a rare, X-linked, neurological disorder that was previously only reported in 
sporadic, singleton cases. In addition this study hopes to identify the underlying molecular 
mechanisms leading to a more severe, lethal phenotype in the male sibling and a less severe 
manifestation in the female sibling. Our approach to study an X-linked disorder in the context of 
integrative DNA and RNA sequencing has only recently was reported and is described in Chapter 
3 (Szelinger et al. 2014). 
Beta-propeller protein-associated neurodegeneration (BPAN) is a newly recognized member 
of the neurodegeneration with brain iron accumulation (NBIA) group of disorders (MIM:300894). 
The disorder is also known as static encephalopathy and neurodegeneration in adulthood 
(SENDA). BPAN is characterized by developmental delay and intellectual disability in early 
childhood, followed by neurodegeneration, and characteristic MRI findings of hypointensity on T2-
images in the globus pallidus and substantia nigra (Haack et al. 2012). Clinical symptoms 
deteriorate after adolescence with progressive loss of psychomotor skill, rigidity, and reduction or 
complete lack of language skills (Haack et al. 2013). Key hallmark of adult BPAN is dystonia, 
Parkinsonism, and dementia. A subset of patients show Rett-like symptoms, ocular defects, and 
gastrointestinal dysfunction (Hayflick et al. 2013). Most of the diagnosed are sporadic, singleton 
cases with a wide ethnic spectrum. Mutations in WDR45, a member of the WD40 repeat domain 
genes, are known to cause BPAN (Pagon et al. 1993). Patients reported to date are 
predominantly females, carrying de novo, heterozygous single nucleotide variants or small indels 
consistent with an X-linked de novo dominant model (Haack et al. 2012; Hayflick et al. 2013; 
Ozawa et al. 2014; Okamoto et al. 2014). There is a substantial overlap in clinical manifestation 
of BPAN between males and females, which suggest the role of post-zygotic mutations, and 
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chromosomal aberrations (Haack et al. 2012). Phenotypic variability has also been suggested by 
existence of skewed X chromosome inactivation in the germline DNA of some cases (Saitsu et al. 
2013; Haack et al. 2012). X chromosome inactivation (XCI) is a process by which one of the two 
X chromosomes inherited from parents are silenced by epigenetic mechanisms during early 
female embryonic development (Augui, Nora, and Heard 2011). Consequently, in each progeny 
of the cell the same X chromosome will be active leading to a mosaic pattern of X-linked gene 
expression; in a portion of cells the maternally inherited X is active, and in others the paternal X is 
active. Lyon proposed that inactivation occurs randomly in females and therefore the overall 
expression of X-linked genes results in an approximate equal proportion (Lyon 1961). Any 
deviation from this ratio results in skewedness in favor of one of the parental X and in extreme 
cases result in complete silencing of one of the X chromosomes. Skewed XCI can mediate 
phenotypic variability in X-linked diseases (J. I. Young and Zoghbi 2004). 
DNA methylation status is standard assay (HUMARA) to assess the X inactivation ratio of the 
two chromosomes and relies on the methylation status of a polymorphic triplicate expansion in 
the human androgen receptor (AR) gene. Most females are polymorphic of this repeat and the 
two chromosomes can be distinguished (Amos-Landgraf et al. 2006). The methylation status of a 
restriction site in the proximity of the repeat is associated with X inactivation status, and 
enzymatic digest of the un-methylated restriction site (active X, Xa) followed by PCR amplification 
will lead to amplification of the methylated (inactive X, Xi) AR locus. On the other hand, the un-
methylated, active allele will be cut by the restriction enzyme and no amplicon will be generated 
(Allen et al. 1992). Capillary analysis of the amplicon peaks correlates with PCR yield of the 
active and inactive alleles and their normalized ratios give the XCI ratio.  
The contribution of X inactivation to the phenotypic heterogeneity among patients with X-
linked disorders can be best studied by comprehensive genomics methods that reduce the need 
for multitude of molecular tests, and helps in the identification causal genes, and provides a 
unique view of biological processes contributing to phenotype. We performed family-based WES 
and RNA-seq analysis of the sibling pair and their unaffected parents. The male sibling presented 
with a more severe phenotype and expired by the time of this study. The female sibling presented 
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a less severe phenotype consistent with some Rett-like symptoms. Exome sequencing identified 
a de novo, missense variant in WDR45 that was shared by both siblings. RNA-seq analysis 
showed nominally significant differential regulation of WDR45 between the siblings and parents. 
We used allelic expression to directly quantify X-linked, heterozygous SNP allele and combined 
with genotype segregation we found an extreme, non-random XCI in the female patient in favor of 
the maternal X. The de novo mutation showed allele specific expression concordant with the 
biased expression of the maternal X chromosome suggesting that the WDR45 mutant allele 
originated on the maternal X and implicated XCI in phenotypic heterogeneity between the 
siblings. Comparison of RNA-seq data to methylation assay showed high correlation. This is the 
first study of a sibling pair sharing a de novo dominant, X-linked, WDR45 mutation in BPAN.  
 
Materials and Methods 
Exome Sequencing. 
Sequencing and data analysis methods are described in Chapter 4. Materials and Methods. 
RNA-seq 
Sequencing and data processing methods are described in Chapter 4. of Materials and Methods. 
Fragments Per Kilobase Of Exon Per Million Fragments Mapped (FPKMs) were calculated using 
Cufflinks2.2.1 and plots were generated using GGplot2 (R v3.1.3) (Trapnell et al. 2013). We 
performed differential expression analysis between parents and patients using Cuffdiff2 in the 
Cufflinks package. We only retained WDR45 and those genes for analysis that were shown to 
interact with WDR45 from public interaction database BioGRID 3.3 (BioGRID). 
XCI with HUMARA analysis 
Females were enrolled from 29 families from the Dorrance Center for Rare Childhood Disorders 
including affected female patients, and if available their mothers, female siblings regardless of 
affected status, and female grandparents. The enrolled families are listed in Table 14, in Chapter 
4. We obtained DNA and total RNA for a total of 48 participants, 5 of which had already been 
evaluated for XCI and described in Chapter 3. These 48 participants included 10 female patients 
diagnosed with Aicardi Syndrome, previously described by Schrauwen et al. (2015). Genomic 
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DNA from each participant was sent for HUMARA test to Greenwood Genetic Center 
(Greenwood, SC) and RNA-seq was performed as described in Chapter 4 Materials and 
Methods.  
After WES and RNA-seq, the estimation of XCI ratio was performed as described in 
Szelinger et al. (2014) and also in Chapter 3. Briefly, in family trios, and large families, the SNP 
variants were phased for affected patient or sibling if paternal and maternal genotypes were 
available. Maternal and grandmother genotypes were not phased. Next, heterozygous genotypes 
were selected from the X chromosomes and pileup was created from RNA-seq data to count the 
number of reads mapping to each heterozygous allele. The allele counts were used to obtain 
allele ratio for each heterozygous locus. The allele ratio was defined as the read count of the SNP 
allele over the sum of counts for SNP and reference alleles. The distribution of allelic ratios 
across X was fitted to the beta distribution and the mean of the allele ratio distributions were used 
as XCI ratio. These un-scaled ratios were then scaled to 100 scale. Scaling was performed by 
taking the ratio of 100 and the cumulative value of the ratios of the 2 chromosomes for each 
patient. This difference factor was then multiplied by the un-scaled ratios of each X 
chromosome’s allelic ratios to obtain the scaled XCI ratio. Complete skewing of XCI was defined 
as a ratio of <2:98/>98:2, extreme skewing was <10:90/>90:10, moderately skewed as 
<20:80/>80:20, and random XCI as >20:80/<80:20. 
To estimate the distribution of the XCI ratios in our cohort the XCI ratios were binned 
based on the more dominant alleles for the RNA-seq experiment and from the inactive allele from 
the HUMARA assay. The bins were defined as 50-60, 60-70, 70-80, 80-90, and 90-100. XCI ratio 
of 59:34 is binned into the 50-60 category and a ratio of 81:18 is binned into the 80-90 category, 
respectively.  
Calculation of statistical significance and Spearman’s rank correlation was performed by 
the cor.test function in the R statistical package and visualized by GGplot2 (R v3.0.3). 
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Results 
Clinical Description 
We present a family with two siblings affected with BPAN enrolled into the Dorrance 
Center for Rare Childhood Disorders under a human research protocol approved by WIRB (Table 
1). The family id for this family is 0103 (Chapter 4, Table 13). 
The older sibling (Patient 0103_1) is a male who expired at age 18. He was born 4 weeks 
early, 4 lb. 15 oz., without complications. He rolled over front to back, and was able to sit with 
support; but was noted to be delayed by 6 months of age. MRI at 10 months suggested a white 
matter process. He developed infantile spasms and myoclonic seizures at 1 year, and was 
treated with vigabatrin and adrenocorticotrophic hormone (ACTH). He regressed. He has had 
intractable epilepsy since then, with continued daily seizures including myoclonic seizures, staring 
spells, and tonic seizures with apnea. At age 2, he has hypotonic, but with hyperreflexia, clonus 
and up going toes. By age 5, physical findings were of spastic quadriplegia, hypertonia, with 
cortical thumb posture. With time, he had progressive spastic quadriplegia with contractures, 
progressive scoliosis, cortical visual impairment and bilateral sensorineural hearing loss. 
Longitudal Magnetic Resonance Imaging showed cerebral and cerebellar atrophy, white matter 
volume loss, T2 and GRE hypointensity in the globus pallidus (GP) and substantia nigra (SN). 
This female child (Patient 0103_2) is now 14 years old. Birth history was unremarkable, 
with a birth weight of 7 lb. 9 oz. She rolled over at 5 months, and was able to sit if propped up. 
Delayed development was noted early, and was seen by neurologist at 17 months. She was 
hypotonic; unable to sit with support, had poor visual fixation and tracking, and poor hand use. 
Seizures, consisting of tonic stiffening, appeared at around age 2 years, and have persisted. 
Seizures have been better controlled than her brothers. She made slow progress in her 
development but remains in a wheelchair most of the time. She is able to walk with assistance, 
hold a cup, throw toys, and tries to communicate. Features noted at multiple examinations include 
poor eye contact, bruxism, hand clasping, truncal hypotonia, peripheral hypertonia with 
hyperreflexia, features that are suggestive of Rett syndrome. MRI scans have suggested white 
matter volume loss, hypointensity in the GP and SN similarly to brother’s MRI. 
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Table 1. 
Clinical features of the patients with BPAN. 
 0103_1 (P1) 0103_2 (P2) 
General Characteristics 
Age (y) 18 14 
Gender Male Female 
Neuropsychiatric Symptoms 
Intellectual Disability Severe Moderate 
Developmental 
Delay 
+ (6 mo) + (<1y) 
Behavioral Problems + + 
Cognitive 
Dysfunction 
Progressive  Non-progressive 
Psychopathology  Rett-like symptoms 
Neurological Symptoms 
Current Status Expired Wheelchair/short assisted 
walks 
Communication - Few words 
Seizures present + (1y) + (2y) 
Visual Impairment +  + 
Dystonia + + 
Seizures Epileptic, myoclonic, tonic tonic 
Muscle function Spastic quadriplegia, contractures Hand clasping, hypotonia 
Radiology features 
MRI 
hypointensity in globus pallidus, 
substantia nigra 
hypointensity in globus 
pallidus, substantia nigra 
Cerebral atrophy + n.a. 
Genetic tests 
Karyotype 46 XY Karyotype 46 XX 
Fluorescence in situ hybridization Chromosomal microarray 
FragileX, mtDNA point mutation 
screen, MeCP2 sequencing, Leber 
hereditary optic neuropathy gene 
test 
MeCP2 sequencing, 
neuronal ceroid-
lipofuscinoses, CLN3, 
CLN6 gene test 
Molecular testing 
Very long chain fatty acids Plasma amino acids 
Lysosomal enzymatology Urine organic acids 
Electron microscopy for leukocytes Plasma lactate, pyruvate 
Neuronal Ceroid-Lipofuscinoses 
enzymatology 
Acylcarnitine profile 
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Exome analysis. 
An average of 13.9 Gb of mappable bases were sequenced for average target coverage 
of 103X, and greater than 85% of the target regions were covered by at least 30X. Please refer to 
Appendix B  for QC metrics of  exome sequencing. 
Variant analysis identified 642,202 SNVs and short indels in the family. To identify the 
causal variant we annotated 16,126 missense, nonsense and short indel variants. BPAN is 
primarily a sporadic disease with singleton cases, and this family has two affected, thus we 
focused our attention on autosomal recessive and de novo variants. Due to the severe, well-
characterized phenotype, we also postulated that X-linked variants may contribute to disease 
therefore we also evaluated variants on the X chromosome. In both affected children 140 
autozygous, 27 compound heterozygous, and 17 X-linked candidate variants were identified. In 
addition de novo variants in the male child (n=57), female child (n=42), and in both children 
(n=25) were uncovered. Evaluation of the candidate variants for pathogenicity, led to the 
identification of a de novo missense variant in WDR45 shared by the siblings (Table 2). The male 
sibling was hemizygous and the female sibling was heterozygous for the mutant allele. This 
variant was found in exon 10 (NM_007075.3, c.758T>C, p.Leu253Pro), and both parents carried 
a homozygous wild type genotype (Figure 3B). The average exome sequencing depth of the 
locus across the family members was 105 ± 33X above base quality cutoff of 10 (phred scaled). 
This mutation was not observed in the Exome Aggregate Consortium’s over sixty thousand 
unrelated exomes (Exome Aggregate Consortium) and had a moderate conservation score of 1.5 
by phyloP, and was conserved across multiple vertebrates (Figure 3C).  
Previously, Verhoeven at al reported a wheelchair bound, adult female with severe 
intellectual disability diagnosed with BPAN carrying an in-frame deletion at c.752-74del six bases 
upstream from the variant identified in the male and female siblings (Verhoeven et al. 2014). 
Overlap between the phenotypic manifestations between the siblings and reported case supports 
this variant as likely causal. WDR45 is a repeat domain protein and amino acid changes in the 
repeat domains structure through missense variants can interfere with protein folding and 
function.  
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Table 2. 
Candidate variants by whole-exome sequencing. 
chr:pos Gene Model cDNA aa 
Variant 
type 
MAF NHLBI 
(EA/AA/All) 
MAF      
1,000 
Genom
e 
phyloP SIFT 
12:53343231 KRT18 de 
novo 
c.274G>C p.Ala92Pro missense NA NA 2.43 0 
X:48933095 WDR45 de 
novo 
c.758T>C p.Leu263Pro missense NA NA 1.51 0 
15:40648398 PHGR1 AR c.215G>A p.Gly48Asp missense NA NA 2.29 0 
4:10502936 
CLNK AR 
c.1084C>
T 
p.Arg362Cys missense NA 0.2 2.52 0 
4:10586571 c.92C>T p.Pro31Leu missense 6.2/1.2/4.5 3.0 1.36 0 
chr10:1697959
3 
CUBN AR 
c.5924C>
T 
p.Pro1975Le
u 
missense 1.1/0.1/0.7 1.4 0.03 0.01 
chr10:1693249
0 
c.8635C>
A 
p.Leu2879Ile missense 3.7/0.5/2.7 0.9 2.59 0.27 
chr15:5252795
1 
MYO5C    AR 
c.2878A>
G 
p.Lys960Glu missense 2.1/0.5/1.6 1.6 0.96 1 
chr15:5254361
5 
c.1634C>
A 
p.Ser545Tyr missense 1.5/0.3/1.1 0.6 2.87 0.08 
4:43256191 
UBR1 AR  
c.4642A>
G 
p.Thr1548Al
a 
missense 7.4/1.7/5.4 3.3 0.96 1 
4:43317071 c.2695A>
G 
p.Ile899Val missense 3.0/0.5/2.2 1.0 2.87 0.08 
chrX:12905546
4 
UTP14
A 
X 
linked 
c.1249G>
A 
p.Glu417Lys missense 0.05/0.0/0.0
3 
NA 2.49 0.54 
Model = Inheritance, AR = autosomal recessive, MAF= minor allele frequency, NHLBI= NHLBI Exome Sequencing project 
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Figure 3. WDR45 variant allele. A. Family pedigree, F=father, M=mother, P1=affected male, 
P2=affected female. B. Sequencing traces obtained from Exome Sequencing (a) and mRNA 
sequencing (b) of c.758C>T nucleotide variant in WDR45 for each individual. Variant allele is 
boxed across the traces. C. Amino acid conservation of WDR45 variant allele across vertebrates.  
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We sequenced an average of 73.4 million bases across the family members. This 
includes the smallest library size of 26.8 million reads for the affected male sibling (0103_1) and 
the largest library size of 128.1 million reads for the mother (0103_3) (Appendix C). RNA-seq 
analysis of female sibling’s X chromosome variants revealed 117 heterozygous SNPs with 
dbSNP137 identifier expressed at a coverage above 20X. These were phased to 62 maternal and 
55 paternal SNPs. We found 96 unphased, heterozygous SNPs in the mother. Based on the 
allelic ratio distributions the female child had a moderately skewed XCI ratio of 87:7 while the 
mother had random XCI of 56:37. Scaling the XCI ratios to 0-100 scale the XCI ratios were 
extreme 93:7, and random 59:41, for the patient and the mother, respectively (Figure 4). 
Distribution of phased SNP alleles expressed from maternal X indicated bias against the 
expression of paternally inherited SNP alleles in the female child and suggested that the paternal 
X chromosome was only active in approximately 7% of the whole blood cells. The mutant allele in 
WDR45 also showed a biased expression with over 97% of reads mapping to the mutant allele 
and result in an allelic ratio of 0.97. The bias seen towards the maternal X expression and 
expression bias to similar degree toward the mutant allele suggests that the mutant allele 
originates on the maternal X. 
 WDR45 is transcribed in whole blood and the male sibling showed the lower expression 
of WDR45 compared to female sibling (FPKM= 51.0 vs. 78.77) (Table 3). Using Cuffdiff2 we 
compared the siblings to the parents to find that WDR45 is dysregulated at a nominal significance 
(p=0.045), showing a downregulation of the WDR45 transcript. This suggests a disruptive effect 
of the missense variant to mRNA stability. WDR45 mediates protein-protein interaction, so we 
selected 7 genes that were shown to interact with WDR45 (Behrends et al. 2010; Oláh et al. 
2011; Fischer 2008; Emanuele et al. 2011). We found that LHX6 was not expressed in whole 
blood and only APP is dysregulated at a nominal level (p=0.049). This upregulation was primarily 
caused by the male sibling whose expression of APP was the highest. None of the nominal 
significance estimates remained significant after Benjamini-Hochberg correction.  
 
Table 3. 
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Expression of WDR45 and its interacting proteins. 
Gene|Ensembl ID FPKM (0103_1) 
FPKM 
(0103_2) 
FPKM 
(0103_3) 
FPKM     
(0103_4) Log2fold p value 
UBC|ENSG00000150991 521.21 795.34 1124.93 515.55 -0.538 0.224 
CLNS1A|ENSG00000074201 35.71 44.51 29.02 26.38 0.252 0.418 
LHX6|ENSG00000106852 0 0 0 0 0 - 
SLC25A11|ENSG00000108528 26.49 35.41 43.29 29.03 -0.475 0.413 
APP|ENSG00000142192 31.44 13.40 13.28 11.82 0.615 0.049 
ATG2A|ENSG00000110046 13.92 11.15 19.13 6.49 -0.197 0.506 
ATG2B|ENSG00000066739 3.71 2.93 2.65 1.97 0.320 0.427 
WDR45|ENSG00000196998 51.00 78.77 86.76 93.36 -0.771 0.045 
 
 
Figure 4. X inactivation by X-linked allele expression ratios. Then scatter plots show the allelic 
ratio of X-linked SNP variants. The corresponding reference allele ratios are not plotted. When 
the SNP alleles are phased an overall expression pattern of the parent-of-origin chromosome can 
be observed. We show the ratio of X-linked alleles between the pseudo-autosomal regions PAR1 
and PAR2 on the terminal ends. A. The distribution of phased SNP alleles in P2 indicated a 
biased expression in favor of the maternally derived SNPs (magenta), over the paternal (green) X 
chromosome alleles. Histogram indicates a bimodal allelic ratio distribution. The black dot 
indicates the allelic ratio of the variant in WDR45 suggesting that source of the mutation is the 
maternal X. Colored horizontal lines show the means of the paternal and maternal allelic ratio 
distributions scaled to 1, at 0.93 and 0.07, respectively. B. The distribution of allelic ratios in the 
mother. These X-linked variants are not phased and so colored uniformly. Histogram of the allelic 
ratios indicates non-normal distribution without evidence of bimodality. The two horizontal lines 
indicate the mean of the predicted allelic ratio distributions inferred from the data at 0.56 and 
0.37, respectively.  
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In order to compare the utility of RNA-based estimation of XCI ratio, we determined XCI 
ratio from RNA-seq and from methylation assay by HUMARA for 48 total females from the Center 
For Rare Childhood Disorders. This cohort included 21 affected female patients (44%), 23 
unaffected mothers (48%), 3 unaffected siblings (6%), and 1 grandmother (2%). We found 9 of 
the 48 enrolled female participants were uninformative (~19%) for the methylation assay due to 
homozygosity at the AR locus. Population scale analysis of heterozygosity in HUMARA analysis 
suggested ~8% of females are not polymorphic, and comparison with population data indicated 
that our cohort was enriched for uninformative female (Fisher’s p=0.0372) (Amos-Landgraf et al. 
2006). The enrichment of uninformative females was likely due to enrollment of families with 
multiple, related females homozygous for the AR allele. Methylation assay reports the XCI ratio of 
inactive AR allele over the active allele, and the signal peaks are scaled to 100. In un-scaled 
measurement, the ratio of the two X chromosomes did not always add up to 100 as the HUMARA 
assay does (Table 2). This is the result of variance in chromosome wide SNP expression  across 
X. Un-scaled allelic ratios revealed 4 females with skewed XCI (>80:20) (~8%), when scaled, this 
number increased to six females (~12.5%)(Table 4). Of the 4 females predicted to have skewed 
XCI 2 were affected patients indicating that approximately 10% of female patients will have 
skewed XCI. We observed complete skewing in a single affected female patient (0118_1) based 
on methylation and categorized as extreme skewing by RNA-seq (Table 4). Not one participant 
had complete skewing by RNA-seq suggesting that X chromosome silencing is not complete 
across X, and that some genes may be expressed from both chromosomes. We also observed 
extreme skewing in 3 participants by methylation (0118_2, 0011_2, 0049_2), which were 
categorized as extreme (0118_2) moderately skewed (0049_2) and random XCI (0011_2) by 
RNA-seq. While only 2 participants (4%) had extreme skewing by RNA-seq, the methylation 
analysis identified 4 participants (8%). Interestingly 3 of the 4 participants with extreme skewing 
were mothers of affected female patients. This corresponds with previous reports that skewing 
can increase with age (Knudsen et al. 2007).  
In 19 of the 48 participants segregation analysis could help us determine the phase of 
inactivation by analysis of parental variant calls. Nine participants showed biased expression of 
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the paternal X. Additionally, nine females showed biased expression of maternally inherited X 
suggesting that in our small cohort the choice of maternal of paternal silencing is random. In a 
single  case the parent-of-origin could not be determined because XCI was completely random 
and the phased allelic ratios were equal. In this female allelic ratio of additional phased SNPs 
could potentially help decipher parent-of-origin. On average 142±40 heterozygous SNP was 
evaluated within the X-linked regions for each female. The distribution of X inactivation ratio 
estimates from random 50:50 to 100:0 is right skewed towards the random XCI obtained from un-
scaled RNA-seq data with 20 females (42%) of females categorized in this group (Figure 5). The 
distribution of XCI ratios between scaled and HUMARA data follow similar trend suggesting that 
scaling shift the ratios toward a normal distribution. We also observed two families (0002, 0047) 
with familial homozygosity at the AR locus which would normally be an uninformative test, allelic 
expression shows random XCI in each case increasing the available information for a more 
comprehensive view of molecular data. In addition in 4 of the 9 uninformative cases we were also 
able to determine the phase of X inactivation.  
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Table 4.  
Results of XCI ratio estimation by HUMARA and RNA-seq. 
Family  individual status HUMARA* RNA-seq
+ 
(un-scaled) 
RNA-seq++ 
(scaled) 
preferentially 
silenced X 
# X-linked 
SNPs 
0001 0001_1 affected 62:38 69:30 70:30 Xp 144 
0001 0001_2 mother 65:35 59:39 60:40  139 
0001 0001_3 sibling 60:40 46:44 51:49 Xp 212 
0004 0004_2 mother 70:30 60:35 63:37  157 
0011 0011_1 affected 77:23 68:30 69:31 Xm 163 
0012 0012_1 affected 56:44 50:47 52:48  157 
0014 0014_2 mother 65:35 61:31 66:34  191 
0016 0016_2 mother 62:38 57:34 63:37  166 
0018 0018_2 mother 71:29 75:22 77:23  150 
0019 0019_1 affected 53:47 54:38 59:41 Xm 128 
0019 0019_2 mother 55:45 64:34 65:35  100 
0020 0020_1 affected 60:40 59:42 58:42  219 
0025 0025_2 mother 65:35 43:54 44:56  129 
0029 0029_1 affected 52:48 49:48 51:49 Xp 132 
0033 0033_1 affected 63:37 57:39 59:41 Xm 122 
0033 0033_2 mother 64:36 61:35 64:36  138 
0034 0034_2 mother 64:36 58:34 63:37  159 
0046 0046_1 affected 50:50 47:46 51:49  241 
0048 0048_1 affected 70:30 56:38 60:40 Xp 92 
0048 0048_2 mother 79:21 61:30 67:33  98 
0049 0049_1 affected 71:29 64:28 70:30 Xm 156 
0091 0091_1 sibling 68:32 61:38 62:38 Xp 116 
0091 0091_3 grandmother 70:30 75:17 82:18  66 
0117 0117_2 mother 55:45 47:47 50:50  114 
0139 0139_2 mother 58:42 59:34 63:37  142 
0140 0140_2 affected 60:40 62:42 60:40  143 
0152 0152_2 mother 51:49 50:46 52:48  63 
0157 0157_1 affected 55:45 46:41 53:47 Xm 97 
0002 0002_2 affected uninformative 47:47 50:50 equal 156 
0002 0002_3 sibling uninformative 63:35 65:35 Xp 188 
0002 0002_3 mother uninformative 74:25 76:24  189 
0008 0008_9 affected uninformative 47:45 51:49 Xm 123 
0034 0034_1 affected uninformative 73:25 74:26 Xp 194 
0047 0047_1 affected uninformative 49:48 51:49 Xp 171 
0047 0047_2 mother uninformative 74:25 75:25  159 
0059 0059_2 mother uninformative 65:33 66:34  144 
0091 0091_2 mother uninformative 48:48 50:50  96 
0157 0157_2 mother 74:26 72:12 86:14  69 
0008 0008_2 mother 88:12 73:23 76:24  96 
0014 0014_1 affected 83:17 72:23 76:24 Xm 239 
0023 0023_1 affected 84:16 77:22 78:42 Xm 133 
0024 0024_2 mother 81:19 62:29 68:32  134 
0059 0059_1 affected 82:18 67:27 71:29 Xm 134 
0018 0018_1 affected 84:16 81:18 82:18 Xp 103 
0011$$ 0011_2 mother 93:7 78:23 77:23  148 
0049 0049_2 mother 90:10 81:19 81:19  133 
0118 0118_1 affected 100:0 90:6 94:6  140 
0118 0118_2 mother 96:4 90:8 92:8  119 
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*=ratio is defined by the proportion of methylated (inactive) X over the proportion of unmethylated 
X (active). +=ratio is defined by the allelic ratio of higher frequency SNP alleles over SNP alleles 
with lower frequency. ++=XCI ratio is scaled to 0-100 from un-scaled ratios by normalizing the 
additive proportions of the SNP ratio distributions to 100. 
$$=Light grey shaded rows indicate samples where only methylation assay predicted extreme X 
skewing. Dark grey shaded rows indicate cases where both HUMARA and RNA-seq predicted 
extreme skewing. Xp= paternal X chromosome, Xm=maternal X chromosome 
 
 
Figure 5. Distribution of X inactivation. The axes indicate 5 arbitrary bins of X inactivation ratios 
and the percent of total samples in each category. Each estimation method is listed in the legend. 
Un-scaled estimates of XCI by RNA-seq indicate an enrichment of XCI ratios at the random 50:50 
level due to the difficulty of the algorithm to differentiate between overlapping allelic ratio 
distributions. 
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Previous studies of allelic expression XCI estimates have been inconclusive whether 
direct expression based XCI analysis correlate with DNA methylation (Amos-Landgraf et al. 2006; 
Swierczek et al. 2012). To that effect, we evaluated the correlation between the RNA-seq derived 
XCI estimates and the HUMARA method. Correlation was estimated for the 39 informative 
datasets with both HUMARA and RNA-seq data.  Using Spearman’s rank-order correlation we 
found statistically significant correlation between expression and methylation based estimates 
(Figure 6). There was strong linear correlation between HUMARA assay results and un-scaled 
RNA-seq estimates (Spearman: S= 1636.727, ρ = 0.834, P= 4.157e-11). Scaling the expression 
estimates improved the linear relationship and significance although at the more extreme XCI 
ratios HUMARA predicted twice as many extreme events than expression methods (Spearman: 
S= 1472.278, ρ = 0.850, P= 6.801e-12). This may resulted from the fact that expression 
estimates are based on the mean of the allelic ratio distribution and variance in allelic expression 
due to incomplete silencing of X, influence of imprinting, cis-, trans-regulatory elements on SNP 
expression may moderate extreme ratio estimates. Moreover, scaling the expression estimates 
preserved strong correlation with un-scaled ratios overall, although in families 091 and 0157 
scaling resulted in a shift from random XCI to moderately skewed which can impact biological 
interpretation. Scaling the RNA-seq data did not significantly changes un-scaled estimates, as 
correlation of the two RNA-seq estimates was significant (Spearman: S= 410.518, ρ = 0.958, P= 
2.2e-16). 
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Spearman’s ρ = 0.834  
p value = 4.1 e-11 
Spearman’s ρ = 0.851  
p value = 6.8 e-12 
Spearman’s ρ = 0.958  
p value = 2.2 e-16 
A B 
C 
Figure 6. Correlation of XCI ratio estimates 
by RNA-seq and HUMARA. A=HUMARA 
compared to un-scaled allelic ratios. 
B=HUMARA compared to scaled allelic 
ratios. C=un-scaled and scaled allelic 
ratios. 
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Discussion 
In this study, we obtained insight into the phenotypic variability in beta-propeller 
associated neurodegeneration by the first integrated whole-exome and RNA-seq study of a male-
female sibling pair diagnosed with BPAN. Characteristic features like brain iron accumulation in 
the globus pallidus, and the substantia nigra, progressive neurological and psychomotor decline 
and seizures, Parkinsonism and dementia in adulthood are all common diagnostic of BPAN. 
BPAN is also known as static encephalopathy of childhood with neurodegeneration in adulthood 
and heterogeneity has been reported in disease manifestation (Saitsu et al. 2013; Hayflick et al. 
2013). The male sibling, who has passed on, presented a more severe phenotype including 
epileptic, myoclonic seizures, spastic quadriplegia, and cerebral atrophy. The female sibling 
shows Rett-like symptoms including hyperreflexia, truncal hypotonia, and hand clasping, she is 
able to walk short distances, and manifests white matter volume loss.  
Sequencing in the family revealed a shared, de novo dominant missense mutation in the 
X-linked WDR45 gene. WDR45 is a member of the WD repeat domain proteins with multiple 
homologs on the autosomes (Haack et al. 2012). It contains multiple, conserved 40 amino acid 
residues usually terminated by a tryptophan-aspartic acid repeat residues(D. Li and Roberts 
2001). Their role has been implicated in signal transduction, regulation of protein complex 
formation, and cell-cycle control. WD repeat proteins contain a symmetrical, seven-bladed, beta-
propeller motif that mediates protein-protein interaction (Haack et al. 2012). WDR45 has been 
implicated in autophagy, the cell’s intracellular degradation system that transports cytoplasmic 
molecules for degradation to the lysosomes (Lu et al. 2011). Saitsu et al. (2013) showed using 
autophagic flux assay that WDR45 mutant lymphoblastoid cell lines present a blockage in the 
autophagic flux and affect autophagosome formation. Knockdown of rat Wdr45 results in 
accumulation of autophagic structures (Lu et al. 2011). In addition the importance of autophagy in 
neurodevelopmental disease has been implicated as mice lacking autophagy in neurons were 
seen to develop psychomotor dysfunction (Hara et al. 2006). 
We identified a missense mutation in exon 10 of WDR45 that leads to the substitution of 
a conserved leucine to proline (Figure 3C). This amino acid residue change was in the 6th WD 
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repeat domain of WDR45. Previously an in-frame deletion was reported 2 amino acid residues 
upstream in this exon in a middle aged female who is wheelchair bound, with severe intellectual 
disability, and tonic, clonic seizures that overlaps with female sibling’s phenotype (Verhoeven et 
al. 2014). All three males reported thus far carried frameshift indels (Haack et al. 2012). It has 
been suggested that males with germline mutations are non-viable, and severity may depend on 
when the mutations occur during development. The siblings share a de novo mutation in germline 
DNA suggesting a low probability for the mutation to occur after embryogenesis. This is 
supported by the fact the male sibling was severely affected. However the female sibling showed 
milder phenotype suggesting that if the mutation occurred prior embryogenesis some other 
molecular mechanism may have altered her symptoms.  
Previously, X inactivation was implicated as a mechanism that may explain phenotypic 
similarity between males and females and for the second part of our study we looked at new 
approach to study the role of X inactivation in the heterogeneity between the siblings. Using RNA-
seq instead of traditional methylation assay, we found that the female patient had a 93:7 
extremely skewed XCI in favor of the maternal X chromosome. To determine the chromosome 
where the mutation situated, we had to rely on allele frequency data from RNA-seq, as germline 
mutation occurred de novo. However, correlating the chromosome wide allelic ratios to the allelic 
expression of the wild type and mutant alleles could be used to infer the parent-of-origin of the 
chromosome with the mutant allele of the variant and wild type allele. Allele specific expression 
was observed at the mutant allele from allele ratio of 0.48 in the DNA to 0.93 in RNA. By 
inference, we concluded that the SNP allele likely resides on the maternal X chromosome. This 
was supported by almost complete loss of the wild type allele expression. The dominant allele, 
the SNP allele however showed very similar allele bias to the maternally inherited SNP alleles. 
This finding implicates maternal germline or gonadal mosaicism as the mother’s blood DNA 
shows only wild type alleles. Previously, a familial Rett Syndrome case also implicated maternal 
germline mosacism as a mechanism to phenotypic heterogeneity among sibling with same X-
linked mutation (Venâncio et al. 2007). In addition, Danda et al. reported two female siblings with 
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a rare X-linked Oculo-facio-cardio-dental (OFCD) syndrome (MIM 300166) with a shared de novo 
mutation in BCOR an X-linked gene that was only found in the siblings (Danda et al. 2014). 
RNA-seq also identified a possible mode for phenotypic variability. We found that the 
male sibling had most reduced expression of WDR45 in blood and loss of function mutations in 
this gene lead to loss of protein product suggesting a reduced mRNA stability (Saitsu et al. 2013). 
However the female patient not only shows higher WDR45 abundance in blood, she shows 
expression of the wild type allele suggesting that a portion of her cells express the normal protein. 
Saitsu et all showed that both missense and loss-of-function variants lead to protein degradation 
suggesting that the male sibling is likely have no protein expression in whole blood thus 
autophagy is severely impacted (Saitsu et al. 2013). It has been shown that even in genes that 
are subject to X inactivation a leaky expression can be detected in mice hybrid cells, suggesting 
that even at low wild type allele frequency the female patient may produce the wild type protein 
(F. Yang et al. 2010). BPAN phenotype is mostly brain specific, so the possibility that the female 
patient expresses some level of wild type protein, and that the boy only expressed the mutant 
could lead to the male lethality and a rescue of the more severe phenotype in the female sibling. 
To elucidate the role of X-inactivation in the phenotypic spectrum of this sibling pair, parent-of-
origin of X inactivation of other reported cases of BPAN may be necessary as those female 
patients with skewed XCI have not been completely characterized (Haack et al. 2012; Saitsu et 
al. 2013).  
 RNA-seq analysis of XCI showed high correlation with DNA methylation assay. 
Traditionally skewing has been estimated by the methylation assay of the AR locus. This assay 
has shown good correlation with other quantitation methods based on pyrosequencing of cDNA 
(Mossner et al. 2013). Other expression based methods showed little correlation highlighting the 
problematic nature of using a small number of genes to determine XCI (Swierczek et al. 2012). 
Instead of selecting alleles in specific genes, integration of the genomic and functional 
sequencing data we were able to study allelic expression across the X-linked region of X greatly 
improving our ability to predict XCI status. The mean of X-linked SNP allele expression rather 
than one or few genes can reduces noise and improve accuracy (Cotton et al. 2013). It should be 
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noted that while HUMARA method was uninformative in 9 cases due to homozygosity at a single 
locus, leveraging over hundred high quality, expressed alleles in each participant’s RNA-seq 
method provided an XCI estimate in each participant. Variability of SNP allele expression across 
chromosome X resulted that that the ratio of Xi and Xa did not add up to 100 in most cases. Thus 
a slightly different scale confounded comparison of un-scaled XCI estimates to HUMARA assay. 
This inconsistency in allelic expression can be attributed to variable silencing of genes across X 
(Carrel and Willard 2005). Thus, pre-selection for genes that are only expressed from the active X 
may be able to bring XCI estimate by expression to same scale as HUMARA, but may reduce the 
number of SNPs to estimate XCI. Our method for scaling allele ratios and provides a basis to 
compare XCI ratios by HUMARA and allelic expression. 
RNA-seq approach identified two female patients from the same family with extreme 
skewing. The female patient with extreme XCI was diagnosed with Aicardi Syndrome. Although 
previously, Eble et al. (2009) showed that 18% of Aicardi patients have extreme skewing, the 
mother in this family is un-affected suggesting a different mechanism to this patient’s phenotype. 
Although familial skewed XCI are rare and may be by chance alone, some cases have been 
reported in haemophilia B and X-linked adrenoleukodsytrophy suggesting that genetic 
mechanisms of unidentified gene mutations may contribute to the inheritance of the mutation 
(Ørstavik, Orstavik, and Schwartz 1999; Z. Wang et al. 2013). 
RNA-seq and segregation analysis could identify the parent-of-origin of XCI in 19 
patients, aiding interpretation in the context of clinical symptoms. In half of the cases the paternal 
X and other half maternal X was silenced. Our cohort suggests that selection of X to be 
inactivated by the X inactivation process is not determined by the origin of the X chromosome but 
is likely determined by genetic and epigenetic factors of each chromosome. This is supported by 
studies showing that the choice of X inactivation can be influenced by epigenetic events that are 
not well understood (Gribnau et al. 2005). 
In conclusion, we successfully applied integrated DNA and RNA sequencing to better 
understand the molecular mechanism of an X-linked disorder and its heterogeneity in a case of 
affected sibling pairs with shared de novo mutation. The two siblings share the same mutation but 
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XCI ratio analysis, shows that there is low expression of the wild type allele in a subset of the 
female sibling’s cell that can lead to a less severe phenotype. We found that WDR45 was most 
dysregulated in the male patient supporting the phenotypic heterogeneity between the siblings. 
Segregation analysis of parental genotypes and XCI analysis implicate maternal gonadal 
mosacism as the most likely source of the mutation and molecular mechanism. In addition we 
performed RNA-seq on a total of 48 females from our study, which showed high correlation with 
standard methylation assay. We were able to identify a familial extreme inactivation that pointed 
out the role X inactivation played in the female patient’s phenotype. Our method improved on 
current assay by reporting XCI for all subjects that were uninformative for the methylation assay 
and added parent-of-origin information to standard quantitative analysis. Integration of next-
generation sequencing methods in rare diseases will lead to a more comprehensive view of 
disease etiology and reduced need for individual clinical assays in patient management. 
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CHAPTER 3 
CHARACTERIZATION OF X CHROMOSOME INACTIVATION USING INTEGRATED ANALYSIS 
OF WHOLE-EXOME AND MRNA SEQUENCING  
Introduction 
In this chapter we set out to develop a method to quantify X inactivation ratio using 
simultaneous sequencing of DNA and RNA. We first use simulated data to show the utility of 
integrated data to quantify the proportion of active and inactive X chromosomes in females. Next 
we apply this method to a clinical case where skewed X inactivation was identified prior this 
study.  
Diagnosing and uncovering the genetic basis of disease has been revolutionized by 
WES, allowing discovery of new disease genes and improving the rate of clinical diagnosis for 
rare genetic conditions. Indeed, the genetic basis of childhood disorders can be identified in 
approximately 25% of patients, where successful molecular diagnosis frequently has a major 
impact on patient management and treatment (Dixon-Salazar et al. 2012; Y. Yang et al. 2013). 
Prioritization of candidate variants for the remaining patients remains challenging due mainly to 
insufficient understanding of the functional consequence of substantial fraction of candidate 
variants (Gilissen et al. 2012). Large scale functional characterization of genomic variation by 
simultaneous DNA and RNA sequencing from a patient can reveal genotype-phenotype 
correlation, can highlight gene expression profile that is associated with the studied genetic 
condition, and allows immediate evaluation of in silico prediction algorithms to the effect genomic 
variants have on gene expression, alternative splicing, exon usage, gene fusions (Z. Wang, 
Gerstein, and Snyder 2009). In breast and pancreatic cancer integrated analysis of DNA and 
RNA has been successfully utilized to obtain insight into molecular mechanisms that explain 
pathogenicity and uncovered potential therapeutic targets to improve patient management (Shah 
et al. 2012; Craig et al. 2013; Liang et al. 2012). In addition, RNA-seq has been utilized in the 
context of the affect epigenetic modifications have on gene expression (Babak et al. 2008; X. 
Wang et al. 2008). Integrative analysis of WES and RNA-seq data in X-linked disorders may also 
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be informative both in diagnosis and gene discovery for phenotypes emerging caused by 
epigenetic changes such as XCI (Lyon 1961).  
In the process of XCI, in females, cells undergo epigenetic inactivation of one of the 
inherited, parental X chromosomes resulting in consecutive daughter cells expressing one X 
(Muller 1932; Augui, Nora, and Heard 2011). The proportion of cells with either parental X as the 
active is defined by the XCI ratio that ranges from 50:50 random to 100:0 completely skewed. 
Epigenetic analysis of X chromosome in unaffected females indicate that XCI ratio normally 
distributed in the general population (Amos-Landgraf et al. 2006). Although, on the cellular level 
X-linked alleles are expressed in a dominant fashion, in cell populations X-linked alleles show 
mosaic pattern of expression, which can lead to heterogeneous phenotypes in females who are 
carriers for disease causing, deleterious mutations (Migeon 2006). In X-linked neurological 
disease, mode and magnitude of XCI can influence disease severity and outcome (Ørstavik 
2009). Indeed, case-control studies demonstrate that skewed XCI is common among females 
who are carriers for X-linked Mental Retardation disorders (XLMR) (Plenge et al. 2002). XCI may 
also lead to asymptomatic carrier status by selective advantage of cells expressing the wild-type 
alleles(Van Esch et al. 2005). One of the difficulties diagnosing females with X-linked diseases 
and skewed XCI is the broad and overlapping description of clinical phenotype, the limited 
availability of similar patients, and lack of high-throughput, expression-based methods to estimate 
XCI(Ørstavik 2009). Routine, clinical method to estimate XCI ratio rely on the HUMARA 
differential DNA methylation assay that targets a polymorphic short tandem repeat (STR) in the 
human androgen receptor gene (AR) (Allen et al. 1992). Methylation of this repeat is associated 
with XCI. Although >90% of females are polymorphic at this site, it provides expression 
information indirectly from DNA, and, relies on a single locus (Amos-Landgraf et al. 2006). There 
is also conflicting evidence whether DNA methylation can reflect the quantitative expression ratio 
of active X (Xa) to inactive X (Xi) compared to allele-expression-based methods (Busque et al. 
2009; Swierczek et al. 2012). Using next-generation sequencing of DNA and RNA 
simultaneously, we can scan for potential disease causing variations, and at the same time learn 
about the functional implications of genomic changes with the additional benefit of learning about 
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transmission of alleles and potential imbalance in chromosome X expression. By phasing X-
linked variant alleles, we can learn about the mode, or parent-of-origin of imbalance, and the 
magnitude can be estimated from direct measurement of relative expression of chromosome-
wide heterozygous alleles.  
In this chapter we present genetic and functional analysis from high-throughput 
sequencing of WES and RNA-seq to both (1) identify potentially pathogenic genetic mutations 
and (2) identify XCI ratio using phased and unphased allele-specific expression analysis. We 
show that high-throughput sequencing can be utilized to estimate XCI ratio on simulated data and 
we apply our approach to a patient with undiagnosed, heterogeneous phenotype. Using family-
trio based WES with segregation analysis, we characterized a de novo, heterozygous deletion on 
Xp22.31 as potentially pathogenic, and we identified a moderately skewed XCI ratio from the 
RNA-seq experiment. Integration of exome and expression data revealed that the deletion 
occurred on the paternal X (Xp), and skewed XCI favored the expression of the cytogenetically 
normal, maternal X (Xm), suggesting a mechanism for the mild neurological phenotype.  
 
Materials and Methods 
In Silico Experiment 
XCI results in two cell populations in females, one expressing Xm, the other expressing 
Xp. In theory, the degree of cellular mosaicism of X-linked allele expression can be estimated by 
RNA-seq using count-based approach (Figure 7A). In this approach, we obtain digital 
measurement of allele expression from Xm and Xp by counting sequenced reads mapping to 
each allele, which is directly related to the expression of the chromosome with the allele. On the 
X chromosome, the allele counts come from either Xa, or Xi, and the ratio of allele frequencies at 
a heterozygous locus correlates with the overall XCI status of the Xp and Xm chromosomes in 
the tissue. However, epigenetic modifications, including DNA methylation, cis-, and trans-acting 
elements, and chromosome strata can influence allele expression at a single locus. Therefore, 
chromosome-wide heterozygous allele frequency ratio can provide a better estimate of the overall 
expression of each parental X. In addition, when the transmission of the allele can be determined 
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from parent to offspring by segregation analysis, and variants can be assigned a parental origin 
(i.e. phase), phasing the alleles can identify the parental X that is preferentially inactivated or 
activated. To evaluate this approach, we simulated RNA-seq reads with female, heterozygous 
genotypes from a pool of known, X chromosome SNPs in coding regions from the ESP6500 
NHLBI Exome Sequencing Project (NHLBI Exome Sequencing Project,). The 4996 SNPs were 
randomly binned in two sets analogous to maternal or paternal SNPs (i.e. phased SNPs) by rand 
function of a perl script. In the first set, the alternative allele of the genotype was assigned as 
paternal (Alt-P, n=2520), and in the second set (Alt-M, n=2476), the alternative allele was 
assigned as the maternal allele. Using seqtk FASTA processing tool (seqtk) the Alt-M and Alt-P 
alleles were introduced into two separate chromosomes X transcriptome fasta files containing 
known transcripts greater than 500bp from Homo sapiens.GRCh37.62.gtf. The two modified fasta 
files were analogous to an X transcriptome with maternal variant alleles and one with paternal 
variant alleles. Next 10 million, 100bp paired reads in fastq format were generated, mapping to 
the two transcriptome files from above (5 million read1 and 5 million read2) using wgsim 0.3.1-r13 
fastq simulator (wgsim). Command line options for wgsim included zero indel error rate, an outer 
distance of 150bp between the paired reads, a uniform Phred quality score of 40 for each base, 
and a 0.001% base error rate. The combination of these two parental, Alt-M, and Alt-P allele 
containing fastq files in various ratios followed by mapping them back to the chromosome X 
reference, and followed by estimation of allelic expression by read count provides the basis for 
the estimation of XCI ratio. Essentially, after the two modified fastq files with 10 million reads 
were generated, seqtk was used to subsample them randomly, and merge each set into a single 
fastq file analogous to the reads obtained through RNA-seq of an experimental sample. When, for 
example, XCI ratio of 75:25 was simulated, 7.5 million correctly paired reads were randomly 
sampled from Alt-M alleles containing fastq file and 2.5 million were subsampled from Alt-P fastq 
file and merged. In theory, after alignment and allele count, there would be a 75:25 allelic 
imbalance in favor of the Alt-M alleles to an overall chromosome wide 75:25 ratio since 
approximately 75% of reads contain alleles from Alt-M. Using this approach, RNA-seq reads were 
simulated for 11 expected X inactivation ratios: completely skewed X inactivation (100:0), 
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extremely skewed X inactivation (95:5, 90:10), moderately skewed X inactivation (85:15, 80:20), 
and random X inactivation (75:25, 70:30, 65:35, 60:40, 55:45, 50:50).  
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Figure 7. Schematic view of estimation of XCI ratio from read counts data. (A) Overview of the 
simulation study. From a reference transcriptome (a), two haplotypes are simulated with known 
variant alleles (b). Sequence read simulator generates reads with error attributes using the two 
haplotypes as reference (c). The reads from both read simulations are merged and aligned back 
to the original reference (d, dashed lines). Counting the number of reads mapping to each known 
allele, the allelic ratio of mapped variant alleles can be determined (e). The overall XCI ratio is 
determined for large number of variants by estimating the mean of the allele ratio distributions of 
multiple alleles (f). (B) Workflow of XCI estimation from RNA-seq experiment using phased and 
un-phased approaches. Essentially, RNA-seq reads are aligned followed by obtaining the 
transcriptome pileup at each sequenced loci. This is followed by counting the number of reads 
mapping to each allele across the transcriptome. Next, loci are reduced to those that contain 
heterozygous calls in the genomic DNA and allelic ratio is calculated at each heterozygous locus. 
If there is no available information on the phase of X-linked alleles at heterozygous loci, the un-
phased, X-linked allelic ratios are evaluated for their distribution using semi-parametric model and 
XCI is reported from the parameters of the semi-parametric model. When transmission of alleles 
can be obtained from DNA data, the phased, X-linked allele ratios are evaluated by the beta 
distribution and XCI reported from the parameters of the beta model with the phase of XCI. 
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Estimation of XCI Ratio. 
Estimation of XCI ratio followed similar steps in both the in silico experiment and for the 
patient (Figure 7B). Reads were aligned to human reference genome GRCh37.62 using TopHat2 
(Kim et al. 2013). Alignment of next generation sequencing data has reference bias that may 
influence the allelic ratio estimate of SNP alleles. Reduction of bias can be achieved by read 
alignment to diploid reference incorporating parental genotype information or by reduction of 
mapping stringency by increasing the number of mismatches allowed in a read for alignment 
(Rozowsky et al. 2011; Stevenson, Coolon, and Wittkopp 2013). Therefore five and four 
mismatches per 100bp read length were allowed in the in silico and clinical experiments, 
respectively. Allele counts were obtained by generating a chromosome wide pileup with SAMtools 
mpileup command (H. Li et al. 2009). Bases with Phred quality score > 20 were counted only in 
the in silico and clinical experiments. Pileup was parsed by an in-house perl script. Next the allelic 
ratio at each heterozygous locus was calculated by dividing the number of reads mapping to the 
variant allele with the total number of reads mapping to the locus. After allelic ratio calculation the 
SNPs were further filtered for quality by following procedure: (1) SNPs within the PAR1 and PAR2 
pseudo-autosomal regions were filtered out as they follow autosomal inheritance and can bias 
XCI ratio(Mangs and Morris 2007) (2) Filtered for high confidence variant loci from exome dataset 
with a genotype filter score of PASS by GATK VariantRecalibrator (McKenna et al. 2010). (3) Loci 
without a dbSNP identifier were filtered out (4) Variants with less than 20X coverage were filtered 
out.  
First, phased alleles were used to estimate XCI ratio. Phasing was performed in the in 
silico experiment by assigning the heterozygous variants into their respective Alt-P and Alt-M bin, 
and by genotype phasing of the trio in the family study as described below. Phasing of X-linked 
heterozygous variants allows us to evaluate the functional profile of each inherited parental copy. 
By estimating the parameters (mean, variance) of each copy’s allele ratio distribution we can 
estimate the proportion of cells with Xm or Xp as active and inactive (eg. mean allelic ratio of 
paternal alleles of 65% and mean allelic ratio of maternal alleles of 35 equals an estimated XCI 
ratio of 65:35). To control for over-dispersion of read count data from RNA-seq, phased allelic 
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ratios were fitted to the beta distribution to estimate their mean and variance using the fitdistr 
module of MASS package in R (MASS) (Skelly et al. 2011; Zhou, Xia, and Wright 2011; 
Hardcastle and Kelly 2013; Sun 2011).  
Next, XCI ratio was also estimated without phasing the alleles. When phasing information 
is unavailable we can lose our ability to define the activity of the parental chromosomes. In this 
case, the inheritance is unknown and the distribution of allele expression from the two 
chromosome copies may overlap suggesting similar proportion of cells with one of the parental 
copies active. However, alleles sampled from the two chromosome copies can have their unique 
distribution pattern resulting in multi-modal allele distributions. Multi-modal distributions can be 
understood as a mixture of two or more distributions and thus mixture models based on the 
expectation maximization (EM) algorithm may be used to estimate the parameters of each 
component or mode of the distribution. The problem with normal mixture modeling is that the 
number of components in the data set can greatly affect outcome and advised to account for prior 
modeling. The semi-parametric (SP) model, however, has no assumptions about the modality or 
the normality of the data and can also approximate the parameters of each component in a data 
distribution. In estimation of the inactivation status of the X chromosomes, the mean allelic ratios 
estimated by the SP model can directly correlate to the proportion of cells carrying the variant 
alleles. Thus, allelic expression captured in component 1 and 2 of a multi-modal allelic distribution 
can be thought of as indicators of the proportion of activity of parentally inherited chromosomes in 
the tissue. The SP method is motivated by the fact that the choice of a parametric family may not 
always be evident from the distribution of the data, as it is in over-dispersed and heavy-tailed 
distributions (Hunter, Wang, and Hettmansperger 2007). We applied Bordes et al. stochastic 
expectation-maximization algorithm for estimating SP model parameters for unphased data 
(Bordes, Chauveau, and Vandekerkhove 2007). The mean of the estimated component 
distributions were utilized as the expression status of each inherited chromosomes but were blind 
to the origin of alleles and applied to define the XCI ratio.  
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Family Study 
The participating family of Northern European ancestry provided written consent and was 
enrolled into the Center For Rare Childhood Disorders Program at the Translational Genomics 
Research Institute (TGEN). The patient was 12 years old at the time of enrollment and verbal 
assent was obtained from her and documented in writing by the consenting staff person. In 
addition, written consent for the minor under the age of 18 years was obtained from the parents. 
All additional participants over 18 years of age provided written consent at the time of enrollment. 
The study protocol and consent procedure was approved by the Western Institutional Review 
Board. The primary goal of enrollment is to utilize family-trio based WES in the clinical diagnosis 
of previously undiagnosed, rare conditions suspected of genetic cause. The female child, now 14 
years old had no clinical diagnosis at the time of enrollment, although complex neurobehavioral 
condition was suspected based on manifesting phenotype of emotional instability, attention 
deficit, and delays in development and learning. She was born at 38 weeks gestation, and 
required minimal respiratory assistance. There were early concerns about her development, as 
she didn’t walk until 13-14 months of age. Behavioral problems were noted at age 2, consistent 
with current phenotypic description above. Treatments with medications for poor attention, 
impulsivity, repetitive behaviors, and learning difficulties started at age 5. She did not have 
convulsive seizures, but subtle events consisting of staring, loss of awareness, and 
tremulousness had been observed. MRIs of the brain were normal; EEG showed right posterior 
temporal sharp waves. The patient had an older unaffected brother, and her neurological 
examination was normal showing concrete ability to respond and interpret questions. Previous 
genetic analysis of genomic DNA from whole blood by array-based comparative genomic 
hybridization (aCGH) identified a heterozygous deletion between positions 6.4-8.1 Mb on 
chromosome X. Additionally, HUMARA DNA methylation assay at the AR gene identified 85:15 
skewed X inactivation within peripheral blood, providing a hypothesized mechanism for the 
patient’s moderate phenotype. To find possible causal variants that may explain her condition and 
to validate previous genetic and epigenetic findings whole-exome and RNA-seq sequencing was 
completed on genomic DNA and mRNA isolated from peripheral blood for the mother, father, and 
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patient. Whole blood was collected into EDTA Blood tubes and PaxGene RNA tubes. Genomic 
DNA was isolated with DNeasy Blood & Tissue Kit (Qiagen, Germantown, MD), and total RNA 
was isolated from PaxGene RNA tubes using PaxGene Blood miRNA kit (Qiagen, Germantown, 
MD) following manufacturer’s suggested protocol. Exome capture and library preparation was 
performed with 2µg of input genomic DNA for each participant using the TruSeq DNA sample 
preparation kit v2 and the TruSeq Exome Enrichment kit v2 (Illumina, San Diego, CA) following 
manufacturer’s guidelines. The three DNA samples were sequenced as part of a pool of 6 
multiplexed libraries on two lanes of a HiSeq2000 v3 flowcell using version 3 of Illumina’s 
multiplexed paired–end sequencing chemistry for 101 bp read length (Illumina, San Diego, CA). 
RNA library preparation was performed for each family member from 1.5µg of total RNA using 
Illumina TruSeq RNA Sample Prep Kit v2 according to manufacturer’s instructions (Illumina, San 
Diego, CA). The three RNA samples were sequenced as part of a multiplexed pool of 4 samples 
on a single lane of a HiSeq2000 v3 flowcell using version 3 of Illumina’s multiplexed paired–end 
sequencing chemistry for 101 bp read length (Illumina, San Diego, CA).  
Binary base calls files were generated by the Illumina HiSeq2000 RTA module during 
sequencing and were converted to demultiplexed fastq files using CASAVA 1.8.2 (Illumina, San 
Diego, CA). Quality filtered reads from exome data were aligned to reference genome with BWA 
0.6.2-r126 (H. Li and Durbin 2009). Binary alignment files were converted and coordinate sorted 
into the standard BAM format using SAMtools 0.1.18 (H. Li et al. 2009). Aligned reads were 
realigned around short insertion and deletions and duplicate reads were filtered using Picard 1.79 
(picard). This followed aligned base quality recalibration with GATK 2.2 (McKenna et al. 2010). 
Flowcell lane level sample BAMs were then merged with Picard 1.79 if samples were sequenced 
across multiple lanes. Variant calling was done by UnifiedGenotyper and genotype quality 
recalibrated using VariantRecalibrator as described in the best practice methods of GATK 2.2 
(DePristo et al. 2011).  
Demultiplexed fastq files obtained from the RNA-seq experiment were aligned to human 
reference genome using ensembl.63.genes.gtf of annotated, known transcripts with TopHat2 
(Kim et al. 2013). Aligned reads were assembled into transcripts with Cufflinks 2.0.2 using known 
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transcript annotation in ensembl.63.genes.gtf as guide and we used annotated high abundance 
transcript annotation of ribosomal RNA and mitochondrial genes in an 
ensembl.63.genes.MASK.gtf. Post transcript assembly, Cufflinks was used to calculate the 
relative concentration of each annotated transcript by assigning an FPKM value (Fragments Per 
Kilobase of transcript per Million mapped reads) to each gene and transcript (Trapnell et al. 
2010). 
Calculation of physical coverage.  
To determine the boundaries of the interstitial deletion on X, sequence read counts were 
obtained across X chromosome in a 100 bp sliding window for the mother and child using 
previously described methods (Craig et al. 2013). This script uses the SAMtools package to parse 
the exome BAM file for the patient and mother (H. Li et al. 2009). The algorithm uses a sliding 
window across the selected chromosome in 100 bp length, and for each read mapping within the 
window finds its mate pair and fills in the gap between the read pairs, then counts this gapped 
read as one read mapping within the window. This raw read count per 100bp window is then 
normalized by dividing the raw read count with the total reads mapping to the sum of sliding 
windows. Next, the normalized coverage in each window is transformed to log2 scale in both the 
mother and child and log2 transformed normalized read count is deducted from each other as 
described in Equation 1: 
  
 Plotting log2 differences across chromosomes allows detection of large chromosomal 
deletions and amplifications, where a log2 difference of -1 means a heterozygous deletion in one 
of the copies. 
Genotype phasing.  
While any given SNP or indel could be potentially causative towards a disease 
phenotype, SNPs could also be used as markers for segregation analysis. In this study, we were 
interested in the parental origin (i.e. phase) of the deletion and the X inactivation skewing. We 
refer to the process of phasing as determining the parent-of-origin of a molecular variant (i.e., a 
!log 2( #!reads!mapping!to!100bp!window!for!case#!reads!mapping!in!all!100bp!windows!for!case ) − log 2( #reads!mapping!to!100bp!window!for!control#reads!mapping!in!all!100bp!windows!for!control )
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heterozygote SNP or mRNA transcript containing a SNP), recognizing that phasing can have 
broader meanings. In our analyses, we use SNPs as markers to phase a genetic interval or 
region, where the interval could be a deletion, gene transcript, or chromosome. For example, if 
the patient is “A/T” for a SNP, the mother is “A/T” and the father is “A/A”, we can determine the 
“T” allele is from the mother. Larger events can also be phased by examining SNP genotypes 
contained within the larger event (i.e., a deletion); however, this requires that one recognize that 
SNP genotypes should be recoded to match their ploidy. For example, males containing a single 
X chromosome should be understood to be “A” and not “A/A”. Likewise, SNPs within a deletion 
should be understood to be “T”, rather than “T/T”. 
 
Results 
Estimation of XCI Ratio from Simulated Data.  
We developed a simulation study for 11 datasets to estimate XCI pattern from paired, 
RNA-seq reads. For each dataset, 4996 loci provided read count information to estimate XCI and 
on average 1600 SNPs had a minimum read depth of 20. After phasing, the allelic ratios were 
fitted to the beta distribution and their parameters estimated. The distributions showed increased 
mono-allelic expression from 50:50 random to 100:0 completely skewed XCI (Figure 8). As 
expected, at 50:50 XCI ratio the maternal (Alt-M alleles) and paternal (Alt-P alleles) distributions 
almost completely overlap with their mean ratios at around 0.5 indicating bi-allelic expression and 
suggesting approximately equal expression of both chromosomes (Figure 8, 50:50). At each 
expected XCI ratio, the experimental, mean XCI ratios obtained from the beta distributions of the 
phased allelic ratios showed high concordance with expected XCI (Table 5). Although we 
compensated for read mapping bias by allowing 5 mismatches, our results show some deviation 
from the expected mean XCI in each dataset. Since our reads were generated against only 
known transcripts of 500bp or longer, some sequence homology between transcripts and the 
other regions of chromosome X may have resulted in read bias affecting allelic ratio estimates. As 
we shift expected allelic ratios from 50:50 random toward completely skewed 100:0, we observed 
an increased bimodality with the two phases separating into discrete distributions. 
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Table 5.  
Estimation of XCI Ratio of in silico phased SNPs by beta testing. 
Expected 
XCI ratio 
(%) 
Alt-M  
 mean ratio 
(%) 
SD 
Alt-P 
mean ratio 
(%) 
SD 
Observed 
XCI Ratio 
(%) 
100:0 99.64 1.81 0.06 0.31 99.64 : 0.06 
95:5 95.46 11.88 3.91 10.83 95.46 : 3.91 
90:10 90.63 15.12 7.96 14.63 90.63 : 7.96 
85:15 84.82 14.35 13.11 14.79 84.82 : 13.11 
80:20 78.91 12.91 18.01 15.40 78.91 : 18.01 
75:25 74.31 12.63 22.59 11.61 74.31 : 22.59 
70:30 69.76 14.02 28.87 10.94 69.76 : 28.87 
65:35 63.25 11.59 34.11 10.78 63.25 : 34.11 
60:40 58.76 11.47 39.15 11.58 58.76 : 39.15 
55:45 54.05 11.51 42.88 14.08 54.05 : 42.88 
50:50 49.25 11.79 47.84 12.00 49.25 : 47.84 
XCI = X inactivation, SD = standard deviation 
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Figure 8. Phasing and distribution of in silico allelic ratios. Histograms of showing the allelic ratio 
distribution after each heterozygous SNP in the in silico data is assigned phase. Each 
heterozygous SNP allele was covered with at least 20 reads. Alt-M allelic ratios [magenta] and 
Alt-P allelic ratios [green] in bins of 20. Dark bars indicate SNP ratios that overlap between 
phased groups. Colored lines are the kernel density estimates of the phased allelic ratio 
distributions. 
 
 
Coverage analysis indicated high correlation between expected and observed XCI ratios. 
Although Pearson’s correlation was above 0.990 from coverage as low as 10X, correlation 
coefficient convergence with expected was achieved at > 0.999 above 20X suggesting that as 
low coverage RNA-seq experiments may be used for XCI ratio estimation (Figure 9). Unphased 
allelic ratio distribution followed a similar distribution pattern to phased dataset (Figure 10). 
Application of SP model to unphased allelic ratios resulted in consistent estimation of expected 
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XCI ratios (Table 6). The mean may be biased by the number of SNP markers available and 
other factors such as variants in genes that normally escape inactivation. However, our simulation 
shows that when relatively large number of markers is available, both beta distribution and SP 
model can consistently estimate the XCI ratio to the expected (Table 7). 
 
 
Figure 9. Correlation of expected and observed XCI ratios.  
(A) The mean allelic ratio of the Alt-M alleles the in silico data to their corresponding expected 
allelic ratio. For example in 70:30 simulation, Alt maternal alleles have an observed mean allelic 
ratio of 69.0. (B) The mean allelic ratio of Alt-P alleles from each in silico dataset. Eg. in 70:30 
simulation, Alt-P alleles have an observed allelic ratio of 27.6. Each color indicates the correlation 
of observed vs. expected ratios at minimum sequence coverage of 10X, 20X, 30X, 40X, and 50X. 
Pearson correlation coefficient was highest at r > 0.9998 above 20X read coverage. 
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Figure 10. Un-phased allelic ratio distributions. Histograms showing the allelic ratio distribution 
after each heterozygous SNP in the in silico experiment when phase is not assigned. Each 
heterozygous SNP had to be covered with at least 20 reads. Black lines indicate the Gaussian 
kernel density of unphased allelic ratio distributions. Similar to phased experiments, the shift of 
distributions from unimodality in random XCI (50:50) toward bi-modality as XCI becomes more 
skewed towards 100:0 complete skewing. 
 
 
 
 
 
 
 
 
 
  52 
Table 6.  
Estimated XCI ratio of un-phased data by semi-parametric method. 
 
Expected XCI 
ratio 
Component 1 
mean allelic 
ratio (%) 
Standard 
Deviation 
Component 2 
mean allelic 
ratio (%) 
Standard 
Deviation 
Observed XCI 
ratio 
100:0 99.6 2.2 0.0 1.1 99.6:0.0 
95:5 94.8 6.2 5.2 6.2 94.8:5.2 
90:10 88.9 9.1 9.7 8.5 88.9:9.7 
85:15 84.7 10.2 13.7 9.4 84.7:13.7 
80:20 78.9 11.5 18.7 11.0 78.9:18.7 
75:25 74.3 12.0 24.2 12.0 74.3:24.2 
70:30 69.0 12.8 27.6 12.4 69.0:27.6 
65:35 64.7 12.5 32.7 12.5 64.7:32.7 
60:40 58.0 13.9 37.0 13.6 58.0:37.0 
55:45 51.0 14.8 49.7 14.9 51.0:49.7 
50:50 48.6 14.0 47.8 14.0 48.6:47.8 
 
 
 
Table 7.  
Variant coverage and XCi ratio. 
 
Expected 
XCI total ≥10X ≥20X ≥30X ≥40X ≥50X 
100:0 4878 3163 1606 723 288 119 
  95:5 4887 3203 1681 756 332 160 
90:10 4882 3180 1590 694 308 136 
85:15 4891 3168 1598 708 316 138 
80:20 4894 3203 1591 693 323 131 
75:25 4887 3176 1595 738 310 140 
70:30 4875 3166 1627 712 293 137 
65:35 4891 3165 1591 686 287 132 
60:40 4878 3186 1623 727 313 143 
55:45 4891 3239 1695 724 348 151 
50:50 4879 3205 1597 703 312 126 
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Exome Analysis 
WES resulted in an average of 139 million paired reads with average insert size of 249 
base pairs [bp] corresponding to an average 14.8 gigabases (Gb) on the HiSeq2000 platform for 
the trio. After quality filtering, the 121 million average reads were aligned to reference with an 
88% alignment rate. Approximately 97% of target regions had a mean base coverage of 10X 
(Table 8). Joint variant calling identified 85,708 single nucleotide variants (SNVs) and short indels 
in with 85.96% of calls in dbSNP135 (dbSNP). Functional evaluation of calls identified 42,192 
(46%) missense, 344 non-sense (0.38%), and 48,373 (53%) silent variations. 
Transition/transversion ratio was 2.31 for all calls, and 2.447 for dbSNP variants. We applied 
various filtering approaches described elsewhere, but extensive search within Clinvar (Landrum 
et al. 2014), The Human Gene Mutation Database (HGMD) (Stenson et al. 2003), and OMIM 
(OMIM) did not identify any unambiguous genetic variants that likely caused or contributed to the 
child’s phenotype (Gilissen et al. 2012). 
Table 8.  
Summary metrics of Exome sequencing. 
 
Mappable 
Paired 
Reads                      
(M) 
Mappable 
Unique  
Paired 
Reads      
(M) 
Paired 
Reads 
Mapped          
(M) 
Mapped 
Bases       
(Gb) 
On/Near 
Target 
Mapped 
Bases    
(Gb) 
Mean 
Coverage 
Captured 
Regions      
(X) 
Target 
Regions 
Coverage 
>10X     
(%) 
Fold 
Enrichment 
Child 138.58 121.30 107.22 10.79 8.13 85.71 98.05 26.17 
Mother 145.77 128.17 113.15 11.39 8.54 88.79 97.73 25.71 
Father 133.88 115.60 101.66 10.22 7.78 84.25 97.66 26.6 
Average 139.41 121.69 107.35 10.80 8.15 86.25 97.81 26.16 
M = million, Gb = Gigabases, X= number of times locus was sequenced 
 
Characterization and Phasing of Xp22.31 Deletion  
Absence of candidate rare variants focused our attention to the previously identified 
interstitial deletion on Xp22.31. We compared log2 normalized physical coverage of the 
daughter’s exome to the log2 normalized coverage of the mother’s (see Materials and Methods), 
and observed those regions where the ratio fell below the threshold coverage of -1. Comparative 
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analysis identified the deletion as heterozygous at Xp22.31 with breakpoints at 6,451,600 and 
8,095,100, respectively (Figure 11). Similar comparison to the father’s exome indicated that father 
was hemizygous for this region; therefore the deletion occurred de novo. The distal breakpoint is 
approximately 50bp upstream of VCX3A and the proximal breakpoint resides within the first 
100bp of miR-651, a microRNA gene with no known biological function. The deletion 
encompasses 1,643,501bp harboring five genes and two microRNA genes (Table 9). This region 
was in concordance with the aCGH. The deletion was phased to Xp based on rs5933863, at 
X:7,270,694 G>A in the 3’ un-translated UTR region of the STS gene (NM_000351). The affected 
child’s genotype was homozygous G/G, the mother’s was heterozygous G/A, and the father’s was 
homozygous alternative A/A. Recoding based on anticipated ploidy, the child’s genotype is “G”, 
the mother remains “G/A”, and the father with a single X chromosome is recoded “A”. Principles 
of X-linked inheritance dictate that the child must have a heterozygous genotype G/A at this 
position. Since she is missing the paternal allele A and has an apparent genotype of “G”, there is 
evidence that the region containing this SNP on Xp was deleted resulting in an out-of-phase 
genotype (Table 10). This out-of-phase coding SNP was validated by Sanger method in the trio 
(Figure 12).  
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Figure 11. De Novo Deletion on Xp22.31.  
(a) Chromosomal view of log2 coverage difference between affected child and mother obtained 
by WES. The log2 difference of normalized read coverage between affected child and mother is 
shown on the y axis, with each blue dot indicating log2 difference in normalized sequence 
coverage in a 100bp window. The red line across the chromosome is the mean log2 differences 
across a sliding window of 25. A large deletion on chromosome X is recognizable in the child 
indicated by drop in log2 difference to -1 between 0-10Mbase. (b) Zoomed in view of reduced 
sequence read coverage between 6.4 - 8.1Mbase of the short arm of the chromosome. The pink 
shaded area indicates the deletion breakpoints predicted by aCGH analysis that overlaps with 
deletion seen by the exome coverage analysis. Gene tracks above the x-axis was obtained from 
UCSC Genome Browser and contains the deleted genes VCX3A, HDHD1, STS, VCX, PNPLA4 
genes and MI4767 microRNA genes. 
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Figure 12. Determining phase of rs5933863.  
Next-generation sequencing traces visualized using the Integrated Genomic Viewer (IGV) and 
below them the corresponding Sanger traces of rs5933863 G>A alleles in the STS gene that 
helped determine phase and origin of the 1.7Mb deletion on chromosome X (J. T. Robinson et al. 
2011). Patient’s IGV and Sanger traces (a) indicate that she is either homozygous G/G or 
hemizygous “G” genotype at this position. The mother’s (b) and the father’s (c) traces indicate 
that they are “G/A” and “A” genotype, respectively.  
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Table 9.  
Genes within 6,4-8,1 Mb interstitial deletion. 
Gene Gene Name Start End Strand RefSeq ID OMIM  Phenotype 
VCX3A 
Variably charged, X-
linked 3A 
6,451,659 6,453,159 - NM_016379 300533 XLI/MR 
MIR4767 microRNA 4767 7,065,901 7,065,978 + NR_039924   
HDHD1 
Haloacid dehalogenase-
like hydrolase domain 
containing 1 
6,966,961 7,066,231 - NM_001135565 306480  
STS 
Steroid sulfatase, 
isozyme S 
7,137,472 7,272,682 + NM_000351 300747 XLI 
VCX 
Variably charged, X-
linked 
7,810,303 7,812,184 + NM_013452 300229  
PNPLA4 
Patatin-like 
phospholipase domain 
containing 4 
7,866,804 7,895,475 - NM_004650 300102  
MIR651 microRNA 651 8,095,006 8,095,102 + NR_030380   
 XLI=X-linked ichtyosis, MR=mental retardation 
 
Table 10.  
Genotype phase of X-linked SNPs within the 6,4-8,1 Mb interstitial deletion 
Chr:pos ref alt rsID 
Proband Mother Father 
gt ploidy depth 
(ref) 
depth 
(alt) 
gt ploi
dy 
depth 
(ref) 
depth 
(alt) 
gt ploid
y 
depth 
(ref) 
depth 
(alt) X;727069
4 
G A rs5933863 G/G 1n 33 0 G/A 2n 46 43 A/A 1n 0 28 
X:727099
6 
A A rs1131289 G/G 1n 0 79 G/G 2n 2 176 G/G 1n 0 75 
X:727222
5 
G A rs13648 A/A 1n 0 1 nc - - - A/A 1n 0 1 
X:786737
8 
T C rs3470971
7 
C/C 1n 0 96 C/C 2n 0 141 C/C 1n 0 56 
X:786743
5 
G A rs1200998
9 
A/A 1n 0 72 A/A 2n 0 122 A/A 1n 0 57 
X:786766
8 
G C rs7739847
3 
C/C 1n 1 2 G/C 2n 2 4 C/C 1n 0 1 
X:786773
2 
A G rs6639976 G/G 1n 0 2 G/G 2n 0 1 nc - - - 
chr=chromosome, pos=position, ref=reference allele, alt=alternative allele, rsID=dbSNP137 id, 
gt=genotype, 1n=haploid, 2n=diploid, nc=no call by lack of coverage 
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Estimation of XCI Ratio from RNA-seq experiment.  
Sequencing the patient’s mRNA resulted in an average of 116 million paired reads per 
sample mapping to human reference genome (Table 11). From the exome variant call set 1,729 
single nucleotide variants including indels mapped to chromosome X, of which 901 were called 
heterozygous in the affected child. 374 calls were heterozygous SNPs within transcripts, and 325 
were X-linked, outside PAR1 and PAR2 regions (Mangs and Morris 2007). 226 variants were high 
quality with score PASS by GATK Variant Recalibration. Next we selected variants that were 
previously documented in dbSNP build 135. A total of 83 SNPs were covered with at least 20 
reads. 37 phased to Xm and 44 to Xp, and two Mendelian errors. The 37 Xm alleles were from 23 
genes, with 19 genes with a single heterozygous expressed variant and four had more than two 
heterozygous expressed variants. The 44 Xp alleles were from 31 genes, and 22 of them had a 
single heterozygous variant expressed and 9 had more than one heterozygous variant. The allele 
ratio distribution indicated bimodal distribution showing lower expression of paternally inherited 
heterozygous SNPs (Figure 13). The XCI ratio estimated from phased alleles was 82.7:20.3 
(approximately 83:20), and from the unphased allelic data was 82.2:19.2 (approximately 82:19), 
consistent with moderately skewed X inactivation with a ratio of 85:15 obtained by the HUMARA 
methylation assay. The integration of phase information had minimal affect to final estimate 
indicating the power of the SP model. In addition to the patient, we estimated XCI ratio in 4 
additional female individuals from our clinical sequencing center (Figure 14). In each case XCI 
was estimated by our RNA-seq approach and the HUMARA assay. A single case was 
uninformative for the HUMARA, caused by homozygosity at the methylation sensitive repeat 
sequence of the AR locus (Figure 14, S34). In 3 out of the 5 cases (60%), the HUMARA method 
suggested moderately skewed XCI ratio (>80:20) (Figure 14, S14, S18, S23). However, 
expression analysis supported strong correlation between the three methods only in the clinical 
case of this report where skewed XCI was estimated by all three methods (Figure 14, S18). In 
three of the remaining four cases skewed XCI was not supported by the RNA-seq analysis 
(Figure 14, S14, S23, S34). In a single case all three methods predicted random XCI ratio (Figure 
14, S11). In general there is a high concordance between the three approaches with the beta and 
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the SP methods have the highest concordance (Pearson’s r = 0.99), but these approaches have 
weaker correlation with HUMARA (SP Pearson’s r=0.84, beta Pearson’s r= 0.80). In general, we 
see a lower XCI ratio estimated by allele expression analysis than by HUMARA. Estimates of XCI 
ratio may be biased by reference bias in read mapping, insufficient coverage at heterozygous 
loci, and by heterogeneous gene expression driven by DNA methylation and cis-acting regulatory 
mechanisms. 
 
Table 11.  
Summary metrics of RNA-seq 
 
Quality 
Reads    
Mapped           
(M) 
Reads 
Mapped  
in Pairs         
(M) 
Reads 
Mapped  
in pairs          
(%) 
Mappable 
Bases 
 (Gb) 
Mapped 
Bases 
(Gb) 
FPKM >1.0           
#genes/total 
annotated 
on X 
Median 
Insert 
Size 
Child 95.44 84.13 88.15 8.047 8.046 346 /2688 154 
Mother 154.90 135.39 87.41 13.538 13.537 374/2688 156 
Father 99.18 83.11 83.8 8.894 8.893 362/2688 154 
Average 116.51 100.88 86.58 10.161 10.159 361/2688 155 
M = Megabases, Gb = Gigabases, X= number of times locus was sequenced 
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Figure 13. Phased allelic expression on chromosome X. (A) Allelic ratio of heterozygous SNPs 
show bimodal distribution of the expressed maternal (magenta dots, n=37) and paternal (green 
dots, n=44) alleles indicated biased expression of the inherited chromosomes. (B) Chromosome-
wide allele frequency of the phased alleles from RNA-seq indicate that overall, maternal X has a 
preferential expression in the patient with mean ratio across X of 0.82.7±0.083 (dashed magenta 
line), compared to paternal alleles of 0.20.3±0.095 (green dashed line). Biased expression in 
favor of the maternally inherited alleles is preserved across the entire length of the chromosome. 
However, alleles within genes that potentially escape X inactivation can show bi-allelic expression 
as defined by an allelic ratio 2SD outside the mean of the phased allele ratios (colored, dotted 
lines). Essentially all high quality heterozygous SNPs with a minimum of 20X coverage could be 
phased based on transmission of alleles within the X-linked region. SNPs where transmission of 
alleles could not be determined (clear circle) lie predominantly in the pseudo-autosomal region 
(PAR1) except two Mendelian errors. 
 
PAR1 PAR2 
A B 
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Figure 14. Estimation of XCI ratio in 5 patients. XCI estimated in five female patients. The x-axis 
indicates the approach (Beta= beta distribution of phased allelic expression, Hum= HUMARA 
DNA methylation assay, SP= semi-parametric method of unphased allelic expression). The y-axis 
indicates the XCI ratio (eg. S11 XCI ratio by Hum = 75:25). XCI ratio estimated by fitting allele 
ratios to the beta distribution can provide information about parental bias in XCI ratio as in the 
patient (S18) has 82.7:20.3 biased XCI that favors the expression of Xm (magenta). The ratio of 
allele expression from the maternal chromosome to the allele expression from the paternal 
chromosome (blue) gives the XCI ratio. In S18, using the beta model, we were able to determine 
that moderately skewed XCI ratio favored the expression of Xm compared to Xp. We had no 
phase information on the AR locus for the HUMARA assay, thus phase of XCI could not be 
determined. Homozygosity at the AR locus, in S34 shows uninformative HUMARA test, 
underlying the utility of RNA-seq in XCI estimation. The SP method does not consider allele 
phase to estimate the parameters of allele distributions, so phase of XCI could not be determined. 
RNA-seq estimates random XCI (<80:20) in S14 and S23 compared to moderately skewed XCI 
(>80:20) by HUMAR. S18 and S11 show complete concordance between the three methods. 
There is no clear trend that would indicate a higher likelihood of biased inactivation of either 
parental chromosome.  
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Identification of Genes that Escape X inactivation 
Phased, allele-specific expression analysis highlighted a number of variants in genes that 
may escape inactivation. Escape of X inactivation results in bi-allelic expression of genes from Xa 
and Xi in the same cell and can contribute to phenotypic variability in females who are carriers of 
X-linked disease (Carrel and Willard 2005). Therefore a catalogue of escape genes in clinical 
evaluation may contribute to the better understanding of clinical symptoms and may offer 
treatment options. We identified escape genes in the patient by examining 325 heterozygous loci 
across X and the deviation of their allelic ratio from the mean allelic ratio of each phased 
distribution. We defined a candidate escape gene by having a heterozygous SNP with an allelic 
ratio two standard deviations (2SD) outside the mean allelic ratio of the chromosome-wide allelic 
distribution and showing bi-allelic expression. Bi-allelic expression was defined as allelic ratio 
between 0.1 and 0.9. Therefore if a paternally inherited variant had an allelic ratio of 0.49 and the 
mean allele ratio of the chromosome-wide paternal alleles was 0.203 with a standard deviation of 
0.09, that variant allele ratio was greater then 2SD from the mean, thus was bi-allelic expressed. 
Of the 325 X-linked heterozygous alleles 15 showed bi-allelic expression in 12 genes, but 7 
variants were considered false positive owing to low read coverage (<7X)(Table 12) (Y. Zhang et 
al. 2013). Comparison of the sufficiently covered variant loci to chromosome wide XCI screens in 
hybrid cell lines and fibroblast indicated that in 4 of the 6 escape genes, XCI status was 
consistent with previous assignments of genes as escaping from XCI using both hybrid cell line 
and fibroblast data. Protein Convertase 1 Inhibitor (PCSK1N) and Plexin A3 (PLXNA3) both 
suggest escape status in the patient, and were previously reported as subject of XCI (Carrel and 
Willard 2005; Y. Zhang et al. 2013). PCSK1N and its associated propeptide may have a role in 
body weight and behavior in mice, and Plexin A3 is a co-receptor of the axon guidance receptor, 
Neurophilin-2 (NRP2) but their dosage affect owing to XCI remain to be elucidated (Morgan et al. 
2010). The distribution of genes that are shown to escape XCI was consistent with the regions 
that contain the highest density of escape genes, and were mostly located on the short arm of 
chromosome X (Disteche 1999). 
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Table 12.  
Escape of XCI. 
position dbSNP 
variant 
phase 
allelic 
ratio 
read 
depth 
Gene ID Carrel et al. 
X:3,524,309 rs6567569 paternal 0.49 55 PRKX Escape 
X:10,203,342 rs41305355 maternal 0.38 8 CLCN4 Heterogeneous 
X:10,204,267 rs4830442 maternal 0.50 12 CLCN4 Heterogeneous 
X:15,339,588 rs148660178 maternal 0.50 2 PIGA Subject 
X:15,801,330 rs12841514 paternal 0.55 20 CA5B Escape 
X:15,801,643 rs28707735 paternal 0.56 9 CA5B Escape 
X:15,802,800 rs5980189 paternal 0.50 4 CA4B Escape 
X:20,143,370 rs13179 paternal 0.50 10 EIF1AX Escape 
X:41,374,523 rs5918192 paternal 0.60 5 CASK Subject 
X;46,358,046 rs148701104 paternal 0.50 2 ZNF673 - 
X:48,690,749 rs11538178 paternal 0.47 15 PCSK1N Subject 
X:100,881,434 rs6995 paternal 0.50 4 ARMCX3 Subject 
X:132,438,872 rs1129980 paternal 0.50 2 GPC4 Heterogeneous 
X:153,694,334 rs5945430 paternal 0.50 8 PLXNA3 Subject 
X:153,759,858 rs1050757 paternal 0.67 3 G6PD Subject 
 
Discussion 
In this study we applied integrated WES and RNA-seq to simultaneously evaluate the 
functional effect of coding variations in the process of clinical diagnosis. Although previous clinical 
testing suggested a mechanism for the patient’s disease, with the combined analysis of the trio 
exome and the patient’s RNA expression that we are now able to hypothesize a mechanism for 
the observed phenotype. Variant filtration approaches after trio WES did not result in the 
identification of strong candidate causal variations. Although there was suggestive evidence from 
the aCGH that the disease pathology may be related to a heterozygous deletion on Xp22.31, it 
was only with incorporation of SNP phasing and comparative analysis of sequenced reads that 
we were able to determine that the deletion occurred de novo. Genes associated with 
neurological dysfunction including a number of variable-charge X-linked genes lie within the 
deletion (VCX, VCX3A) (Jiao et al. 2009). Although we were not able to detect lymphocyte 
expression of any of the VCX genes, there is suggestive evidence these genes have roles in 
cognitive function. VCX3A overexpression in rat hippocampal neurons increase neurite outgrowth 
that may positively influence synaptic plasticity (Jiao et al. 2009). Furthermore, some males who 
are hemizygous for a recurrent Xp22.31 deletion and have X-linked ichtyosis (OMIM 308100) also 
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demonstrate mental retardation (Van Esch 2005). This region appears to be a hotspot for copy 
number changes, complex duplications, and triplications, suggesting that the instability of this 
region may contribute to disease risk (P. Liu et al. 2011). The inherent limitation of our approach 
is that our resolution to define the exact genomic content of the deletion is reduced by exome 
sequencing and can only be circumvented with whole-genome sequencing approaches.  
Phased and unphased allele-specific expression in the patient was concordant with the 
HUMARA assay and indicated moderately skewed XCI.  
The contribution of skewed XCI to her condition is not clear, although the phased XCI ratio allows 
us to develop a hypothesis for the molecular mechanism that underlies her condition. One could 
hypothesize that random XCI in the patient and potential dominant negative affect of the deletion 
would result in a severe neurological condition. However, females who are carriers for deleterious 
chromosomal mutations may not present clinical symptoms owing to selective advantage and 
preferential expression of the normal X (Plenge et al. 2002; Desai et al. 2011). These females are 
usually heterozygous for an X-linked deleterious allele and have skewed XCI. The patient has 
skewed XCI and is heterozygous for the deletion but showing some mild neurological condition, 
suggesting that the preferential expression of the cytogenetically normal X may be compensating 
for the deleterious affect of the deletion. While insufficient cases have been reported to provide 
statistical significance, females who were diagnosed with Xp22.31 microduplication and 
preferentially silenced the X with the microduplication had normal phenotype while those who 
preferentially express the X with the microduplication had intellectual disability (F. Li et al. 2010). 
It is plausible that loss of a chromosome copy at Xp22.31 has different clinical manifestation than 
copy gain. Therefore the contribution of Xp22.31 rearrangements to neurological dysfunction 
need further study. For the patient sequenced in this study, our data are consistent with a model 
that the preferential expression of the cytogenetically normal, maternal X may have contributed to 
her mild cognitive phenotype. 
  Our ability to uncover molecular mechanisms by DNA and RNA-seq in patient’s surrogate 
tissue (peripheral blood) that may correlate with phenotype in the central nervous system argues 
for potential benefit in clinical diagnostic cases that remain unresolved. This is supported by a 
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number of studies that find a strong correlation in gene expression profile in blood with affected 
status in such diseases as Parkinson’s Disease and Huntington’s Disease (Scherzer et al. 2007; 
Borovecki et al. 2005). Previous studies evaluating the methylation status of X-linked genes and 
overall XCI patterns across various tissues show that XCI is concordant between tissues, 
including blood and brain (Bittel et al. 2008; Cotton et al. 2011). However, these studies were 
performed in females with no known neurological condition and showed that variable XCI status 
exists in about 12% of X-linked genes and variance between tissues increases with age. Studies 
in Rett syndrome and XCI in mice show some evidence that deleterious alleles lead to 
preferential silencing of the mutant X in brain tissue, but their correlation with blood has not been 
well characterized. (J. I. Young and Zoghbi 2004). In females with Rett Syndrome there is 
evidence that skewed XCI correlates with disease, however correlation between blood and brain 
XCI pattern was low in a small sample set. Therefore the use of whole blood to predict XCI 
patterns in the brain and their correlation to disease susceptibility remains to be elucidated.  
Our simulation proposed an approach to estimate XCI ratio using chromosome-wide SNP 
expression and found that phased and unphased SNPs can equally estimate the ratio with both 
beta and SP model. Even if research and clinical sequencing application will be limited in 
sequence coverage, our method is able to predict XCI at high concordance with expected as low 
as 10X coverage. Our method also allowed for base error rate therefore providing a more realistic 
sequence data. Our approach based on read count, and relative ratio estimation of variant alleles, 
can be applied to other sequencing platforms and to other expressed regions of the genome that 
are targeted by RNA-seq. Principles of skewed expression demonstrated in this study could be 
relevant to imprinted portions of autosomes and therefore applicable to disorders like Prader-Willi 
and Angelman syndromes (Biliya and Bulla 2010). Skewed expression of autosomal 
heterozygous alleles can be markers for imprinted regions, and may uncover cis-regulatory 
elements.  
Although, in our small dataset, XCI estimation from RNA-seq analysis was not fully 
concordant with the methylation assay, direct measurement of allele expression may provide a 
better estimate of the true cellular activity of each inherited chromosome copies. HUMARA assay 
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targets a single genomic locus and relies on the methylation of a repeat sequence targeted by 
methylation sensitive restriction enzyme. Deletions, copy number changes, homozygosity at the 
AR locus, enzymatic and PCR inefficiency, hypo-methylation of restriction enzyme target, 
difficulties associated with data interpretation, and the challenges associated with the 
amplification of repeat regions may influence assay results (Swierczek et al. 2012).  
Our approach is dependent on the accuracy and sensitivity of multiple SNP markers 
expressed in the X-linked region. There is heterogeneity in the regulation of X-linked gene 
expression by epigenetic mechanisms, therefore, sampling alleles from multiple genes with 
various expression levels to infer XCI ratio may be inconsistent with previous methods but 
excluding alleles from genes that escape XCI can provide an inaccurate picture of the X 
chromosome activity, and molecular characteristics of the tissue source (Carrel and Willard 
2005). Therefore, we did not filter out alleles from genes that were previously reported to escape 
XCI. This may have contributed to an overall lower XCI ratio estimates by RNA-seq compared to 
the methylation assay. In addition, methylation based assessment of XCI may not be concordant 
with expression based methods owing to differences in assays and applied analytical methods. 
Challenges in RNA-seq experiments include technical and analytical variability that may affect 
XCI ratio therefore transcription-based validation assays may be useful to improve our approach 
(Carrel and Willard 2005; Moreira de Mello et al. 2010; Swierczek et al. 2008). The use of direct 
expression analysis of multiple SNP markers may also increase our power to accurately estimate 
XCI, providing a basis to improve our definition of clinically significant XCI ratio boundaries. 
However a more systematic screening of XCI by RNA-seq across a series of X-linked disorders in 
females may greatly enhance our understanding of the underlying cause of phenotypic variability. 
WES identified a deleterious deletion on Xp22.31 that is in a hotspot for chromosomal 
rearrangements and associated with a number of neurological conditions. In addition, using 
allele-specific expression analysis from RNA-seq we were able to define XCI ratio in simulated 
and experimental data. Although the number of individuals reported, and the number of 
heterozygous alleles in the X-linked region may be small, both the SP and beta models could 
reliably estimate XCI from RNA-seq data. The benefit of the SP model is that parental sequencing 
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and genotype phasing is not necessary to estimate XCI, it compares well to XCI based on allele 
phasing, and can be applied to individuals only. The combined genomic and functional data 
allowed formulating hypothesis for the molecular mechanism for the patient’s symptoms, which 
can provide a basis for further clinical studies and patient management. However, extensive 
functional analysis is required to assess if our hypothesis based on sequencing blood RNA can 
be applied to a neurological condition. Finally, our study also represents an application of high-
throughput sequencing methods and their simultaneous utilization to study epigenetic 
mechanisms in the clinical settings and how they contribute to genetic basis of a heterogeneous 
disease. Rapid decrease in sequencing costs, improved analytical methods, comprehensive, 
integrative sequencing approaches will likely be used more in the future and may replace 
traditional methods that may be uninformative owing to atypical disease phenotype, low-
throughput, high costs and invasiveness. 
In conclusion, we showed the utility of combined analysis of genomic and functional 
variations on a chromosomal scale to determine XCI ratio. Application of this method showed 
concordance with currently available clinical test thus provides a sensible alternative in studies 
that apply next-generation sequencing to study complex, hard-to-diagnose phenotypes. In 
addition, we showed that the use of integrated approach can provide insight into the underlying 
molecular process potentially correlating with her symptoms. 
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CHAPTER 4 
INTEGRATED ANALYSIS OF DNA AND RNA SEQUENCE DATA IN RARE CHILDHOOD 
DISORDERS BY MULTIVARIATE OUTLIER ANALYSIS OF RARE FUNCTIONAL VARIANTS  
Introduction 
 In this chapter we set out to develop a novel framework to study the functional impact of 
germline DNA variants derived from patient specific tissue, to improve standard variant 
prioritization methods by integrated DNA and RNA sequencing. Identifying the genetic basis of 
disease in rare childhood disorders is often hampered by discerning which variants from a list of a 
few dozen to a few hundred variants are functional, and thus the focus of this chapter is to 
describe an approach for prioritizing those variants with a functional impact on transcription. A 
germline variant can have a variety of functional effects on transcription, including but not limited 
to exposing cryptic splicing sites causing in-frame exon skipping, causing premature truncation of 
transcription or altering promoter binding. 
RNA-seq is a high-throughput approach that provides qualitative and quantitative 
information on the impact of functional variants by sequencing the transcriptome or transcribed 
RNA species including mRNA, long non-coding RNAs (lincRNA), small-RNAs in a tissue of 
interest relating to specific condition (Z. Wang, Gerstein, and Snyder 2009). This approach works 
essentially like DNA sequencing except the millions of sequenced mRNA fragments are mapped 
to a known transcript structure of the genome, or assembled without a reference transcript map to 
detect novel transcripts (Ozsolak and Milos 2010). The most commonly investigated properties of 
the transcriptome are alternative mRNA transcription and processing (de Klerk and 't Hoen 2015). 
Choice of promoter, exon splicing, alternative poly-adenylation directly impact the mRNA 
composition of the cell and can result in cellular heterogeneity affecting clinical phenotypes 
(FANTOM Consortium and the RIKEN PMI and CLST (DGT) et al. 2014; H. Zhang, Lee, and Tian 
2005; Florea, Song, and Salzberg 2013).  
Current RNA-seq analytical approaches provide multitude of information on the functional 
portion of the genome including but not limited to gene and isoform expression, differential gene 
and isoform expression, allele-specific expression, and alternative splicing and exon usage. 
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One common RNA-seq analysis approach is the estimation of transcriptome abundance 
of the sequenced sample, either alone, within groups, or by comparison to others. The number of 
reads mapping to transcript relates to its expression but within-sample, across-sample biological 
and technical variability during RNA-seq can influence estimates and only provide a relative 
expression level. Transcript abundance is impacted by the presence of isoforms, recognizing that 
we are measuring fragments that are typically much smaller than the overall transcript (in the 
case of Illumina next generation sequencing). A single gene may have many different types of 
transcripts, or here referred to as isoforms, representing possibly alternatively spliced variants of 
an mRNA species with different composition of exons. Due to ambiguity in read mapping, reads 
may map to multiple isoforms. There are numerous statistical approaches to resolve this 
uncertainty based on known exon structure and the quality of mapping reads (H. Jiang and Wong 
2009; Trapnell et al. 2010). Currently the most common measures to quantify the expression of a 
transcript are transcript per million (TPM) and fragments per kilobase of transcript per million 
reads mapped (FPKM) (B. Li and Dewey 2011; Trapnell et al. 2010).  
Finding genes harboring functional variants that are differentially expressed between two 
or more conditions has become a routine experimental design to study phenotypic variability in 
human disease. This approach is based on estimating the change in read counts in expressed 
transcripts between conditions followed by statistical testing if the change is greater than what 
would be expected just due to random variation. The final result of a differential expression study 
provides an estimated magnitude of change in expression (fold change) and its significance (p-
value) (Rapaport et al. 2013). Differential expression analysis can provide a list of genes that are 
associated with given predictors (i.e. affected, unaffected) or responses (i.e. treated, untreated). 
There is extensive literature on experimental designs and analytical strategies for differential 
gene expression studies using RNA-seq which is beyond the scope of this study (Rapaport et al. 
2013; Finotello and Di Camillo 2015; Oshlack, Robinson, and Young 2010). 
Another analysis approach for RNA-seq is to measure allele specific expression (ASE), 
which was a core concept behind our prior chapter on X-inactivation. While in that chapter we 
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were looking at a chromosome-level impact, ASE is more narrowly defined as the unequal 
expression of two copies of the same gene and this imbalance in expression can be important in 
phenotypic variability in human disease. ASE in extreme cases can result in monoallelic 
expression of only one copy of a gene while the other is silenced, by significantly biased 
expression of the two alleles. ASE may also result in allele specific transcript expression 
presenting biased expression a transcript with one allele over the other. This pattern of 
expression may be influenced by epigenetic gene regulation, XCI, or parental imprinting (Fang et 
al. 2012; Moreira de Mello et al. 2010). ASE studies utilize heterozygous loci across the 
transcriptome and quantify the relative proportion of the mRNA expression between the two 
alleles (Main et al. 2009). Mapping bias present in RNA-seq against alternative alleles present 
challenges for accurate estimation of ASE and can be tackled by the creation of reference 
genomes that contain both reference and alternative alleles or by adjusting the mapping 
algorithms for alignment stringency (Rozowsky et al. 2011; Stevenson, Coolon, and Wittkopp 
2013). Genetic variants that result in allele specific gene expression are also called expression 
quantitative trail loci (eQTL) that have been shown to have population and tissue specificity 
(Lappalainen et al. 2014; Battle et al. 2014). ASE analysis provides a direct measurement of the 
allelic differences by counting the number reads mapping to the two alleles, and provides a 
probabilistic significance estimate of the difference in the from of a p-value. 
 Alternative splicing results in the differential inclusion of exons into mRNA. Splicing is the 
most prevalent regulatory mechanism with 95% of genes undergoing splicing (E. T. Wang et al. 
2008). The major splicing events are exon skipping, alternative use of splice donor and acceptor 
sites, intron retention and mutually exclusive exons (de Klerk and 't Hoen 2015). Most common 
mechanisms genetic variants impact exon usage is by exon skipping which occurs in 
approximately 30% of human and mouse genes showing great diversity in exon usage across 
tissues (Sugnet et al. 2004; Florea, Song, and Salzberg 2013). Detection of alternatively spliced 
mRNA transcripts and their exon structure is based on counting sequenced reads in a pre-
defined exon map of the transcriptome and then performing a comparative estimation of the 
difference among conditions (Anders, Reyes, and Huber 2012). This approach can provide 
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information on the diversity of transcripts with various combinations of exon usage, and quantifies 
the difference (fold change) between the conditions allowing for hypothesis-based analysis.  
Non-sense mediated decay (NMD) is an important mRNA quality control mechanism that 
has been associated with over 10% of all human diseases (Bidou et al. 2012). NMD is caused by 
mutations that lead to premature termination codon (PTC) in the mRNA sequence. PTC can lead 
to the degradation of mRNA transcript and to non-functional protein or truncated polypeptide. 
Authentic stop codon or upstream mutations resulting in the change in the open reading frame 
can lead to PTC, therefore variant calling and annotation has a major role in the prediction of 
NMD transcripts. Optimally variant detection should be in genomic context as variant callers for 
RNA-seq are still in their infancy (Piskol, Ramaswami, and Li 2013). The next step is to correlate 
the stop codon signal to abundance of transcript where PTC lies. This is challenging because 
genes have multiple splice variants and therefore we need to identify the transcript where the 
stop codon lies, or infer NMD from read counts mapping to the wild type and mutant allele. There 
are some methods that detect NMD sensitive transcripts (Vitting-Seerup et al. 2014), but most 
commonly simple allele ratio estimates are used to infer NMD (MacArthur et al. 2012). 
Outlier detection is one of the major steps in many “omics” applications. High-throughput 
“omics” generate large amount of data and obtaining the most important information, and to 
perform a coherent analysis many times starts with identifying observations that deviate from the 
bulk of the data. Thus, outliers are data that deviate so much from other observations that are 
suspected to be generated by other mechanisms (Hawkins 1980). A data point that is an outlier 
from the other data may be indicative of low sample quality, sample stratification, technical noise, 
and can suggest biologically important features that correlate with clinically important traits. It is 
therefore important to identify them prior analysis or as the goal of the analytical process. 
Outlier analysis can be grouped into two main groups, univariate and multivariate 
methods. Univariate statistical models often rely on assumptions made about the distribution of 
the data, with the expectation that that data points are independently distributed (Ben-Gal 2005). 
Essentially, a univariate model would calculate the sample mean and standard deviation 
of a single variable and classify outliers as measurements that are 2 or 3 standard deviation away 
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from the mean. Visually univariate outliers can be detected by using scatterplots, QQ plots or 
boxplots. Univariate methods have difficulty when multiple outliers exist in the sample data. This 
can be attributed to the fact that when multiple outliers exist in the same direction, the mean of 
the sample data shifts and the standard deviation estimates increase so the lesser outlier falls 
within the standard deviation limit and thus goes undetected. This is called the masking effect. In 
other cases where large outliers shift the mean and the standard deviation so much as other 
observations become outliers as well is called swamping effect (Ben-Gal 2005). Statistical 
methods like the Grubb’s test (Grubbs 1969) or the Tietjen-Moore test (Tietjen and Moore 1972) 
exist to compensate for effects biasing outlier estimation, but require the knowledge of expected 
number of outliers in the data and assume normal data distributions.  
In RNA-seq, where data distributions do not follow normal distribution univariate 
measurements are fitted to Gaussian, Poisson, or beta distributions and outliers are estimated 
based on the probability that point belong to the data distributions. Such approaches are utilized 
in differential gene, exon or transcript expression studies that use a gene-by-gene technique to 
test whether a single measure in a patient’s condition (i.e. expression of a gene) is significantly 
different from the expression of the gene in a control condition/group. In essence, these tests like 
DESeq, or DEXSeq, use read count data to quantitate expression level, and assuming a Poisson 
or negative binomial distribution, model the expression levels between conditions to estimate the 
probability that the gene is an outlier in the patient (A. Roberts et al. 2012; Love, Huber, and 
Anders 2014). However analysis of the transcriptome is performed over thousands of genes, and 
multiple testing corrections may leave biologically relevant, outlier genes off the list of significant 
differential expression list.  
As described above RNA-seq provides information on multiple transcriptomic features 
and analyzing them individually provides information about the impact of genomic variation to the 
specific RNA feature. However, true understanding of biological systems, like transcriptome and 
its diversity can be best explained by integrating measurements from multiple transcriptomic 
features. Essentially, the identification of genes that are significantly impacted by genetic variation 
can be best studied if multiple measurements from allelic expression, exon usage, transcript 
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diversity, or gene level expression can be combined and evaluated simultaneously. Patterns in 
these complex datasets can provide a means of quantifying truly multivariate patterns that arise 
from the correlational structure of the variables. Multivariate analysis also highlights patterns that 
are redundant in univariate analysis, provides means to identify patterns and relationships 
between variables that may be missed by univariate analysis. As an example, identification of 
alternative exon usage obtained from a single measurement for a patient that may be considered 
as a measurement error can gain biological importance if gene or transcript level measurements 
are combined with exon measurements and multiple variables indicate an outlier pattern of the 
exon when applied to multivariate algorithm. Thus, multivariate analysis of multiple variables is 
best suited for high dimensional data sets. Detection of outliers in multivariate models is only 
possible by identifying interactions between the different variables within the class of data. 
Essentially, by adding additional dimension to univariate data, outliers detected by univariate 
method can be confirmed or rejected, or new outliers can be identified relying on multiple 
measurements. Thus taking into account the relationship of the multivariate is a critical step in 
multivariate analysis. Some of the more common multivariate outlier methods include statistical 
models, and data-mining techniques (Ben-Gal 2005). Statistical models are based on the 
identification of observations that lie relatively far from the center of the multivariate data 
distribution. Data mining techniques apply clustering of multiple variables into distinct clusters that 
may include multiple observations indicating relationship of observations in multi-dimensional 
space. Multivariate analysis is not computationally intensive and can be used as an unbiased 
data exploratory tool simply summarizing the variability in the data (Jombart, Pontier, and Dufour 
2009). 
One of the most extensively applied multivariate statistical approach for RNA-seq data is 
principal component analysis (PCA) (Yeung and Ruzzo 2001). PCA is primarily used to reduce 
multi-dimensional data into as few components as possible that explains the greatest variability in 
the original data. PCA based methods work best for data that is transformed to normalize data 
distribution and stabilize variance. The transformation results in creation of linearly uncorrelated 
variables from possibly correlated variables that negatively impacts clustering of variables and 
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impacts the number of outliers detected (Yeung and Ruzzo 2001). Un-correlating the variables 
allows for the estimation of distances between the variables using Euclidian distance. PCA is also 
sensitive for the scale of the variables. In quality control procedures of RNA-seq experiments 
using gene expression abundance measures across multiple samples as multivariate, PCA can 
identify samples whose expression do not adhere to group indicating potential quality issues (Ellis 
et al. 2013). In cancer, PCA allows for separation of normal samples from samples with different 
stages of tumor progression (Veytsman et al. 2014). Using a subset of genes and their 
expression profile outlier PCA can also identify sub-populations of cells among hundreds of 
single-cell RNA-seq experiments (Buettner et al. 2015).  
The most common multivariate approach that takes into account the relationship between 
variables in a multivariate data space is the Mahalanobis distance (MD) (Mahalanobis 1936). 
Given n observations from a p-dimensional dataset, the algorithm first estimates the mean of 
each variable, followed by estimation of covariance between each variable. This is followed by 
taking the square root of the quadratic multiplication of mean difference and inverse of covariance 
matrix. Mahalanobis measures the distance for each observation from the multidimensional mean 
(centroid) of the data distribution given the covariance (De Maesschalck and Jouan-Rimbaud 
2000). An observation is a multivariate outlier if its probability falls under a threshold given a 
degrees of freedom. Since Mahalanobis scores follow a Chi-Squared distribution for normal data 
the degrees of freedom equals the number of variables in the dataset.  
The advantage of MD is that it does not have assumptions about the scale of the 
variables and does not require data normalization, or transformation. In addition it allows for 
integration of large number of variables that are only limited by the number of observations, as 
MD works best when number of observations exceeds the number of variables. The utility of 
multivariate outlier analysis and Mahalanobis distance to quantify outliers has been demonstrated 
by Kothari et al. (2013) who applied continuous variables of absolute gene expression and fold 
change from differential gene expression in a two-dimensional data space to identify kinase 
expression signatures across hundreds of samples that may be targets for pharmacogenomics 
treatment in breast and pancreatic cancer. In addition, Schissler et al. (2015) applied log2 
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transformed gene expression measurements from paired normal and tumor tissue of the same 
breast cancer patient in a two-dimensional data space to identify dysregulated pathways. In this 
approach the MD is calculated for each gene within its respective pathway with the initial 
assumption of no difference in gene expression between the normal and tumor tissues. Thus the 
MD is interpreted as a signed magnitude of differential expression between tissues incorporating 
the variance of other genes within the pathway where the gene lies. The average of gene specific 
MD scores for each pathway were then used to define the pathway as potentially relevant 
clinically. These two approaches underscore the utility of MD in large cohorts where patients with 
outlier expression signatures are studied for specific genes, or in single-patient cases where all 
expressed genes are evaluated for outlier gene signatures that may be associated with 
phenotype. Both methods show the utility of MD when variables of the same or different scales 
are studied.  
However, the application of traditional gene-level expression signatures in cross patients 
studies can mask distinctive signals from single patient, and may not fully explain the significance 
of the gene signature to disease mechanism.  
To address this, we present a framework to apply multivariate outlier analysis of multiple 
transcriptomic signatures of gene and exon expression from RNA-seq in a group of 29 patients 
with rare genetic conditions (Figure 15). Our cohort includes patients with or without genetic 
diagnosis, but enrolled patients present clinical symptoms that are difficult to categorize and do 
not easily fit into any clinical disease phenotype. Thus in a sense our cohort is a collection of 
clinical outliers. We use gene and exon expression to search for transcriptional multivariate 
patterns that are rare, and outliers in the multivariate data space. Specifically, our analysis 
framework leverages multivariate outlier analysis by MD, recognizing that there are thousands of 
possible genetic variants in standard clinical exome sequencing to make diagnosis in any given 
pediatric disorder of unknown etiology. The goal is to provide MD score based on the expression 
profile for each candidate variant, such that those with the highest score are indicative of outlier 
expression pattern supported by gene and exon data within our cohort. In this case, if there were 
500 candidate variants one would perhaps choose for in depth functional analysis the variants 
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with highest scores before those with lower scores. Thus, we will utilize the hypothesis that 
variants with substantial impact on transcription by their outlier score would be more likely to be 
functional, and thus more relevant than a non-functional variant when considering the variant with 
a phenotype or disease in any child. Multivariate analysis by Mahalanobis distance of outliers 
provides a tested and established approach to integrate gene and exon expression values for 
patient specific variants so they can be simultaneously interpreted with clinical information.  
In this chapter, genomic information in the form of rare variant annotation from family 
based DNA sequencing are integrated with MD scores for each patient. Integration of genomic 
data with MD scores was expected to identify rare, functional variants that have significant impact 
on transcription, and provide a basis to further reduce the list of potential candidate variants in 
rare disease diagnosis. Our results show that gene-based MD scores have association with 
variants predicted to have high functional impact. We also found that frameshift variants had 
higher outlier scores than variants in other functional classes. Using this approach we found that 
presumed causal variants previously identified by DNA sequencing in a subset of cases showed 
large functional impact corroborating the genomic findings and supporting causality. Integration of 
RNA-seq based outlier analysis also revealed new candidate variant in previously undiagnosed 
case, suggesting the utility of integrated DNA-RNA analytical approaches in the diagnosis of rare 
childhood diseases. 
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Figure 15. Schematic overview and workflow. We prepared an integrative DNA and RNA 
sequencing data set by combining family-based whole exome data with family-based RNA-seq 
analysis results for 29 patients from the Center for Rare Childhood Disorders at TGen. Exome 
data was obtained from family sequencing, variants were called, annotated and filtered by in-
house analytical pipeline for all 29 patients. RNA-seq was performed for the same family 
members followed by differential gene and exon expression analysis between each patient and 
their parents. Multiple measures were taken from each differential analysis and used to perform 
multivariate outlier analysis by Mahalanobis distance for each expressed gene and exon in the 29 
patient cohort. MD scores obtained for each patient transcriptome data were integrated with 
variant annotations from exome sequencing to a final tabulated variant table utilized for variant 
prioritization. 
 
 
Materials and Methods 
Patients 
Patients with undiagnosed genetic condition from 32 families were selected from the 
Dorrance Center for Childhood Disorders between 2012 and 2014. Enrollment criteria into the 
Center’s study included, but were not limited to previously undiagnosed, possibly severe 
condition, an ambiguous genetic origin, and negative, or inconclusive genetic tests prior 
enrollment.  
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Standardized clinical assessment was performed by the referring physician or by the 
center’s clinical staff. All patients went through standard clinical evaluation prior enrollment, and 
remained undiagnosed. Clinical evaluation varied case-by-case and included but were not limited 
to karyotyping, genetic panel testing, mitochondrial DNA genotyping, magnetic resonance 
imaging, chromosomal microarray testing, enzymatic assays. Most patients exhibit some form of 
neurological phenotype and were characterized as one of the following condition: Neurologic, 
Multi-system, Musculoskeletal structural, Cardiac (Table 13). Written informed consent was 
obtained from the patients at the time of enrollment, or from parent/guardian for patients under 
the age of 18. The Western Institutional Review Board (WIRB) approved this study. 
The goal of the center is to obtain consent and to collect biospecimen from the patient 
and his/her biological parents. Recognizing that not all family members could be consented and 
whole blood obtained, we define a family trio, with exome, and/or whole genome, and RNA 
sequencing was performed in the patient and their biological parents. In addition we define a 
singleton where whole genome or exome sequencing could be performed only in the patient. 
Furthermore, we define a large family where exome and\or whole genome sequencing was 
performed for patient, biological parents, affected or unaffected siblings, grandparents, uncles, 
and/or aunts. Finally, we define a parent-child duo in those families where exome or whole 
genome data could only be obtained from one of the biological parent and the patient. For 
detailed clinical description of each patient please refer to Appendix A. 
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Table 13.  
Study patients. 
Family Patient (Gender) Ethnicity 
Family 
History 
Age/Age of 
Onset Organ System Clinical Diagnosis 
0001 1(F) Caucasian N 15y/<1mo Neurologic Neurotransmitter Disorder 
0002 1(F) Caucasian Y 13y Unaffected Migraine 
0002 2(F) Caucasian Y 21y/5y Cardiac, Neurologic 
Intellectual disability, (Wolfe-
Parkinson-White syndrome) 
0002 4(M) Caucasian Y 18y/8y Neurologic Hemiplegic migraine 
 0002 
 5(M) Caucasian Y 9y/<2y Neurologic 
Leigh Syndrome; 
Mitochondrial encephalopathy 
0004 1(M) Caucasian N 17y/4mo Neurologic Developmental Delay | ID | Microcephaly 
0005 1(M) Caucasian N 6y1/<1mo 
Neurologic, 
Musculoskeletal 
structural 
Nystagmus|Motor 
Delay|Feeding Disorder 
0006 1(F) Middle East C|Y 12y/2-3y 
Neurologic, 
Musculoskeletal 
structural 
Ataxia with sensory 
neuropathy 
0008 1(F) Indian N 17y/3-4mo Musculoskeletal/structural 
progressive 
leukoencephalopathy|spastic 
|global cerebral atrophy 
0016 1(M) Asian N 10y/6y 
Neurologic, 
Musculoskeletal 
structural 
progressive cerebellar 
ataxia|dystonia 
0018 1(F) Caucasian N 15y/2y Neurologic ADHD, Autism Spectrum Disorder 
0019 1(F) Caucasian Y 11y/<1mo Neurologic non-progressive cerebellar ataxia, infantile dystonia 
0024 1(M) Middle East C 17y/2 mo Neurologic Aicardi-Goutieres Syndrome 
0025 1(M) Caucasian N 6y/<1mo Musculoskeletal structural 
motor delay, hypotonia|feeding 
disorder 
0049 1(F) Caucasian N 11y/<1mo 
Neurologic, 
Musculoskeletal 
structural 
Cockayne Syndrome, COFS-2 
0091 1(M) Caucasian Y 9y/5y Neurologic Schizophrenia 
0103 1(M) Hispanic Y 19y1/6mo Neurologic NBIA| BPAN 
0103 2(F) Hispanic Y 14y/<1y Neurologic NBIA| BPAN 
0117 1(M) Caucasian N 10y/birth Neurologic congenital nystagmus, Pelizaeus–Merzbacher-like  
0139 1(M) Caucasian N 19y/prenatal Cardiac, neurologic 
Situs inversus; developmental 
delays, chronic lung disease 
0152 1(M) Caucasian N 3y1/<1y Multi Leigh Syndrome 
0157 1(F) Caucasian N 5y/1y7mo Neurologic Developmental Delay 
0011 1(F) Caucasian N 8y/<1mo Neurologic Aicardi Syndrome 
0014 1(F) Caucasian N 14y/<1mo Neurologic Aicardi Syndrome 
0033 1(F) Caucasian N 7y/3mo Neurologic Aicardi Syndrome 
0034 1(F) Hispanic N 3y/<1mo Neurologic Aicardi Syndrome 
0046 1(F) Afr.American/Caucasian N 4y/3mo Neurologic Aicardi Syndrome 
0047 1(F) Caucasian N 14y/3mo Neurologic Aicardi Syndrome 
0048 1(F) Caucasian N 8y/3mo Neurologic Aicardi Syndrome 
0118 1(F) Caucasian N 18y/3mo Neurologic Aicardi Syndrome 
0059 1(F) Caucasian N 9y/3mo Neurologic Aicardi Syndrome 
0012 1(F) Caucasian N 12y/3y Neurologic Developmental delay, autism spectrum disorder 
0020 1(F) Caucasian N 5y/birth Multi Neonatal progeroid disorder, failure to thrive 
0023 1(F) Hispanic N 7y/<1y Neurologic 
Infantile choreoathetosis; 
dystonia, rigidity; cognition is 
near normal 
0029 1(F) Caucasian Y 6y/<2y Neurologic Leukoencephalopathy 
0140 1(F) Caucasian N 5y/10mo Musculoskeletal  
Abbreviations: F=female, M=male, N = no family history, C = consanguinity or suspected consanguinity, Y= multiple 
affected within the family, 1 = expired. 
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 The 32 enrolled families consisted of 18 trios (56%), 8 large families (25%), 4 singletons 
(13%), and 2 parent+proband duos (6%) (Figure 16). This cohort is ethnically heterogeneous, 27 
patients are Caucasian (75%), 4 are Hispanic (11%), 1 of African American descent (3%), and 4 
are of Asian descent (11%)In six families, there is a family history of the rare condition with 
multiple affected individuals (0002, 0006, 0019, 0091, 0103, 0029), and we enrolled multiple 
affected patients from families 0002 (n=3) and 0103 (n=2) for a total of 36 patients. One of the 
children (0002_1) is diagnosed as unaffected sibling but we included her due to some mild 
symptoms that we felt was important to decipher the phenotypic heterogeneity within the family. 
From the 32 families 25 families participated in the study described in this chapter (Ch.4), 5 
families in the study described in Chapter 3 and 30 families in the study described in Chapter 2. 
There is an overlap between the studies in terms of participation and participation is described in 
Table 3. Among the 32 families, there were a total of 24 female patients (66.7%) and 12 (33.3%) 
males. The study participants included 10 females diagnosed with Aicardi Syndrome 
(MIM:304050). In two families (0006, 0024) the clinicians reported that there was evidence of 
consanguinity. In 23 patients the primary organ system that is affected is neurologic, for 5 
patients a combination of neurologic and musculoskeletal symptoms were observed. Three 
patients show severe musculoskeletal symptoms, and two patients show extensive multi-system 
clinical symptoms. In ten families, the likely pathogenic, disease causing mutations using exome 
and genome sequencing was identified prior RNA-seq (0001, 0002, 0005, 0012, 0018, 0020, 
0024, 0047, 0049, 0103).  
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Figure 16. Family structure of enrolled patient. 
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Table 14.  
Study Participation and sequencing 
Family WGS Count WES Count RNA-seq Count Study 
0001 - - P|M|F|S1|S2|S3 6 P|M|F|S3 4 Ch4 Ch2  
0002 - - P1|P2|P3|M|F|S 6 P1|P2|P3|M|F|S 6 Ch4 Ch2  
0004 P|M|F 3 - - P|M|F 3 Ch4 Ch2  
0005 P 1 - - P|M|F 3 Ch4   
0006 P 1 - - P|M|F 3 Ch4   
0008 - - P|M|F|S1 4 P|M|F 3 Ch4 Ch2  
0011 P|M|F 3 - - P|M|F 3 Ch4 Ch2 Ch3 
0012 P 1 M|F 2 P 1  Ch2  
0014 P|M|F 3 - - P|M|F 3 Ch4 Ch2 Ch3 
0016 - - P|M|F 3 P|M|F 3 Ch4 Ch2  
0018 - - P|M|F 3 P|M|F 3 Ch4 Ch2 Ch3 
0019 - - P1|P2|P3|M|F|S
1 
6 P1|M|F 3 Ch4 Ch2  
0020 P 1 - - P 1  Ch2  
0023 - - P|M|F 3 P 1  Ch2 Ch3 
0024 - - P|M|F 3 P|M|F 3 Ch4 Ch2  
0025   P1|M|F|S1|S2 5 P1|M|F 3 Ch4 Ch2  
0029   P1|P2|M|F|S 5 P1 1  Ch2  
0033   P|M|F 3 P|M|F 3 Ch4 Ch2  
0034   P|M|F 3 P|M|F 3 Ch4 Ch2 Ch3 
0046   P|M 2 P 1  Ch2  
0047   P|M|F 3 P|M|F 3 Ch4 Ch2  
0048   P|M|F 3 P|M|F 3 Ch4 Ch2  
0049   P|M|F 3 P|M|F 3 Ch4 Ch2  
0059   P|M|F 3 P|M|F 3 Ch4 Ch2  
0091   P|M|F|S1|G 5 P|M|F|S1|G 5 Ch4 Ch2  
0103   P1|P2|M|F 4 P1|P2|M|F 4 Ch4 Ch2  
0117   P|M|F 3 P|M|F 3 Ch4 Ch2  
0118   P|M 2 P|M 2  Ch2  
0139   P|M|F 3 P|M|F 3 Ch4 Ch2  
0140   P 1 P 1  Ch2  
0152   P|M|F 3 P|M|F 3 Ch4 Ch2  
0157   P|M|F 3 P|M|F 3 Ch4 Ch2  
Total  13  90  90    
P,P1,P2,P3= proband, M=mother, F=father, S,S1,S2= unaffected sibling, Ch2=Chapter 2, 
Ch3=Chapter 3, Ch4=Chapter 4 
 
Biospecimens 
We collected from each consented study participant whole blood in Vacutainer Blood 
Collection Tube (Becton, Dickinson and Company; Franklin Lakes, NJ) and in PaxGene RNA 
tube (Qiagen; Germantown, MD). Genomic DNA isolation was performed in multiple stages 
depending on the time of enrollment. Patients DNA enrolled prior January 2013 was isolated at 
Barrow Neurological Institute using Wizard SV Genomic Purification System (Promega, Madison, 
WI). From 2013 blood collections were sent out for DNA and total RNA isolation at GeneDx 
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(Gaithersburg, MD). From 2014, genomic DNA isolation was performed under Clinical Laboratory 
Improvement Amendment (CLIA) standard operating procedures. RNA isolated at TGEN followed 
standard manufacturer recommended protocol using PaxGene Blood miRNA kit (Qiagen; 
Germantown, MD). 
Whole Genome Sequencing 
Whole Genome Sequencing was performed for a total of 13 individuals, including 3 
parents-proband trios, and 4 singletons proband. Genomic DNA from 10 of the 13 individuals 
were prepared and sequenced at Illumina Whole Genome Sequencing Service (Understand Your 
Genome, Illumina FastTrack), and one trio was prepared and sequenced at TGEN (Table 3). 
TGEN library preparation was performed using Illumina suggested whole genome library 
preparation protocol with some modifications to achieve sequencing libraries with longer than 
500bp insert size. 1µg of genomic DNA was fragmented using random shearing by sonication on 
the Covaris S1 system to a target insert size of approximately 1000bp. After fragmentations the 
sheared fragments were blunt end repaired and A base added to the 3’ end of the DNA 
fragments. Barcoded adapters ligated to fragments by an A-to-T ligation step followed by size 
selection on agarose gel. DNA bands corresponding to approximately 1000bp were sliced out of 
the gel and purified using the Quantum Prep Freeze’N’Squeeze DNA Gel Extraction Spin 
Columns (Bio-Rad, Hercules, CA). Purified genomic DNA was consequently PCR amplified, and 
quantitated by qPCR, followed by equimolar pooling. The pooled trio was sequenced on a single 
HiSeq2000 flowcell using multiplexed, paired sequencing chemistry for 100 bp read length. 
Whole Exome Sequencing 
Coding regions were captured using TruSeq Exome Enrichment Kit v2 (Illumina, San 
Diego, CA) and SureSelectXT Human All Exon V5 (Agilent, Santa Clara, CA) following 
manufacturer recommended protocol. Sequencing was performed after prepared samples were 
pooled in pools of 6 for TruSeq Exome libraries, or pools of 8 for SureSelect libraries. Each pool 
was sequenced on two lanes of a Hiseq2000 flowcell using multiplexed paired end chemistry and 
101bp read length with a goal of 100X coverage.  
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RNA preparation and sequencing 
Total RNA was isolated from PaxGene blood tubes (Qiagen, Georgetown, MD) using 
manufacturer recommended protocol. The purity of the total RNA was assessed using Nanodrop 
ND-1000 (Thermo Scientific, Wilmington, DE), and integrity was assessed by BioAnalyzer 2100 
(Agilent, Santa Clara, CA). Samples with an RNA integrity number (RIN) of at least 5 were used 
in this study. mRNA libraries were prepared using Illumina TruSeq stranded RNA library 
preparation kit and Illumina TruSeq RNA library preparation kit v2 (Illumina, San Diego, CA). The 
choice of kit was consistent within families. The Illumina sample preparation kits utilize oligo-dTs 
hybridized to magnetic beads to purify the mRNA molecules followed by thermal fragmentation. 
The fragmented RNA molecules were converted to first strand cDNA by random hexamer primers 
and reverse transcriptase enzyme. DNA Polymerase I and RNase H were used to polymerize 
second strand of cDNA. Double stranded cDNA molecules were end repaired to obtain blunt 
ends, which was followed by ligation of a single A base to each 3’ end. Sequencing adaptors with 
unique barcodes and T overhang were ligated to A-tailed cDNA fragments creating a final 
sequencing library. Libraries were amplified to increase cDNA yield for sequencing and final 
amplified libraries are quantified by qPCR. Final libraries were evaluated for fragment size 
distribution using Agilent BioAnalyzer 2100. Stranded RNA library preparation includes addition of 
Actinomycin D to reduce DNA-dependent synthesis during first strand cDNA synthesis. Strand 
specificity was achieved by incorporating dUTP instead of dTTP in second strand of cDNA. 
Quantified libraries were equimolarly pooled based on qPCR concentrations into pools of 4, and 
final library pools were quantified before cluster generation for sequencing. Each pool was 
sequenced on a single lane of a HiSeq2000 flowcell using multiplexed, paired end sequencing 
chemistry for a 101bp read length. 
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Bioinformatics Analysis 
Upon completion of sequencing runs, raw basecall files were converted to sequenced 
reads in FASTQ format using CASAVA 1.8.2 (Illumina, San Diego, CA). The fastqc package was 
used to evaluate the raw reads for overall quality (fastqc). Reads were aligned to human 
reference genome hs37d5.fa from the 1000 Genomes Project. The reference genome contained 
contigs associated with ribosomal unit, cancer causing viruses, and ERCC spike-ins. Alignment 
was performed by mem module of the Burrows Wheeler Aligner (BWA v0.7.8) (Li 2013), and 
binary alignment files were generated by SAMTOOLS v0.1.19(H. Li et al. 2009). After alignment 
the base quality scores were recalibrated and joint indel realignment was performed on the BAM 
files of each family member using Genome Analysis Toolkit (GATK v3.1-1)(McKenna et al. 2010). 
Duplicate read pairs were marked using PICARD v1.119 (picard). Single nucleotide 
polymorphisms (SNPs), short insertion and deletions were identified using HaplotypeCaller 
module of GATK. 
RNA data 
 Reads were aligned to human reference genome hs37d5.fa as described above. 
Alignment was performed by Spliced Transcripts Alignment to a Reference (STAR_2.3.1z_r395) 
(Dobin et al. 2012) and binary alignment files were generated by SAMTOOLS v0.1.19(H. Li et al. 
2009). Alignment was facilitated using known transcript structure of the human genome from 
Homo sapiens GRCh37.74.gtf (ftp://ftp.ensembl.org/pub/release-74/gtf/homo_sapiens/). 
Duplicate read pairs were marked using PICARD v1.119 (picard). Final bam alignments were 
used to estimate gene expression abundance in the form of normalized FPKM values (Fragments 
Per Kilobase Of Exon Per million Fragments Mapped) using the Cufflinks 2.2.1 package(Trapnell 
et al. 2013). Library size normalization was performed across all the families presented as 
follows: Post BAM file generation, individual BAM read alignment files were processed by 
cuffquant module of Cufflinks. Cuffquant essentially takes a transcript annotation and an 
alignment file from the RNA-seq experiment and pre-processes the information in the alignment 
with reference to the transcript coordinates by generating a binary output that is an input to 
cuffnorm, reducing the computational burden on the normalization step. The sample level output 
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of cuffquant module is the input for the next module called cuffnorm. Cuffnorm takes input 
reference annotation and a list of output files from cuffquant, and it normalizes FPKM 
abundances across all the input based on geometric mean of all samples in the normalization and 
controlling for library size. We normalized FPKM abundances across 79 enrolled participants from 
25 families including patients and their biological parents described in this chapter. 
We used the cuffdiff2 module of Cufflinks to estimate differential gene expression of 
annotated transcripts. In each comparison the biological parents were assigned as “control”, and 
thus differential gene expression was based on parent compared to offspring/patient. Cuffdiff 
applies a geometric normalization method the number of fragments mapping to each transcript 
and applies an algorithm that considers cross-replicate variance and uncertainty in read mapping 
to different isoforms of the same gene(Trapnell et al. 2013). It models fragment counts using the 
beta negative distribution and reports change in expression between conditions (eq, parents, 
patient) on gene level with statistical significance. Cuffdiff2 calculates the log2 foldchange of gene 
expression between conditions. In those genes where one of the conditions had zero mapped 
fragments the foldchange is positive or negative infinity depending which condition has zero 
fragments.  
Normalized FPKMs and cuffdiff2 analysis output were inserted into an in-house relational 
database. The Mongo database was based on dynamic, document style data structure that 
allowed for horizontal and vertical scaling giving flexibility to storage and access to ever-
increasing omics data (mongo). We reduced the cuffdiff2 output by filtering out genes assigned 
“FAIL”, “LOWDATA”, “HIDATA”, or “NOTEST”. 
Estimation of alternative exon usage was performed using the R 3.1.2/Bioconductor 
package DEXSeq v.1.12.2(Anders, Reyes, and Huber 2012). This method is based on the counts 
of mapped reads overlapping well annotated exons. If read overlaps exon boundaries of multiple 
overlapping transcripts with different boundaries for the exon, DEXSeq merges all the boundaries 
of the exons into a single feature and breaks it up into multiple “counting bins”. Reads were 
counted that overlap exon boundaries in protein coding regions using a flattened gtf annotation 
based on Homo sapiens.GRCh37.74.gtf. We excluded all overlapping exons of different genes to 
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reduce the number of merged exons as DEXSeq does not count overlapping exons into their own 
respective bins. After read count DEXSeq uses sizefactor obtained from the geometric mean 
coverage of each exon across conditions to report normalized exon coverage “exonBaseMean” 
as the abundance estimate of exon expression. The read count dispersion due to technical and 
biological variability is estimated for each condition and a generalized linear model is used to 
estimate differential exon usage for each counting bin(Anders, Reyes, and Huber 2012). Based 
on DEXSeq read count we estimated a normalized coverage difference between the conditions 
(E). For each sample we calculated the total number of reads mapping to all counting bins (Na, 
Nb…Nn). Next we obtained the ratio of counts per bin (Ci) over all the reads mapping to all 
counting bins for each sample across all counting bins. Finally we obtained a relative coverage 
difference in each exon (Ei) between the conditions by dividing the normalized count in the 
condition 1 (patient) with sum of normalized counts in condition 2 (parents) as seen in Equation 2: 
𝐸𝑖 = 𝐶𝑖𝑎𝑁𝑎Σ 𝐶𝑖𝑏𝑁𝑏  
The DEXSeq output and the calculated coverage difference were inserted into in-house mongo 
database. We used exonBaseMean and normalized coverage difference (nDiff) as 
measurements in multivariate outlier analysis of exons expression. 
Variant Annotation Matrix 
Variants identified by the HaplotypeCaller were inserted into mongo database for each 
family from VCF formatted variant list, followed by annotation by snpEff according to Homo 
sapiens GRCh37.74 annotation(Cingolani et al. 2012). SnpEff annotated variants with their 
predicted functional impact on amino acid change, protein structure. We included annotations for 
known canonical transcripts only. In addition, variants were annotated with prediction scores for 
functional, pathogenic affect (SIFT, CADD, MutationTaster), conservancy (phyloP, phastCons), 
and population frequency (dbSNP141, Exome Sequencing Project, 1000 Genomes) using the 
collection of annotations stored in dbNSFPv2.8 (P. C. Ng and Henikoff 2003; Kircher et al. 2014; 
Schwarz et al. 2014; X. Liu, Jian, and Boerwinkle 2013; Pollard et al. 2010; Siepel et al. 2005; 
  88 
Consortium et al. 2010). Genotype-phenotype correlation from ClinVar was added. ClinVar 
contains genomic variants and their relationship to observed phenotype, health status, 
categorizing them based on likeliness of pathogenicity(Landrum et al. 2014). We also added 
disease gene annotation from Clinical Genomics Database(Solomon, Nguyen, and Bear 2013) 
which contains over 3000 genes that are know to be associated with genetic conditions. This 
database was curated into adult and pediatric disease causing genes with information on 
available intervention, and primary organ system to be affected. Population frequency estimates 
from large-scale exome sequencing project, the Exome Aggregation Consortium were also added 
to variant annotations (Exome Aggregation Consortium). We removed all variants that fell within 
5’ and 3’ UTR regions, introns, upstream or downstream of genes, intergenic variants with the 
expectation that most rare, functional variants that may be detected by mRNA sequencing will lie 
within amino acid coding regions. Variants with a phred-scaled genotype confidence quality (GQ) 
of less than 90, and phred-scaled probability estimate (QUAL) that the SNP event exist of less 
than 500 as described in the VCF format guide were removed (Consortium et al. 2012). 
Annotated variants were further filtered for an estimated allelic frequency of less than 5%, a 
measurement taken from the maximum population frequency of the population frequencies 
reported in dbNSFP v2.9(X. Liu, Jian, and Boerwinkle 2013).  
Multivariate Outlier Analysis  
 Central to multivariate analysis is the definition of objects and the number and nature of 
variables that is to be analyzed for each object. In addition interpretation of multivariate data 
depends on the relationships we set out to observe; whether we are looking for relationship 
between the objects or the variables. (Jombart, Pontier, and Dufour 2009). In this study we 
defined objects as patients and the variables as measurements obtained from RNA-seq analysis 
with the intention to study relationship between patients in terms of outlier behavior. Outlier 
behavior was estimated in a gene and exon level. Thus for each expressed gene and exon we 
built two-dimensional matrices with two vectors. In each matrix we tested a single gene or exon 
with n objects and p variables. In gene-based matrix the variables included two vectors of 
continuous values of log2 transformed, normalized gene abundance defined by the FPKM value 
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from Cufflinks, and log2 fold change expression difference between each patient and their 
parents from Cuffdiff. In exon-based matrix for n objects we included two vectors with continuous 
values of log2 transformed, normalized exon coverage defined by exonBaseMean value in 
DEXSeq, and log2 normalized exon expression difference defined by the nDiff value as described 
above in Methods. We set following rules for estimation of the distance scores for each gene: 1) 
each vector had to have the same dimension, thus both FPKM and log2foldchange must be 
obtained for a patient, 2) genes with zero covariance were filtered out, 3) each value within the 
vectors had to be numeric, thus genes with a log2foldchange of negative or positive infinity were 
given an arbitrary value of -19 or +19, respectively. We applied this method to account for the fact 
that in differential expression, the lack of read fragments in one of the two condition results in a 
logarithmic ratio that may not capture well biological significance. Since, we were looking for 
extreme events, insufficient read fragment coverage can indicate biologically important events 
that one could pursue. 4) We defined the detection limit of a gene to FPKM ≥ 0.1, and required 
that >90% of objects have an expression above defined limit. For each gene that passed 
detection criteria we added 0.1 to the FPKM to facilitate our ability to transform the FPKM values 
to a logarithmic scale and apply uniformly scaled data for distance analysis. 
Estimation of Mahalanobis distance for expressed exons followed similar rules as 
described for genes. We used exonBaseMean of ≥1 as our detection limit and required at least 
90% of patients to have an expression above detection limit. We performed logarithmic 
transformation of exonBaseMean and nDiff prior Mahalanobis distance analysis.  
We used the native Mahalanobis function of the R statistical package wrapped in a perl script to 
first query our database of RNA-seq expression results for each gene and exon across the 29 
patients followed by loading the descriptors into the n x p vector matrix for distance analysis in R 
programming language(Rv3.1.2). MD score (MD) was determined for each object (n) in the n x p 
matrix with respect to the vector means (µ) for each vector p, and the covariance (S) of all vectors 
as shown in Equation 3: 
MD2 = (p - µ)’S-1(p - µ) 
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Statistical Analysis.  
We evaluated the gene-based and exon-based MD scores using a non-parametric 
Kolmogorov-Smirnov test to compare the two data distributions. This test has the advantage of no 
assumptions about normality of the distributions. Similar distributions would suggest that 
measurements are taken from the same data and exon and gene based scores would be 
redundant. Levene’s test for equal variance test was used to test for variance in the MD scores 
grouped based on their functional impact. MD scores were grouped into “high” or “moderate-to-
low” groups as described in the Results section. Levene’s test was used to test the first 
assumption of the Mann-Whitney rank sum test of equal variance. Using Mann-Whitney of the 
MD scores, we are able to compare the variants predicted to have high or moderate-to-low 
functional impact. Mann-Whitney is a non-parametric rank sum test that can test for the null 
hypothesis of no difference in the mean ranks of the data distributions. A significant difference in 
mean ranks between high and moderate-to-low functional impact would indicate a more 
significant impact on transcription by one of the functional classes. Mann-Whitney was performed 
using the Wilcox test.  
In addition the variants were further grouped into nine functional classes including 
frameshift, insertions-deletions, missense, sequence feature, splice site, splice region, start/stop, 
synonymous , start codon as described in the Results section. Kruskal-Wallis test was used to 
test the hypothesis that MD scores among the nine functional classes show different distribution 
of scores. This test is essentially an extension of the Mann-Whitney test for comparing more than 
two data sets. When multiple data distributions are compared the Kruskal-Wallis tests for the null 
hypothesis that the median ranks of all groups come from the same distribution. A significant 
finding would suggest that one of the data distributions is enriched for higher MD scores. Since 
the Kruskal-Wallis does not identify which functional class is enriched for outliers if the null 
hypothesis fails, we performed pairwise, non-parametric test of rank sums by Dunn’s test (Dunn 
1964). Dunn’s test uses average ranking from Kruskal-Wallis rank sum test and test the null 
hypothesis of no difference in pairwise manner. It reports a z score as test statistics based on the 
difference of the average ranks and the sum of ranks between the two groups. The pairwise 
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probability that one random value from a group is larger than a random value from another group 
can then be evaluated for multiple testing corrections. All tests were preformed in R programming 
language using ks.test, levene.test. dunn.test functions. 
 
Results 
 We will present the results in three sections.  In the first section the QC metrics of the 
DNA and RNA sequencing will be shown focusing on the obtained throughput and QC metrics 
that are standard procedures for large scale DNA and RNA sequencing projects.  In the second 
section, we analyze the multivariate MD score’s ability to discern transcriptionally functional 
variants.  In the third section, we will present two families applying the approaches within the 
context of a genetic diagnosis. 
Quality Control Metrics.  We first provide quality control metrics for the sequence data 
we generated.  Between 2012 and 2014 we obtained whole genome data for 7 patients and 6 
parents for 3 trios and 4 singletons for a total of 7 families with WGS data. Median genomic 
coverage for the trio sequenced at TGEN was 23.2 ± 0.5X and for the individuals sequenced at 
Illumina was 43.1 ± 6.5X (Table 15). Genomic coverage analysis indicated that in each TGEN 
prepared genome >90% of bases were sequenced at least 10X depth, and for the Illumina 
genomes >90% of bases for sequenced at least 20X reads depth (Figure 17A). We must 
recognize that the genomes sequenced at TGEN were prepared using non-standard methods to 
obtain long insert library of approximately 1000bp. Standard Illumina library preparation methods 
target a 350bp insert size and kits designed for clinical sequencing service have been optimized 
for throughput and quality. In light of this, the long insert libraries of samples 004_1, 004_2, and 
004_3 have performed well. In addition we sequenced 90 whole exome samples from the 
remaining 19 families. The mean per base coverage for the exome target regions was 85 fold, 
with 93.1% of bases covered more than 10 fold and 67.1% above 50 fold (Figure 17B.) On 
average 4.5 million SNVs and short indels were identified in the whole genome data and 475 
thousand in the exome data. The average dbSNP rate that shows the proportion of variants 
identified previously in human populations is 0.96 for the genomes and 0.94 for the exomes which 
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is in line with previous findings by the 1000 Genomes project (Consortium et al. 2012). We find on 
average the exome data resulted in more non-synonymous variants called 3,695 in exomes 
compared to 2,965 in the genomes. Exome sequencing achieves a higher overall coverage in 
exons than genome sequencing thus increasing confidence in variant calls in exome data. 
Interestingly exome analysis resulted in a lower average calls in start sites (n=151) compared to 
the genomes (n=180). The capture of exon 1 in next-generation sequencing is a known issue 
caused by a higher GC content in first exons. Thus exome kits are challenged by this and the 
optimization of exome capture kits to leverage the efficient capture of first exons with start sites is 
an ongoing process. The results of variant calling and annotation can be found in Table 16.  
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Table 15.  
Quality metrics of Whole Genome Sequencing 
Individual Gender 
Total 
Reads(M) 
Read 
Length 
(bp) 
% Reads 
Aligned 
(Pairs) 
QC 
Aligned 
Bases 
(M) 
Coverage 
(X) 
Insert 
Size 
(bp) 
% 
Duplicates 
004_1 Male 897 101 99.78 88,648 22.6 722 15.05 
004_2 Female 895 101 99.85 88,636 23.7 701 11.99 
004_3 Male 884 101 99.86 87,498 23.3 708 11.73 
005_1 Female 1,163 100 99.51 114,343 35.7 302 2.07 
006_1 Female 1,258 100 99.51 123,051 38.8 304 2.16 
011_1 Female 1,296 100 99.74 127,581 38.7 295 3.81 
011_2 Female 1,762 100 99.73 172,955 52.5 285 4.25 
011_3 Male 1,137 100 99.69 111,390 33.8 294 3.47 
012_1 Female 1,526 100 99.42 149,566 47.6 313 2.78 
014_1 Female 1,565 100 99.60 154,337 48.5 317 2.70 
014_2 Female 1,123 100 99.66 110,738 48.5 323 2.31 
014_3 Male 1,541 100 99.66 152,066 47.5 303 2.95 
020_1 Female 1,310 100 99.89 129,322 39.4 280 3.66 
 Abbreviations; M= million, bp=base pairs. 
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Figure 17. Coverage analysis of WGS and WES. Plot shows sequencing depth obtained for 
whole-genome sequencing (A) and whole-exome sequencing (B).  
A) Samples 004_1, 004_2 and 004_3 are the long insert libraries with a lower overall coverage 
that can be seen by the three curves to the left. In these samples 50% of bases were covered by 
at least 20X The Illumina sequenced samples show that 50% of bases are covered at a minimum 
of 30X (011_3), and in some cases 50X of average depth is achieved for 50% of bases (014_2). 
B) Histogram showing the percent of targets (exons) with average coverage of 10X, 50X, 100X. 
Target coverage for 90 exomes show that samples achieve at least 10X average target coverage 
in >90% of targeted regions, and between 70-80% of targets are covered at 50X for most 
exomes. 
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Table 16.  
Variant call metrics for 32 families.  
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This table shows the variant call summary of the family based whole genome and exome sequencing for all 
study participants presented in all chapters of this dissertation. In terms of quality metrics the most important 
QC metrics include the dbSNP rate and transition-transversion ratio (Ti/Tv). 
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For RNA-seq, on average, 96,5 million reads mapped to reference genome for a total of 
90 RNA-seq libraries (Figure 18A) The smallest library size was 26.8 million reads up to the 
largest library size of 239.8 million reads. Refer to sample-by-sample RNA-seq metrics to 
Appendix C. The RNA content of the prepared libraries shows that on average 60.9% of bases 
were amino acid coding, 29.6% were UTR bases, 5.8% intronic, 3.7% intergenic, and 0.07% were 
ribosomal bases (Figure 18B). We found 14,441 protein coding genes with a median FPKM of 
greater than zero in all study participants. We found 190,219 exons in 18,378 protein coding 
genes with an exonBaseMean above zero and 133,752 exons in 14,055 genes with a median 
exonBaseMean of 1 (Table 17). 
 
Table 17.  
Expression estimates for protein coding genes and exons. 
FPKM 
threshold 
0 0.001 0.01 0.1 1 5 10 50 100 500 1000 
# genes 14,77
1 
14,642 14,484 13,067 10,653 7,745 5,669 1,569 775 139 66 
% genes 79.87 79.18 78.32 70.66 57.61 41.88 30.65 8.48 4.19 0.75 0.36 
baseMean 
threshold 
0 0.001 0.01 0.1 1 5 10 50 100 500 1000 
# exons 190,2
19 
148,09
1 
148,09
1 
148,09
1 
133,75
2 
114,22
0 
102,85
7 
65,23
9 
45,44
5 
12,46
4 
6,00
1 % exons 86.28 67.17 67.17 67.17 60.97 51.81 46.65 29.62 20.61 5.65 2.72 
% genes 100.0
0 
82.91 82.91 82.91 76.47 68.62 64.75 54.14 47.47 23.86 13.8
9 This table shows the number of protein coding genes and their percentage to the total at various expression levels 
estimated for genes (FPKM) and exons (baseMean) 
 
We evaluated the gene expression correlation of protein coding genes to find outlier 
samples that may bias multivariate analysis (Figure 19A). Selection was done gene-by-gene 
those protein coding genes that showed expression >0 FPKM in at least one of the study 
participant (n=15,454). Correlation was also evaluated in the exon usage data. We selected 
exons in protein coding genes that were expressed in at least one of the patients with an 
exonBaseMean of >0 (n=123,945). Family 0002 patients were highly correlated as expected as 
exonBaseMean is calculated across conditions, and in each patient exon usage was compared to 
parents’ exon expression (Figure 19B). Overall correlation across exons was Spearman’s rho 
>0.9 suggesting high quality data. 
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Figure 18. Mapping of RNA-seq data. A) Distribution of high quality sequenced reads across 90 
individuals from RNA-seq presented in all 3 chapters. B) Proportion of bases sequenced across 
individuals in relation to their RNA contents. The horizontal axis shows each prepared samples  
and the vertical axis the % bases mapping to mRNA species.  
 
 
 
 
 
 
 
 
Figure 19. Sample correlations of gene and exon expression. A) Pairwise correlation of 
normalized FPKMs in protein coding genes across 25 families presented in this chapter for outlier 
analysis. The higher the correlation on a 0-1 scale the more red the cell’s color. Each cell 
represents a comparison between two samples. B) Pairwise correlation of exonBaseMean 
between 25 families (29 patients). The more red the cell the higher the correlation. These plots 
show high correlation above 0.8 for gene based expression and >0.9 for exons, indicating that 
sequencing libraries were of good quality. 
 
0.00
0.01
0.02
0.03
0 50 100 150 200
reads (million)
de
ns
ity
0.0
0.2
0.4
0.6
0.8
samples
%
 b
as
es
CODING
INTERGENIC
INTRON
RIBOSOMAL
UTR
A B 
A B 
0139_3
0152_3
0034_1
0025_1
0025_3
0024_1
0004_1
0033_3
0103_3
0004_3
0025_2
0014_2
0152_2
0117_2
0048_2
0059_1
0152_1
0117_3
0139_1
0034_2
0001_2
0001_3
0016_1
0048_1
0033_1
0033_2
0157_1
0103_2
0139_2
0157_3
0024_2
0016_2
0016_3
0018_3
0018_1
0018_2
0091_2
0103_4
0004_2
0091_3
0091_1
0002_5
0049_1
0019_1
0001_1
0005_1
0006_1
0002_6
0047_1
0005_2
0002_1
0002_4
0002_2
0019_2
0103_1
0005_3
0006_3
0047_2
0006_2
0002_3
0034_3
0011_2
0011_1
0014_1
0014_3
0059_2
0008_3
0049_3
0117_1
0008_2
0049_2
0008_1
0024_3
0019_3
0047_3
0157_2
0059_3
0048_3
0011_3
0.9 0.94 0.98
Spearman's rho
0004_1
0091_1
0025_1
0103_2
0103_1
0157_1
0033_1
0018_1
0024_1
0016_1
0059_1
0049_1
0048_1
0117_1
0008_1
0011_1
0152_1
0139_1
0001_1
0034_1
0002_4
0002_5
0002_2
0002_1
0014_1
0019_1
0006_1
0047_1
0005_1
0.94 0.97 1
Spearman's rho
  98 
 
Overall assessment of RNA-seq found that 53.2% of protein coding genes (n=9,831) 
were expressed in at least 90% of samples above the detection limit of FPKM >= 0.1, and 64,1% 
of protein coding exons were expressed above the detection limit of exonBaseMean >=  1.0. This 
allows us to investigate over half of protein coding genes in whole blood for multivariate outlier 
testing analysis (Figure 20). 
 
 
 
Figure 20. Transcript abundance of protein coding genes. The x-axis indicates FPKM thresholds 
and the vertical axis indicates the number of protein coding genes where >90% of participants 
had an FPKM above threshold. The orange color indicates all protein coding genes and the blue 
bars indicate genes in the Clinical Genomics Database. This plot shows that we could study over 
60% of protein coding genes in whole blood above our detection limit of 0.1FPKM. When looking 
at genes that are known to cause disease we obtain a similar percentage at 0.1 FPKM. 
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Multivariate analysis by Mahalanobis distance. We selected RNA-seq data types of 
gene and exon expression as the basis for multivariate analysis because of the availability of 
relatively straightforward techniques to obtain their measurements, and their measurements could 
be used to correlate expression with in silico predictions of variant affect to gene function. Gene 
expression and differential gene expression are the most common methods to quantitatively and 
qualitatively study transcriptomic diversity and its relation to phenotype. These measurements are 
rapidly approaching their applications in clinical studies showing high correlation between 
sequencing platform and improved accuracy in their measurements (S. Li et al. 2014; Risso et al. 
2014). Selection of exons during splicing can have a great impact of mRNA complexity and 
protein diversity in the cell. It is also suggested that over 95 percent of genes are spliced that 
leads to inclusion of different sets of exons in mRNA (E. T. Wang et al. 2008). In addition, exon 
skipping is the most common mechanism of alternative splicing occurring in over 38% of genes 
(de Klerk and 't Hoen 2015). DEXSeq provides exon-by-exon information on splice events without 
considering isoform complexity thus significant findings cannot be correlated with isoforms found 
in the tissue. Sulem et al. (2015) showed that 74% loss-of-function variants, including splice site, 
have effect on all transcripts of the gene.  
Mahalanobis distance is a unitless, descriptive measure of relative distance of a data 
point from the centroid of the data distribution taking into account the correlation of each data 
point within the multivariate dataset by estimating the covariance (Mahalanobis 1936). Calculation 
of a covariance matrix is essentially a normalization method, thus Mahalanobis analysis does not 
requires input data to be normalized or scaled to a common scale. However, as a proof-of-
concept we brought all multivariate to a common scale and used log transformed FPKM, 
exonBaseMean, and nDiff to match log transformed fold change from differential expression. 
Covariance estimation is a critical step in Mahalanobis analysis, because without covariance 
distances between multivariate would simply be the Euclidian distance that does not capture the 
relationship between the data points (De Maesschalck and Jouan-Rimbaud 2000). In addition, the 
large dynamic range of achieved RNA-seq experiments warrants data transformation to improve 
confidence in prognostic metrics and make data more amenable to analytical tools that assume 
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normal distribution of input (Zwiener, Frisch, and Binder 2014; Risso et al. 2014). While our RNA-
seq data does not follow normal distribution even after transformation, Kothari et al. (2013) 
reported successful application of Mahalanobis distance in a multivariate data space of gene 
expression and differential gene expression to identify outlier genes for the discovery of clinically 
actionable kinase gene targets in cancer therapies. 
 In order to integrate candidate variants we calculated outlier MD scores across 29 
patients for genes and exons harboring rare variants by calculating the MD score for each 
candidate variant (post-filtering) and each individual. By example, a variant (GeneX Y555C) 
would have an associated outlier score such as ‘MD score = 1.32’. In total 25,053 variants 
remaining after variant annotation and filtration for frequency were scored in 7,222 genes across 
the patient cohort. The number of variants scored can be found in Table 18. The scores ranged 
between 19.2558-0.0006 for genes and between 25.4-0.0009 for exons. Next we filtered our list 
to those genes with a single variant within patients and obtained 18,834 variants in 7,043 genes. 
The range of scores was 19.3-0.0001 for gene-based scores and did not change for exon-based 
scores (Table 18). The highest gene-based distance score was seen in 0002_4 (MD score = 
19.3) and highest exon score was detected in 0103_1 (MD score = 25.4). 
On average there was 863±200 variants in each patients with scores for both genes and 
their exons. The distribution of gene and exon distance scores indicated non-normal, right 
skewed distribution with very long tails for both scores suggesting that most variants have similar 
functional impact across patients (Figure 21). This follows our expectations that variants with 
functional impact that deviate from general tendencies will be rare and likely patient specific. We 
performed a bootstrap version of Kolgomorov-Smirnov test to find out if the gene and exon MD 
scores come from same distribution in the full and filtered dataset. Hypothesis testing is done with 
the null hypothesis that the two data sets come from the same distribution. Bootstrapping is 
performed by Monte Carlo simulations and allows for non-continuous data or data with many ties. 
Our data has many ties as many variants may have the same MD scores. Two-sample KS test 
indicated that gene scores and exon scores are not coming from the same distribution for full 
dataset and filtered dataset (full: Kolmogorov-Smirnov, D= 0.0491, P= 2.2e-16; filtered D= 
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0.0357, P= 7.735e-11). There are weak, linear relations between gene and exon distance 
measurements and overall exon scores tend to be higher than gene scores. (Spearman’s Rank, 
S = 699004637637, P < 2.2e-16, rho= 0.37232) (Figure 22). Proportion of shared variance 
between the gene and exon ranked scores shows that little variance in one distance is explained 
by variance the other distance (R2=0.1386) suggesting that the two distances capture different 
properties of the transcriptome. 
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Figure 21. Distribution of MD scores. A. Scores for variants across 29 patients with both gene and 
exon scores n=25,053. B. Scores for variants in single hit genes n=18,834. In general we can see 
non-normal, very right skewed distributions. For both gene and exon scores indicating a very few 
MD scores with very high magnitude for the full datasets and the filtered variants as well.  
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Gene and exon measures for 29 patients.  
Sample ID 
# rare, 
coding 
variants  
# variants 
with Gene 
Score 
# variants 
with Exon 
Score  
max/min  Gene 
Score 
max/min 
Exon Score 
# of 
genes 
scored  
# variants 
with 
Gene/Exon 
Scores 001_1 1046 669 622 10.5/0.003 6.5/0.00009 475 594 002_5 1574 1070 928 11.5/0.0003 15.8/0.002 694 902 
002_2 1574 1070 928 8.1/0.003 9.3/0.006 698 906 
002_1 1574 1077 928 6.9/0.0001 12.1/0.001 699 907 
002_4 1574 1077 928 19.3/0.002 5.3/0.003 698 906 
004_1 524 333 314 16.0/0.007 19.8/0.05 243 302 
005_1 863 537 447 6.1/0.002 12.0/0.01 368 434 
006_1 1253 779 686 11.0/0.001 7.5/0.001 531 667 
008_1 1979 1268 1143 13.6/0.0001 17.8/0.007 807 1085 
011_1 2110 1271 1149 6.6/0.0001 9.7/0.005 792 1100 
014_1 2354 1505 1469 12.9/0.05 10.3/0.004 818 1295 
016_1 1994 1292 1955 11.7/0.002 11.8/0.002 566 1092 
18_1 1553 1012 1512 17.3/0.03 21.5/0.006 661 845 
19_1 1508 977 1468 7.2/0.0003 6.2/0.001 629 814 
24_1 1499 960 1473 17.9/0.006 19.7/0.003 634 806 
25_1 1426 944 1394 16.9/0.01 22.5/0.004 645 813 
33_1 1758 1105 1002 10.3/0.00006 20.3/0.001 715 961 
34_1 2022 1351 1153 13.5/0.005 14.4/0.0003 807 1126 
47_1 1330 863 786 10.8/0.0003 5.3/0.0005 593 753 
48_1 1476 899 842 10.9/0.0002 21.7/0.006 636 789 
49_1 1319 871 786 8.5/0.004 7.9/0.0004 594 758 
59_1 1851 1181 1057 11.3/0.0006 22.2/0.0006 780 1012 
91_1 1286 818 738 10.5/0.0002 20.1/0.0002 562 696 
103_1 1731 899 960 15.8/0.0003 25.4/0.3 646 831 
103_2 1731 952 960 13.5/0.003 20.3/0.09 757 861 
117_1 1723 1065 1000 12.6/0.0008 23.2/0.002 836 944 
139_1 1610 1085 985 15.8/0.003 13.3/0.001 684 947 
152_1 1545 1003 916 17.7/0.0005 14.0/0.003 662 882 
157_1 1823 1173 1068 9.6/0.0004 12.4/0.005 848 1025 
This table indicates the range of scores from minimum to maximum for each patient. The last 
column indicates the number of variants successfully evaluated for both gene-based and exon-
based outlier analysis. 
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Figure 22. Gene and exon distance correlations. Black dots indicate variants (n=18,834) and their 
associated gene and exon scores in the 29 patients. There is a general trend of higher exon 
scores. Linear regression suggests a linear relationship between the two scores with a correlation 
coefficient of 0.37 indicating a medium effect size.  
 
Next we evaluated the distribution of MD scores with relation to the variants’ functional 
impact. We defined two variant classes high, and moderate-to-low. Based on available variant 
annotation, high functional impact variants predicted to cause frameshift, start codon loss, stop 
codon gained, stop codon lost, splice donor, and splice acceptor changes. The moderate-to-low 
functional impact variants were defined as missense, insertions-deletions, splice region, 
synonymous, start codon gain, and sequence feature consequences. Levene’s test for equal 
variance within the functional classes revealed that gene scores have the same variance in both 
full dataset (Levene's Test, F=1.1541, P=0.2827) and filtered dataset (Levene's Test, F=0.3218, 
P=0.5705). We found that exon scores in the filtered dataset had unequal variances (Levene's 
Test, F=5.0929, P=0.02403), but in the full dataset variance between functional classes was 
equal (Levene's Test, F=0.0052, P=0.9424). Levene’s Test tests for one of the assumptions of 
Mann-Whitney rank sum test, which is equal variances of the data distributions. Gene and exon 
scores indicate that distributions of distance scores for HIGH and MOD-LOW impact variants are 
similar (Figure 23). Based on the median ranks of gene-based scores we find that variants 
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predicted in high functional impact class have higher distance scores in the full variant list (Mann–
Whitney U ,U =7492668, P=0.006378,two-tailed) and among filtered variants as well (Mann–
Whitney U ,U = 3375335, P= 0.001005,two-tailed) (Figure 24). Exon scores are not associated 
with functional class in either the full or filtered variant list (full list: Mann–Whitney U ,U =3186404, 
P=0.1741,two-tailed, filtered: Mann–Whitney U ,U =7176454, P=0.378,two-tailed). The median 
MD scores for genes were highest for variants with high functional impact (1.57) compared to 
1.28 for moderate-to-low impact variants (Table 19). Results indicate that high impact functional 
variants have larger MD scores than variants with low moderate-to-low functional class based on 
overall gene scores. Lack of difference between the two functional classes among exon scores 
can be attributed to cryptic splice sites and alternate exon usage impacted by missense variants 
(Ahlborn et al. 2015). 
 
Figure 23. Distribution of MD scores within functional classes. Horizontal axis indicates the gene 
and exon scores and the vertical axis shows the density distribution. The orange line shows 
scores for variants in moderate-to-low impact functional class and yellow indicates variants in 
high impact functional class. The distribution of these scores also follows a non-normal, right 
skewed distribution. 
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Table 19.  
MD scores for high and moderate-to-low functional variants. 
  Single Hit Genes Full Dataset 
 Gene Score Exon Score Gene Score  Exon Score 
 High Mod-Low High Mod-Low High Mod-Low High Mod-Low 
Variants (n) 330 18,504 330 18,504 574 24,479 574 24,479 
Mean 2.26 1.96 2.25 1.98 2.13 1.97 2.02 1.95 
Median 1.57 1.28 1.28 1.22 1.52 1.29 1.18 1.20 
 Std.Dev 2.17 2.11 2.58 2.35 2.11 2.37 2.10 2.32 
Min 0.0018 0.0001 0.0054 0.0001 0.0018 0.0001 0.0053 0.0001 
Max 12.66 19.26 12.61 25.45 12.66 19.26 12.81 25.45 
P
er
ce
nt
 25 0.73 0.51 0.53 0.51 0.62 0.58 0.53 0.51 
50 1.57 1.28 1.28 1.22 1.52 1.18 1.29 1.20 
75 2.92 2.91 2.63 2.42 2.78 2.27 2.63 2.39 
95 6.97 8.01 6.17 6.80 6.41 7.67 6.19 6.77 
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Figure 24. Variants in different functional class and their MD scores. Violin plots of the MD 
distance scores based on functional class (i.e HIGH, MODERATE-TO-LOW). a=includes all 
scored variants across the 29 patients. b=scores for single hit genes across 29 patients. Star 
above plot indicates statistical significance by Mann-Whitney test. The exon scores in the MOD-
TO_LOW group have much longer tails indicating large variance within the dataset. Values in 
HIGH functional class have much shorter tails suggesting that variants with prediction of high 
functional impact are more likely have a more uniform behavior. 
 
Analysis of functional effect for variants with high MD scores 
After evaluating variants based on their predicted functional impact we set out to study 
MD scores based on their position and predicted impact on the mRNA structure. We selected 
genes with single coding variant for each patient. Based on available annotation, we defined 9 
functional classes of variants as frameshift (SnpEff=frameshift), insertions-deletions 
(SnpEff=disruptive inframe insertion, disruptive inframe deletions, inframe deletion, inframe 
insertions) missense (SnpEff=missense), sequence feature (SnpEff=sequence feature), splice 
site (SnpEff=splice acceptor, splice donor), splice region (SnpEff=splice region), start|stop 
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(SnpEff=start lost, stop gained, stop lost), synonymous (SnpEff=synonymous, stop retained), start 
codon (SnpEff= start codon gain, initiator codon). Non-parametric analysis of variance of gene 
and exon scores across the nine functional classes shows that distribution of scores are from 
different distributions with different means and medians. (gene scores: Kruskal-Wallis, H=15.604, 
p=0.05, exon scores: Kruskal-Wallis, H=17.584,p=0.02) (Figure 25). Splice site, frameshift and 
nonsense variants have the highest MD scores for genes on average suggesting that they may 
be related with respect to their impact on transcriptional activity (Table 20). Significant 
dysregulation of transcripts by nonsense variants, especially variants causing nonsense-mediated 
decay has been demonstrated in unaffected populations (MacArthur et al. 2012).  
Pairwise comparisons of MD scores by Dunn’s test reveals that frameshift variants 
impact transcription at highest degree among the 29 patients showing statistical difference from 
indels (P=0.01), missense (P=0.002), sequence feature (P=0.001), splice region (P=0.009), start 
gained (P=0.004), and synonymous variants (P=0.003) (Table 21). Frameshift variants (n=175) 
are more likely to have higher Mahalanobis distances suggesting that they impact “outlierness”, 
although this difference is not seen when frameshift variants are compared with splice site and 
start|stop gained or lost variants (Figure 25A). High confidence, loss of function variants resulting 
in the shift of the open reading frame have been implicated as most likely loss-of-function variants 
(MacArthur et al. 2012). Overall, in our dataset, the greatest difference to the effect genetic 
variants have on transcription is between frameshift and sequence feature variants (Bonferroni 
P=0.024).  
The distribution of distance scores for exon usage is more evenly distributed indicating 
that alternative exon usage is not the function of a single variant type (Figure 25B). Pairwise 
comparison of MD scores shows that frameshift, missense, sequence feature, start|stop and 
synonymous variants in exons are more likely impact exon usage than inframe indels in exons 
(Frameshift-VS-indels P=0.019, missense-VS-indels P=0.019,sequence feature-VS-indel 
P=0.020,start|stop-VS-indels P=0.019, synonymous-VS-indels P=0.009). Interestingly, 
synonymous variants show significant difference from sequence features (P=0.003), and from 
splice site variants (P=0.030). Synonymous variants in exons may lie in exonic splice enhancers 
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and they can impact alternative splicing and protein function (Rice et al. 2013; Sheikh et al. 
2013). Our results also suggest that authentic splice site mutations are not necessarily 
accompanied by alternative exon usage and if exon usage occurs they may have similar 
functional impact across patients.  
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Figure 25. MD scores and functional effect. A=gene scores, B=exon scores. There are nine 
functional effect groups, each colored differently. Overall all groups show a non-normal right 
tailed distribution. Exon scores are more uniform than gene scores. Gene scores show that 
frameshift variants have a higher median MD scores than other groups (frameshift median = 
1.703). 
 
 
Table 20.  
MD scores and functional class. 
Gene Score          
 #/class Min Median Mean Max 25% 50% 75% 95% 
frameshift 175 0.0018 1.703 2.228 9.111 0.785 1.703 2.739 6.967 
indels 280 0.0012 1.267 1.901 13.62 0.511 1.267 2.599 5.657 
missense 6,823 0.0003 1.277 1.975 17.72 0.529 1.277 2.619 6.169 
seq. feature 2,390 0.0001 1.233 1.906 15.97 0.498 1.233 2.504 6.294 
splice site 70 0.0172 1.518 2.243 12.66 0.741 1.518 2.914 6.164 
splice region 1,669 0.0003 1.331 2.057 19.26 0.536 1.331 2.715 6.626 
start gained 344 0.0068 1.336 1.776 10.84 0.580 1.336 2.330 5.534 
start|stop 84 0.0038 1.400 2.327 9.552 0.618 1.400 3.084 7.698 
synonymous 6,999 0.0001 1.283 1.965 17.87 0.532 1.283 2.684 6.105 
          
Exon Score          
frameshift 175 0.034 1.312 2.351 12.61 0.481 1.312 3.164 8.825 
indels 280 0.015 1.107 1.667 11.24 0.427 1.107 1.933 5.785 
missense 6,823 0.000 1.227 1.993 24.17 0.512 1.227 2.421 6.884 
seq. feature 2,390 0.001 1.152 1.859 25.45 0.505 1.152 2.301 6.211 
splice site 70 0.003 1.176 1.963 22.67 0.474 1.176 2.389 7.067 
splice region 1,669 0.005 1.161 2.074 12.08 0.454 1.161 2.688 6.875 
start gained 344 0.010 1.14 2.044 24.96 0.426 1.140 2.341 7.782 
start|stop 84 0.057 1.376 2.177 10.7 0.703 1.376 2.831 6.435 
synonymous 6,999 0.000 1.262 2.009 25.43 0.524 1.262 2.493 6.876 
25%,50%,75%,95%= the percentile cutoff value. 
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Table 21.  
Dunn’s test of pairwise comparisons of functional classes. 
Gene 
Score 
         
 
frameshift indels missense 
seq. 
feature splice site 
splice 
region 
start 
gained start|stop 
synonymou
s 
frameshift  0.351 0.086 0.027 1 0.329 0.147 1 0.106 
indels 0.010  1 1 1 1 1 1 1 
missense 0.002 0.441  1 1 1 1 1 1 
seq. 
feature 
0.001 0.357 0.088  1 1 1 1 1 
splice site 0.318 0.119 0.108 0.068  1 1 1 1 
splice 
region 
0.009 0.280 0.148 0.028 0.162  1 1 1 
start 
gained 
0.004 0.399 0.296 0.482 0.087 0.163  1 1 
start|stop 0.284 0.114 0.099 0.059 0.479 0.157 0.080  1 
synonymo
us 
0.003 0.407 0.378 0.057 0.116 0.197 0.264 0.108 
 
 
          
Exon 
Score 
         
frameshift  0.683 1 1 1 1 1 1 1 
indels 0.019  0.692 1 1 1 1 0.691 0.328 
missense 0.168 0.019  0.714 1 1 1 1 1 
seq. 
feature 
0.059 0.110 0.020  1 1 1 1 0.090 
splice site 0.089 0.076 0.110 0.315  1 1 1 1 
splice 
region 
0.268 0.200 0.455 0.386 0.436  1 1 1 
start 
gained 
0.072 0.212 0.132 0.411 0.316 0.357  1 1 
start|stop 0.335 0.019 0.116 0.052 0.071 0.186 0.056  1 
synonymo
us 
0.232 0.009 0.150 0.003 0.030 0.397 0.075 0.151 
 
 
Columns and rows indicate functional class. Clear cells indicate raw p values of the test statistic 
and grey columns show the Bonferroni correction p –values for multiple testing from Dunn’s test. 
Top table indicates pairwise analysis of gene scores, lower table shows pairwise comparisons of 
exon scores. Red values show p<0.05 significance. 
 
Patients with known causal variants. 
In this section we will show result of Mahalanobis scores from RNA-seq. integrated with 
genomic variants. Integration was performed for each patient and for each rare variant that 
remained after filtration described above in the Variant Annotation section of the Material and 
Methods section.  
We investigated 10 patients with genetic diagnosis prior RNA-seq and multivariate 
analysis. Each patient had a presumed causal variant for a total of 7 genes (Table 22). In two 
families multiple affected siblings were diagnosed with a presumed causal variant (0002, 0103). 
In patient 0001_1 the presumed causal DDC gene had an average normalized FPKM of 0.07 
under the detection limit of this study so no outlier analysis could be preformed. The average 
abundance for the remaining 6 causal genes was FPKM=26.78. In two patients the source of 
causal variation was compound heterozygous mutations (0005_1, 0049_1), three patients de 
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novo variants contributed to disease (0047_1, 0103_1, 0103_2), one patient had a autozygous 
variant (0024_1) and 4 patients from families 0001 and 0002 presented causal variants that did 
not follow Mendelian inheritance. For each patient specific variant we calculated the percentile 
rank of the gene and exon distance measurement associated with the variant. In three patients 
the presumed causal variant ranked in the 95th percentile, and for 4 patients ranked in the 90th 
suggesting that presumed causal variants show elevated impact on gene regulation.  
In general, distance measures for genes range from 48th percentile in family 00024 to the 
top ranked gene based distance score in family 0002. The casual variant ranked 48th percentile is 
a homozygous missense variant and the top ranked variant is a missense variant in family 0002. 
In family 0103 the siblings share a de novo variant but their ranks differ from 83rd percentile for 
0103_1 compared to 96th percentile for 0103_2 indicating that difference in transcript regulation.  
MD scores for exons show a greater variance from the 4h percentile in sample 0047_1 to 
ranking at the top in patient 0002_5. In three patients (0049_1, 0002_5, 0002_2) splice region, 
frameshift and cryptic splice site variations resulted in both exon and gene based distance scores 
in the 90th percentile. This suggests that these variants have a role in alternative splicing. In 
cases where gene based distance scores are not accompanied with high exon based distance 
scores suggests that those variants are silent to alternative exon usage, however they may 
negatively impact mRNA stability which is captured by a gene based distance score that is an 
outlier when compared to the other patients. 
Functional importance of our findings were supported by in silico predictions of high 
conservancy by phyloP and moderate deleteriousness by CADD as listed in Table 22 (Siepel et 
al. 2005; Kircher et al. 2014). 
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Table 22.  
Patients with known causal variants. 
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In the following we discuss two cases where we present the utility of our approach in a 
case where casual mutation was known prior RNA-seq and multivariate outlier analysis, and 
another case where candidate variant was identified after DNA-RNA integration and outlier 
analysis. 
The first family (0002) is a Caucasian family of six with three affected siblings and one 
unaffected sibling (Figure 26A).  The genetic diagnosis in MTFMT took several years and without 
knowledge through extensive functional characterization of a cryptic splice-site, the functional 
importance of the causative variant would have been unknown. In many ways, more efficient 
identification of the causal variant in this case is the goal of our outlier analysis.  
Within the family, patient 0002_1 was described as unaffected born in 2002, then started 
complaining about migraine headaches at age 9.  Overall, this patient had an unremarkable 
phenotype.  
Patient 0002_2 was suspected with Wolff-Parkinson-White Syndrome (MIM:194200) and 
with mitochondrial encephalomyopathy at time of enrollment. She has short stature, which was 
treated with growth hormone. She has learning disability, attention deficit disorder. She has 
cardiac conduction defect that is stable and without episodes of tachyarrhythmia. She has 
exercise intolerance and can walk at most 0.25 mile before getting tired. She has amblyopia and 
wears eye glasses. She is weak, has hyperflexible ankle joints, which was stabilized. She is 
stuttering that is suggestive of Tourette’s Syndrome (MIM:137580). She had cardiac 
catheterization, ablation procedure, tonsillectomy and adenoidectomy to improve sleep. Her 
molecular tests showed elevated plasma and CSF lactate. She has cerebral folate deficiency, 
which is treated with leucovorin. She has decreased methyltetrahydrofolate level.   
Patient 0002_4 is a male patient with a suspected mitochondrial disorder. He presented 
with headaches at 8-9 years of age. He has been having hemiplegic migraine since age 15. His 
molecular tests showed elevated plasma lactate. He has normal plasma amino acids, plasma 
lactate, CSF amino acids, CSF lactate, CSF neurotransmitters, neopterin, tetrahydrobiopterin, 
and methyltetrahydrofolate. He presented with normal cardiac function, and ophthalmological 
pulmonary evaluations were normal. His immunohistochemistry is normal.  His skeletal muscle 
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enzymology shows reduced activity of mitochondrial oxidative phosphorylation (OXPHOS) 
complexes I and III; abnormal high-resolution spirometry on cultured fibroblasts. Genetic testing 
for mtDNA deletions, KCN1A, CACNA1A gene testing are negative.   
Patient 0002_5 is an affected male. Clinical diagnosis at time of enrollment was 
Mitochondrial encephalomyopathy with suspected Leigh Syndrome (MIM:256000). He has 
developmental delay and a coordination disorder. He presented with expressive language 
disorder with dysarthric and delayed speech. He has small stature. He is hyper with short 
attention span. Complex I deficiency is likely; decreased ND6 subunit was observed on skeletal 
muscle biopsy. His MRI showed symmetric frontal white matter (pericallosal) lesions and 
symmetric basal ganglia lesions. EKG and ECHO of heart showed no evidence of cardiac 
disease. Areas of T2 signal abnormality involving the genu of the corpus callosum extending into 
the bifrontal white matter with additional lesions located within the inferior left putamen and 
bilateral subthalamic regions. A small area of patchy enhancement involves the genu of the 
corpus callosum and restricted diffusion is noted around the margins of this dominant lesion 
centered in the genu of the CC and the left inferior putamen lesion. Ophthalmic tests showed pale 
optic nerves. MR Spectroscopy of the brain showed a large lactate peak over normal appearing 
right basal ganglia. He is normal for CSF 5’ pyridoxal phosphate, CSF succinyladenosine, CSF 
neurotransmitters, ceruloplasmin, plasma amino acids, urine organic acids, and urine 
mucoplysaccharides. Lysosomal storage panel and tests for disorders of glycosylation was 
normal. He has abnormally low CSF 5-methyltetrahydrofolate, high CSF lactate, high CSF 
alanine. He has significantly increased myofiber lipid with unremarkable immunochemistry but 
showing complex I defect. He has normal muscle levels of Coenzyme Q10. Genetic testing  for 
PDHA1 gene mutations and for mtDNA point mutations and deletions tests was negative. 
 We sequenced the exome and mRNA of the entire family 0002. Exome sequencing 
achieved an average target coverage of 87.7X across targeted regions. Bioinformatics analysis 
identified 473,005 SNP and short indel variants with 95% of them reported in dbSNP141 and with 
a Ti/Tv ratio of 2.1 (Table 16). A total of 1574 protein coding variants in 1326 genes had a 
frequency of <5% and were evaluated for their impact on expression by Mahalanobis distance. 
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Variant prioritization identified a missense variant in exon 4 of MTFMT gene (NM_139242.3, 
c.626C>T, p.Ser209Leu). Patient 0002_5 and 0002_2 were homozygous for this variant and all 
other family members, including parents were heterozygous. (Figure 26C). The identified variant 
was verified by Sanger sequencing (Figure 26B). This variant is known pathogenic variant 
reported by Tucker et al showing that heterozygous mutation result in a frameshift and premature 
stop codon by skipping exon 4 during pre-mRNA processing in patients with Leigh Syndrome 
(Tucker et al. 2011). This finding corroborated suspicion of Leigh Syndrome in 0002_5 and 
resulted in the diagnosis in the affected patients although the phenotypic heterogeneity was noted 
across siblings. Patient 0002_5 phenotype showed similarity with reported cases and thus he was 
diagnosed with Leigh Syndrome. In addition Haack et al later reported that the exon 4 mutation 
was one of the most frequent mutations in defects of mitochondrial oxidative phosphorylation 
(OXPHOS) (Haack et al. 2014).  
Analysis of RNA-seq reads supports exon skipping in the homozygous patients, with 
most reads spanning the exon 3-4 and exon 4-5 boundaries (Figure 26C). RNA-seq read data 
supports that heterozygous family members express a transcript in whole blood that includes 
exon 4 as IGV traces show reads mapping in exon 4. Differential gene expression analysis 
between each patient and their parents shows that MTFMT is more dysregulated among the 
homozygous patients then heterozygous patients (0002_5 p value = 0.00455, 0002_2 p value= 
0.03815, 0002_1= 0.59625, 0002_4= 0.47585). Alternative exon usage analysis corroborates the 
prediction of exon skipping with the two homozygotes suggesting differential usage of exon 4. 
Taken these two RNA-seq analyses together and applying gene abundance and exon analysis by 
multivariate approach shows that gene-based and exon-based scores correlate with severity of 
phenotype and for zygosity. Patient’s 0002_5 was most severely affected and MTFMT gene and 
exon score and the variant in exon 4 had the largest MD scores among all identified rare variants 
(Figure 27A and Table 22). Interestingly his homozygous female sibling, 0002_2 showed a similar 
exon-skipping pattern by RNA-seq reads, although MD scores indicated that variants in other 
genes and exons had greater transcriptional impact (Figure 27B). This variability may be 
indicators of false positives, or suggestive of the effect of other variants that lead to phenotypic 
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heterogeneity presented among patients with the same presumed causal variant. The 
heterozygous siblings show similarly diminished impact of heterozygous MTFMT mutation to its 
transcriptional profile implicating the role of other genetic variants in clinical symptoms of 
mitochondrial condition with MTFMT variant (Figure 27C, D).  
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Figure 26. Family sequencing of the MTFMT variant. A=pedigree of family 0002. B=Sanger 
verification of the causal variant. C= Next-generation sequencing traces of exome and RNA-seq 
experiment for exon 4 including the missense variant. Solid black lines separate the traces for 
each family member. The red rectangle highlights the position of the causal variant with respect 
to exon 4. The exon can be seen by the blue horizontal bar at the bottom of the plot. For each 
family member the image is divided by dashed, black line. The traces above the dashed lines 
indicate the exome reads and the track under the dashed lines indicates the RNA-seq reads.  
0002_4 
0002_2 
0002_5 
Father 
Mother 
0002_1 
0002_2 0002_5 0002_1 0002_4 
0002_6 0002_3   0002_1 
0002_2 
0002_3 
0002_4 
0002_5 
0002_6 
A B 
C 
A
A
A
AA
A
A
A
A
A
A
A
A
A
A
A
AA
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
AA
A
A
A
A
A
A
A
A
A
AA
  119 
 
Figure 27. Expression profile of the MTFMT gene in family 0002. This plot shows the expression 
of MTFMT across the four siblings. A=0002_5, B=0002_2, C=0002_4, D=0002_1. The first 
column shows results of Cuffdiff differential expression for protein coding genes. The horizontal 
axis shows log2 foldchange, and vertical axis is the negative log10 of the probability that the gene 
is significantly dysregulated between the conditions. The second column shows the results of 
differential exon usage analysis. The horizontal axis is the log2 normalized exon coverage for 
exons with normalized coverage >1. The vertical axis shows the log2 normalized coverage 
difference between the patients and the parents. The third column shows a scatterplot of the 
gene-based and exon-based MD scores for the each rare variant. The red dot in each plot 
indicates the MTFMT gene in relation to all other genes in the analysis. Rows A and B are shows 
the siblings with the homozygous genotype for the MTFMT variant. 
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The second family we describe was family 117 with a single affected male.  In this case, 
the genetic basis was not known prior to using the MD score and the candidate variant failed to 
be prioritized to a high enough level to warrant a genetic diagnosis. Effectively, our databases 
indicated this patient as undiagnosed at the time of analysis.  Subsequent review of the initial 
genetic analysis prior to RNA-seq indicated some in the analysis group did view this as a good 
candidate, but the large number of other variants and other patients led to a failure to detect what 
on new inspection became a plausible causal variant for the genetic basis of the child’s disease. 
 Clinical diagnosis at enrollment was suspected Pelizaeus–Merzbacher-like disease with 
no candidate genes identified. The patient presented with nystagmus, hypotonia, delayed 
development. The patient had limited speech to about 5 words, but could use signs. He was 
characterized with a leukodytrophy or significant dysregulation of the myelin sheet that protects 
nerve cells. His MRI scans showed diffuse lack of myelination of subcortical white matter, but with 
time some improvement, especially in the genu of corpus callosum; atrophy of splenium of corpus 
callosum. His urine organic acids test was negative. Genetic testing of PLP1, GJA12, CDG 
screening was negative. His CT scan was negative for calcifications. 
We sequenced the exome and mRNA of the entire family 117. Exome sequencing 
achieved an average target coverage of 93.2X across targeted regions. Bioinformatics analysis 
identified 403,156 SNP and short indel variants with 95% of them reported in dbSNP141 and with 
a Ti/Tv ratio of 2.17 (Table 16). A total of 1723 protein coding variants in 1458 genes had a 
frequency of <5% and were evaluated for their impact on expression by Mahalanobis distance. 
Post integration of MD scores with genetic variants 944 variants from 836 genes were update 
with both gene-based and exon-based distance scores. Next the gene and exon based scores 
were ranked for all 944 variants. Gene-based ranking revealed a compound heterozygous variant 
in the SNAP29 gene. The two variants rank #2 (MD Gene score= 12.29) and the two exonic 
scores ranked #107 of 944 scored variants (MD Exon score= 3.98), and #2 of 944 scored 
variants (MD Exon score= 12.81) respectively. The first variant was predicted to cause a loss of 
start codon in exon 1 (NM_004782, c.2T>C, p.Met1?) had a CADD score of 18, a phyloP of 5.05 
and a genomic coverage of 32X. The second variant is a predicted loss-of-function, frameshift 
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insertion in exon 2 (NM_004782, c.348_349insG, p.Gly118fs) had a genomic coverage of 76X in 
the patient (Figure 28). The mutations were not observed in the Exome Aggregate Consortium’s 
over sixty thousand unrelated exomes (Exome Aggregate Consortium) SNAP29 was classified as 
autosomal recessive disease causing gene in the Clinical Genomics Database. Further 
evaluation revealed that mutations in SNAP29 are known to cause Cerebral dysgenesis, 
neuropathy, ichthyosis, and palmoplantar keratoderma, CEDNIK Syndrome (MIM:609528). 
CEDNIK syndrome was first described by Sprecher et al in two consanguineous families of 
Middle Eastern descent with homozygous frameshift deletion (Sprecher and Ishida-Yamamoto 
2005). To date, patients with CEDNIK syndrome have been reported to carry homozygous 
frameshift insertions or deletions resulting in premature termination of the protein (Sprecher and 
Ishida-Yamamoto 2005; Fuchs-Telem et al. 2011). Common clinical manifestations of the 
disorder are roving eye movement, hypotonia, and malformation of the corpus callosum, 
neuropathy, microcephaly, facial dysmorphism, ichtyosis, and keratoderma. Hemizygous loss of 
function mutations in SNAP29 in patients from non-consanguineous parents diagnosed with 
22q.11.2 deletion syndrome show some overlap with symptoms of CEDNIK patients (McDonald-
McGinn et al. 2013). The patient in this study is from a non-consanguineous family, carrying 
compound heterozygous variants (Figure 28C). Exon 1 mutation, on chr22:21213400:T>C was 
inherited from the father and is a predicted loss-of-function variant (Figure 28B). Exon 2 mutation, 
of 22:21224735:T>TG was inherited from the mother and is also predicted loss-of-function variant 
with a premature stop codon 16 amino acid resides downstream from the frameshift insertion 
(Figure 28A).  
Sequenced reads from RNA-seq support the loss of maternally inherited transcript 
because the patient only express the paternal allele in exon 1 and the maternal insertion is not 
found in exon 2 track (Figure 28C). The mother also lacks reads that map to the insertion 
suggesting that the insertion is a loss-off-function variant in whole blood. This is supported by 
previous findings that frameshift insertions and deletion lead to truncated protein product 
(McDonald-McGinn et al. 2013; Fuchs-Telem et al. 2011). Multivariate outlier analysis suggested 
the importance of compound heterozygous mutation in SNAP29 as gene-based MD score was 
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ranked #2 on variant list (Figure 29). Differential gene expression does not support significant 
dysregulation of SNAP29 in whole blood when parents and affected patient are compared (p-
value = 0.59, Cuffdiff). Exon based scores also ranked on top of the MD score list, however 
sequencing traces show no evidence of exon skipping. Frameshift mutation in exon 2 suggested 
a premature stop codon, therefore a high MD scores for exonic variants can be indicative of 
alternate exon usage, and in essence mRNA degradation by non-sense mediated decay.  
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Figure 28. Exome and RNA sequencing of SNAP29 variant.  
A=Mother, B=Father, C=Patient. Blue center vertical line divides exon 1 and exon 2 tracks. 
Family member tracks are divided by black solid horizontal lines. Dashed horizontal lines 
separate the exome (upper) and RNA-seq tracks (lower). Exon 1 mutation is a 
chr22:21213400:T>C, and exon 2 mutation is a 22:21224735:T>TG their positions indicated by 
red arrows. 
 
 
 
A 
B 
C 
Exon 1 Exon 2 
  124 
 
Figure 29. Expression profile of SNAP29. This plot shows the expression of SNAP29 in patient 
0117_1. A=results of Cuffdiff differential expression for protein coding genes. The horizontal axis 
shows log2 foldchange, and vertical axis is the negative log10 of the probability that the gene is 
significantly dysregulated. B= differential exon usage analysis. The horizontal axis is the log2 
normalized exon coverage for exons with normalized coverage >1. The vertical axis shows the 
log2 normalized coverage difference between the patients and the parents. C=scatterplot of the 
gene-based and exon-based MD scores for each rare variant. The red dot in plot A indicates the 
SNAP gene, in B exon 1 and exon 2 results, and in C the two variants’ MD scores.  
 
Discussion 
In this study, we developed a framework for integrated DNA and RNA analysis of         
high-throughput sequencing data in a multivariate format for 29 patients with rare childhood 
disorders using Mahalanobis distance for outliers to prioritize candidate variants. 
The cohort represented a spectrum of rare neurological and musculoskeletal conditions 
with prolonged diagnostic odysseys and complex phenotype making clinical diagnosis 
challenging. Patients were selected for family-based DNA and RNA sequencing to utilize variant 
segregation with phenotype and used parental transcriptomes for comparative expression 
analysis. We performed outlier analysis on transcriptomic features including genes and exons 
and found patient specific variants that have large impact on transcription and correlate with 
phenotype. We obtained multiple measurements on these features including expression 
abundance and differential expression magnitude and applied these variables in a multivariate 
matrix to determine Mahalanobis distance of each patient specific feature.  
After grouping variants across the 29 families based on predicted functional impact, we 
found that gene-based distance scores were associated with variants predicted to have high 
functional impact. This suggested that variants like splice acceptor, or donor, and stop codon are 
more likely result in an expression signature that is an outlier when gene expressions from 
A B C 
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multiple patients are compared. However, the exon-based scores did not support this finding. 
This may have been caused by multiple factors including the difference how gene and exon 
expression is estimated and also the variance in the scores. Exon score distributions had longer 
tails suggesting a greater variance in the data regardless of functional class (Figure 24). Exon 
expression in DEXSeq is determined by normalizing read counts for each exon across conditions 
which may introduce artifacts for those exons that are significantly differentially used between 
conditions (Hooper 2014). In addition, our estimation of differential exon usage is calculated 
based on the total number of reads sequenced per sample, and in some families the number of 
reads sequenced across samples varies greatly from 26 million to over 200 million reads per 
sample (Appendix C). 
When variants were further categorized based on their predicted effect to mRNA 
sequence, we found that frameshift variants were associated with higher MD scores than other 
functional groups except splice site and start and stop codon variants. This suggests that the 
least frequently occurring variants tend to have the highest impact on transcription in our cohort. 
These three variant groups, frameshift, splice site and start|stop codon were the least frequent in 
our cohort of 18,834 variants (frameshift = 175/18,834, 0.9%; splice site = 70/18,834, 0.3%, 
start|stop codon= 84/18,834, 0.4%) (Table 20). It is important to note that variant annotation and 
classification into functional groups may have an impact on association analysis, and choice of 
annotation tool can be critical in interpretation (McCarthy et al. 2014). Therefore, future studies 
should evaluate those variants for association that are consistently classified between annotation 
tools. In addition prospective studies should increase the number of participants to increase 
power to detect associations between functional variants and their outlier scores. 
We showed that over 50% of protein coding genes could be investigated in this study. 
Gene expression measured in whole blood has great implication to detect functionally active 
candidate variants only if candidate gene activity can be observed in blood. We recognize that 
many diseases manifest their phenotype in certain tissues exclusively. Thus information obtained 
by RNA-seq from whole blood will only be relevant if functional observations made in blood carry 
over to primary tissue. Previous study by Yang et al. (2013) found that exome sequencing 
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achieved diagnostic success rate of 25% sequencing germline DNA in 250 clinical patients. 
Expression profile of published causal genes from Y. Yang et al. (2013) showed that 85% of 
causal genes were expressed in whole blood above the detection limit  we set in this study and 
69% were expressed above FPKM of 1 in our RNA-seq cohort. Using brain tissue data from 
Human BodyMap 2.0 Project analyzed simultaneously with our patient cohort, we found that 97% 
of previously published causal genes by Y. Yang et al., were above our detection limit and 88% 
were expressed above FPKM of 1.  
We demonstrated that in our ten patients who had previous presumed causal variants the 
variants had outlier behavior and MD scores were ranked in the  90th percentile almost 
exclusively. In concordance with previously published data, close to half of presumed causal 
variants were missense (Y. Yang et al. 2013). Interestingly, we found similar proportion of 
presumed causal variants affecting splicing at authentic splice sites, splice regions, and exonic 
splice suppressor elements. This is an enrichment of splice variants compared to previously 
reported clinical sequencing studies (Y. Yang et al. 2013).  This may be caused by our small 
sample size and our selection of extreme cases to be enrolled in our study.  
Our study design was motivated by two factors, 1) diagnosis of rare disease can be 
improved upon by integrative genomics approaches, 2) rare variants have large impact on cellular 
phenotype that can be measured in a high-throughput manner. Unambiguity for a variant’s 
causality can be improved by evidence from gene level signatures either from bioinformatics 
analyses or functional studies (MacArthur et al. 2014). Our approach obtains further evidence by 
integrated analysis of gene and exon based transcriptomic signatures in patient specific tissue. 
The correlation between predictions obtained from DNA sequencing with functional effect was 
previously demonstrated by MacArthur at al, who validated variant predictions of loss-of-function 
mutations causing nonsense-mediated decay in transcriptomic analysis of lymphoblastoid cell 
lines (MacArthur et al. 2012). Our study is another example of the power of integrated genomics 
and functional approaches have in the identification of high impact functional variants.    
 Our approach showed that focused, supervised data from genomic and functional 
sequencing can be efficiently joined and be surprisingly informative when multiple variables from 
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RNA-seq used for outlier analysis. Some of the confounding factors of integrative genomics 
approaches are the size of the data generated, the noise across data types, lack of correlation 
between sequencing technologies (Ritchie et al. 2015). To address these issues, we reduced our 
data to protein-coding variants only, which focused our attention to the most informative regions 
of the genome. In addition we used normalized, log transformed gene and exon abundances to 
reduce noise in the multivariate matrix and between samples. Normalization of gene expression 
across samples is an important issue as technical and biological variation can impact data 
interpretation. Multiple methods are suggested for normalization that are beyond the scope of this 
study, but we used geometric mean developed for DESeq and implemented in Cufflinks 2.2 to 
normalize gene expression across the 25 families (Dillies et al. 2013). We recognize that 
expression estimation is an important topic in RNA-seq and other approaches than FPKM have 
been proposed as more accurate estimators of expression abundance. However, we found that 
Cufflinks version 2.2 incorporated new elements addressing previous concerns of FPKM 
normalization, and its streamlined modular workflow was simple to implement and combined with 
differential gene expression analysis (Trapnell et al. 2013). In future studies of multivariate 
analysis accuracy of outlier estimation may be improved by use of TPM and other abundance 
estimators (B. Li and Dewey 2011).  
  Although the ultimate goal of our study was to find pathogenic variants that are 
supported by functional data, integration of genomic and functional data in our study only reports 
the magnitude of the functional impact with the MD score. Thus our findings in themselves do not 
prove causality. In current literature, most integrative approaches of genomic and functional 
variations test the integrated data for association with phenotype of interest (Schadt et al. 2005; 
Huang et al. 2007). A significant association is usually quantified by a p-value that can be set 
arbitrarily and needs adjustment for multiple testing due to the large number of variants tested. 
Multiple testing correction however in many cases is very conservative and leads to an inflation of 
false-negatives (Johnson et al. 2010). Our study is not powered to perform association analysis 
because we are studying extreme phenotypes with a single patient in most cases.  
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In two families we showed the utility of our approach by verifying the predicted affect of a 
presumed causal variant and by uncovering a new candidate variant. In family 0002, our method 
worked essentially as a validation tool. Based on previous clinical findings, MTFMT was the most 
plausible candidate variant that correlated with observed phenotype. MTFMT’s main role is to 
transfer formyl group to methionyl-trNA (met-tRNAMet). met-tRNAMet is essential in translation 
initiation and elongation in humans. The transfer of a formyl group determines the role of met-
tRNAMet in the translation process. Formylated met-tRNAMet is associated with translation initiation 
in the ribosome, while un-formylated met-tRNAMet is essential in translation elongation(Haack et 
al. 2014). Dysregulation of MTFMT due to mutations have been associated with altered 
mitochondrial oxidative phosphorylation (OXPHOS) due to inefficient translation of OXPHOS 
associated genes (Tucker et al. 2011). To date, mutations in MTFMT have been reported in two 
studies associated with OXPHOS dysfunction (Tucker et al. 2011; Haack et al. 2014). The 
c.626C>T mutation we found in our patients is the most common variant reported in 13 of 16 
OXPHOS cases (Haack et al. 2012). In all but one case this variant was found in a compound 
heterozygous form. Exome Aggregation Consortium data of 60,706 exomes of unrelated 
individuals showed that this mutation had an MAF of about 0.00036%. Interestingly the two 
patients in our study who carry the homozygous mutation show phenotypic heterogeneity. Patient 
0002_5 was diagnosed with Leigh Syndrome. One of the hallmarks of Leigh phenotype is a 
characteristic symmetrical brain lesion in basal ganglia and white matter loss, which was 
documented in the patient’s MRI. In addition, Tucker et al. (2011) previously reported two cousins 
who had MTFMT mutations and cardiac dysfunction leading to a diagnosis of Wolff-Parkinson-
White Syndrome (WPWS). Patient 0002_2 fits the WPWS description. Thus this family is an 
example of the phenotypic heterogeneity in mitochondrial disease. The integration showed the 
significant functional impact of the exon-skipping event that was more dominant in the 
homozygous patients. The full molecular characterization of the DNA-RNA predictions requires 
the addition of proteomic characterization of potential mechanism that lead to heterogeneity in the 
phenotypes of the homozygotes.   
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In family 0117, conventional exome sequencing approach and variant prioritization failed 
to identify the compound heterozygous variant in SNAP29 as a potential candidate and only after 
outlier analysis of gene-based and exon-based scores, coupled with segregation analysis, this 
gene became a candidate. This patient does not fit the clinical description of CEDNIK syndrome, 
however, some phenotypic overlap, multivariate outlier analysis, and published study suggest the 
role of SNAP29 in this patient. SNAP29 is a soluble SNARE protein that has been implicated in 
cytoplasmic trafficking and synaptic plasticity. The importance of SNAP29 in nerve myelination by 
microglia has been previously shown (Schardt et al. 2009). The overexpression of SNAP29 and 
its binding partner Rab3A increased cell surface directed myelin proteolipid trafficking(Schardt et 
al. 2009). Schardt et al. (2009) also shown that in rat brain the remyelination process correlates 
with an increased abundance of SNAP29 in sciatic nerves. Although no previous CEDNIK 
syndrome patient has been shown to have dysmyelination, or myelin related brain phenotype, the 
patient in this study shows diffuse lack of myelination. This patient also shows delayed 
development and abnormalities in the corpus callosum, which are hallmarks of patient 
phenotypes with loss-of-function SNAP29 mutations and CEDNIK syndrome. Previously 
homozygous mutations affecting both copies of SNAP29 showed loss of protein product by 
Western blot analysis (Sprecher and Ishida-Yamamoto 2005). In addition patients with 
heterozygous deletion encompassing SNAP29, and with a heterozygous mutation in the other 
copy of SNAP29 has shown atypical CEDNIK phenotype (McDonald-McGinn et al. 2013). This 
patient has a predicted loss-of-function insertion that is predicted to result in no protein product 
from the maternal copy of SNAP29. However the patient shows expression of the paternal copy 
of the gene containing a loss of initiator codon mutation. This suggests a mechanism for gene 
translation from an alternate start site for translation machinery that may result in a modified N 
terminal of the nascent protein product leading to altered protein function and phenotypic 
presentation in the child. Investigation of the mRNA sequence of SNAP29 shows that there are 
two alternate start codons downstream in exon 2, and ribosomes can initiate translation from 
alternative start codons through leaky scanning (Kozak 2005). In addition, RNA-seq data shows 
that father also expresses the mutant transcript with no phenotypic presentation. Additional 
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molecular characterization of the mutant transcript is needed to connect DNA-RNA findings to 
patient’s phenotype. 
In conclusion, we developed a novel framework of integrating genomic and functional 
information obtained from next-generation sequencing in our efforts to prioritize variants for 
diagnosis of complex, hard-to-diagnose childhood disorders. Our framework of combining 
multiple data types is mostly a proof-of-concept in our investigation of outlier expression 
signatures in patients who themselves are outliers. Our approach needs further development so 
data processing and management can be more streamlined and additional functional data can be 
incorporated into multivariate analysis. The promise of merging large datasets with complex 
information in an efficient and informative way will potentially improve clinical diagnosis, variant 
interpretation, speed up our search for clinically actionable biomarkers and empower novel study 
designs.  
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Family 0001, Patient 0001_1 
Caucasian family of 6 with single affected female.  This is a 14 year-old girl with a history of 
hypotonia, weakness and motor delay. Her parents and three sisters are unaffected. 
Birth history: Second pregnancy for this mother, complicated by mild hypertension during the third 
trimester. Fetal movement may have been reduced compared to her first child. Delivery was 
normal and without complication, with normal Apgar scores.  
By 3-4 months, she was noted to be floppy, with poor head control. Development was notably 
delayed by 8 months (she was babbling, rolling over, able to commando crawl, but not able to sit). 
Neurological evaluations and testing was started by 11 months of age. She was visually attentive 
and had no facial weakness. She couldn’t maintain sitting, she reached for objects without tremor, 
and there was a decrease in axial and appendicular tone. Tendon reflexes were present. EEG, 
blood count, metabolic profile, creatine kinase, lactate, ammonia, Acylcarnitine profile, plasma 
amino acids, very long chain fatty acids, and urine organic acids were all normal. At age 2, 
muscle biopsy did not lead to a specific diagnosis. Enzyme testing for mitochondrial disease was 
negative.  Over the years, consistent findings on exam have been small stature, hypotonia, 
weakness, and decreased endurance. Her speech was dysarthric and difficult to understand, but 
fluent. She was able to walk for short periods, especially after a rest, but she fatigued quickly. 
She had a mild gaze apraxia, poor control of her neck muscles, and hypotonia especially at the 
shoulders and neck. She had a strong grip and briskly active tendon reflexes. Her heel cords 
were tight. Nerve conduction velocities were normal; EMG studies were suggestive of a mild 
myopathic process, without myotonia, or decremental response on repetitive stimulation. 
Edrophonium challenge test did not produce any change in her EMG or improve her strength. 
Cognitive development has always been normal. She never had trouble controlling bladder or 
bowel function.  
At age 7, she had her first spinal fluid examination for neurotransmitter metabolites and pterins; 
this was reported as normal, but re-examination suggested mildly low homovanillic acid (HVA) 
and slightly elevated 3-ortho-methylDOPA. Therapeutic trial of L-DOPA/Carbidopa was not 
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effective; trial of pyridostigmine was also not effective. She and her family were enrolled in the 
research study at the Neurogenetics Center at St. Joseph’s Hospital and TGen.  
At age 8 she was seen at the Mayo Clinic, and EMG (including single fiber EMG) was not 
consistent with a congenital myasthenia syndrome. A second muscle biopsy was not diagnostic. 
Features on examination again included hypotonia, neck muscle weakness, dystonic posturing of 
the feet and episodes of ocular dystonia. A second spinal fluid examination was done and again 
showed slightly low HVA and elevated 3-ortho-methyl-DOPA. A second trial of L-
DOPA/Carbidopa was not effective. She continued to have spells of dystonia in her legs, and 
ocular dystonic attacks (oculogyric crises). She was getting weaker – by age 10, she was using a 
motorized wheelchair, was having trouble chewing, and was losing weight; the idea of placing a 
feeding gastrostomy tube was being contemplated. 
At age 10.5 years, she was started empirically on a combination of bromocriptine and selegiline, 
based on the hypothesis that she might have a variant of AADC (aromatic amino-acid 
decarboxylase) deficiency. She had a dramatic response to this treatment – within 6 months, she 
was completely out of the wheelchair, and was able to walk to school and around school all day; 
she did not have any more episodes of falling.  
At this time, she is active, can walk and run and dance; she does fatigue after a full day of school. 
Her primary problems now remain difficulty with speech, neck and lower back posture, and short 
stature. 
She is maintained now only pramipexole, a dopamine receptor agonist, and has been taken off 
selegiline. 
MRI scan: MRI at 3-4 months of age was normal. At age 2, a second MRI of the brain and spine 
was normal. A third brain MRI done at age 5 was normal. MRI of the C-spine done at age 7 was 
normal. 
Molecular tests: see case description above. 
Genetic tests: at age 7 GCH1 gene testing was normal (for GTP cyclohydrolase deficiency). At 
age 8, gene testing did not detect mutation in the TH (tyrosine hydroxylase) gene. 
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Family 0002 
Clinical Description in Chapter 4. 
Family 0004, Patient 0004_1 
Caucasian family of five with single affected male. Clinical diagnosis at time of enrollment was 
leukoencephalopathy, developmental delay, microcephaly, and intellectual disability. Patient 
could start to walk at age 6. Patient presents hypotonia, developmental delay, autism spectrum 
symptoms, feeding disorder, scoliosis, and microcephaly.  
MRI scan: Normal brain MRI, EEG, and ERG. 
Molecular tests: Enzyme tests were normal for lactate. Tests for plasma amino acids and urine 
organic acids were negative. Muscle biopsy showed normal histology with slightly increased 
cytochrome C oxidase level. 
Genetic tests: Normal Fragile X, MeCP2 sequence, FISH for Angelman, UBE3A sequence 
Family 0005, Patient 0005_1 
Caucasian family of 5 with single affected male. Clinical diagnosis at time of enrollment without a 
suspected causal gene is Pelizaeus-Merzbacher-like disease with nystagmus and motor delay. 
He presented motor delay and nystagmus at infancy with feeding disorder.  
MRI scan: Her MRI initially thought to show abnormal myelination. Follow‐up MRI showed T2 
hyperintensity in dentate nucleus of cerebellum and bilateral thalamic signal abnormalities. 
Molecular tests: Lysosomal enzyme and very long chain fatty acids test was normal. 
Genetic tests:  PLP, GJA12, GJC2 gene and duplication test was negative.  
This patient was enrolled in the study presented in Chapter 4 and his mother was enrolled in the 
RNA-seq-HUMARA study presented in Chapter 2.  
Family 0006, Patient 0006_1 
This is a Middle Eastern family of four with X affected. Here clinical diagnosis at time of 
enrollment without a suspected gene is ataxia with sensory neuropathy, similar to Friderich’s 
Ataxia. Parents are first cousins so parental consanguinity is suspected. Sister is also affected 
with NF1 disease and radius dysplasia. 
MRI scan: not available 
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Molecular tests: not available 
Genetic tests: not available 
Family 0008, Patient 0008_1 
Caucasian family of four with single affected female. Here clinical diagnosis at enrollment without  
a suspected causal gene is progressive leukoencephalopathy, spastic quadriparesis, global 
cerebral atrophy and neurodegenerative disorder. She presented feeding problems as an infant 
including colicky behavior and vomiting. She showed failure to thrive. She was diagnosed with 
cerebral palsy at age 2. At time of enrollment she presents contractures, ocular bobbing, 
myoclonic jerks but reflexes are present. Brain CT scan indicated progressive global atrophy 
without calcifications. 
MRI scan: Abnormal. MRI at 8 month with white matter volume loss. 
Molecular tests: not available 
Genetic tests: She had negative Rett syndrome genetic test, and BAC array indicated no large 
structural variant in here genome. 
This patient was enrolled in the study presented in Chapter 4. She and her mother were also 
presented in the RNA-seq-HUMARA study in Chapter 2. 
Family 0011, Patient 0011_1 
Caucasian family of three with single affected female. Her clinical diagnosis at enrollment without 
a suspected causal gene is Aicardi Syndrome. Prenatal ultrasound showed brain cysts and 
prenatal MRI was suggestive of agenesis of corpus callosum. Congenital “hydrocephalus”; s/p 
fenestration of cerebral cysts; subsequent third ventriculostomy at 3 months. Ophthalmology 
exam at 2 weeks showed choreoretinal lacunae a hallmark of Aicardi syndrome. She presented 
infantile spasms at 3 months of age and has severe developmental delay.  
MRI scan: Post‐natal MRI showed agenesis of corpus callosum.  
Molecular tests: not available 
Genetic tests: not available 
This patient and here mother were enrolled in the study presented in Chapters 1 and 2.  
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Family 0012, Patient 0012_1 
Caucasian family of four with single affected female and unaffected younger brother. Clinical 
diagnosis at enrollment was developmental delay, autism spectrum disorder. Genetic test 
identified de novo interstitial deletion 2q23.1 – q24.2. She had early feeding problems and failure 
to thrive. Presented delayed milestones. At age 3 she was diagnosed with Autism Spectrum 
Disorder. Clinical test showed normal EEG.  
MRI scan: not available 
Molecular tests: not available 
Genetic tests: not available 
This patient participated in RNA-seq and HUMARA comparison of XCI ratio study described in 
Chapter 2. 
Family 0016, Patient 0016_1 
Asian family of four with single affected male and unaffected sister. Clinical diagnosis at 
enrollment was progressive cerebellar ataxia, dystonia. Patient walked at 15 months of age, and 
started talking at 2 years of age. Patient presents dysarthria, motor delay, progressive ataxia, and 
dystonia, tight heel cords. Spine X-ray is normal. 
MRI scan: Normal.  
Molecular tests: Lysosomal enzyme test, plasma amino acid, urine organic acid, acylcarnitines, 
creatine, guanidinoacetate all negative. CPK, alphafetoprotein, B12, ceruloplasmin test are 
normal. Muscle biopsy is normal. 
Genetic tests: Fragile X, MPS7, mtDNA, Ataxia (recessive) panel, spinocerebellar ataxia gene 
panel was all negative. Array CGH found 68kb heterozygous deletion at 1p36.11. 
This patient was enrolled in the DNA-RNA study in Chapter 4 and his mother was enrolled into 
the study presented in Chapter 2. 
Family 0018, Patient 0018_1 
Clinical description can be found in Chapter 2. This family was enrolled in she study presented in 
Chapter 2, and 3. The patient and her mother also participated in the RNA-seq-HUMARA study 
described in Chapter 2.  
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Family 0019, Patient 0019_1 
Caucasian family of six with 3 affected and one unaffected children. Clinical diagnosis of female 
patient at time of enrollment was autosomal recessive non‐progressive cerebellar ataxia infantile 
dystonia. Patient was delivered by C-section for failure to progress; immediately after delivery, 
was arching her back, eyes were rolled up. Arching and rigidity with involuntary eye movements 
continued as a neonate, continued until age 4 yrs. 
Patient was delayed in motor milestones - rolling over at 1 year; sat up at 2 years; pulled to stand 
3 years; walking at 4 years with gait trainer. Clinical examination at age 1.5-2 years showed 
hypotonia, preserved reflexes, tongue thrusting. Patient has poor writing skills, dysarthric speech, 
better cognition, and possible myopathy. Patient has normal nerve conduction and EMG.  
Clinical test at 7 years of age, showed that she could walk with crutches, had broad based ataxic 
gait, able to climb, and movements are slow. She had low muscle tone, head lag, and action 
tremor; but presented no spasticity.  
MRI scan: MRI shows mild cerebellar vermis atrophy. 
Molecular tests: lactate, pyruvate, and lysosomal enzyme levels are normal.  
Genetic tests: MeCP2, Spinal muscular atrophy (SMA) test negative. 
This patient was enrolled in the study presented in Chapter 4 and her mother was enrolled into 
the study presented in Chapter 2. 
Family 0020, Patient 0020_1 
Caucasian family of 5 with single affected female and two unaffected brothers. Clinical diagnosis 
at time of enrollment was Neonatal progeroid disorder, failure to thrive. She has a feeding 
disorder, lipodystrophy, and cutis marmorata. 
MRI scan: Normal. 
Molecular tests: Plasma amino acids, urine organic acids, cholesterol, triglycerides, Acyl 
carnitine profile were all normal. 
Genetic tests: not available 
This patient was enrolled in the study presented in Chapter 2. 
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Family 0023, Patient 0023_1 
Caucasian family of three with single affected female. Clinical diagnosis at time of enrollment was 
infantile choreoathetosis, dystonia. She was born premature at 26‐27 weeks, but she had a 
relatively normal NICU course. She presented apnea at 8 months of age and development 
regressed. She had developmental delay with rigidity, fisting, head lag, and hyperreflexia. She 
has near normal cognition. 
MRI scan: She had two MRIs both of which were normal and EEG was normal as well. CT scan 
for calcification was negative. 
Molecular tests: Urine amino acids, organic acids normal. Total and free plasma carnitine tests 
were normal. Copper and ceruloplasmin were normal. CSF neurotransmitter metabolites, 
tetrahydropbiopterin/neopterin profile, methyltetrahydrofolate, amino acids were all normal. 
Lysosomal enzymes were also normal.  
Genetic tests: MeCP2 point mutation, deletion and duplication gene test was negative. 
Congenital Disorder of Glycosylation was negative. 
This patient was enrolled in the study presented in Chapter 2. 
Family 0024, Patient 0024_1 
Middle Eastern family of seven with single affected male and four unaffected siblings. Clinical 
diagnosis at enrollment was Aicardi-Goutieres Syndrome. Suspected parental consanguinity. 
MRI scan: not available 
Molecular tests: not available 
Genetic tests: not available 
This patient was enrolled in the study presented in Chapter 4 and his mother was enrolled into 
the study presented in Chapter 2. 
Family 0025, Patient 0025_1 
Caucasian family of four with single affected male and unaffected female sibling. Clinical 
diagnosis at enrollment was suspected feeding disorder, choreoathetosis. He had neonatal 
feeding difficulty and showed no reaction to pain. As a neonate he had megacystis, and urinary 
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retention. He presented hypotonia and delayed motor development with poor head control. He 
has bladder-emptying problem. 
MRI scan: Brain MRI showed cavum septum pellucidi. MRI of spine was normal. EMG normal 
Molecular tests: Urine acyl glycines, urine organic acids, and TORCH titers all normal. Normal 
serum CPK, lactate, ammonia all negative. Plasma short chain fatty acids showed mild 
ketonemia. CSF neurotransmitter metabolites, tetrahydrobiopterin, neopterin, 
methyltetrahydrofolate were all normal. Muscle biopsy showed normal ETC complex enzyme 
activity. 
Genetic tests: Array CGH was negative for copy number changes. 
Family 0029, Patient 0029_1 
Caucasian family of seven with two affected siblings (male, and female) and three unaffected 
brothers. Clinical diagnosis at time of enrollment was Aicardi-Goutieres Syndrome.  
The female patient had normal development until age 17 months, when developmental 
regression and spastic quadriparesis developed. 
MRI scan: MRI showed delayed myelination. CT scan showed no calcifications.  
Molecular tests: Lysosomal enzymes test was normal. CSF neopterin was slightly elevated. 
Genetic tests: FISH for Pelizaeus-Merzbacher disease was negative, spastic paraparesis panel 
was also negative. Gene test in SMAHD1 found a heterozygous variant in exon 12 at I448T.  
This patient was enrolled in the study presented in Chapter 2. 
Family 0033, Patient 0033_1 
Caucasian family of 5 with single affected female and unaffected brother and sister. Clinical 
diagnosis at time of enrollment was Aicardi syndrome. She started to present seizures at 10 
weeks of age. She has choreoretinal lacunae.  
MRI scan: not available 
Molecular tests: not available 
Genetic tests: not available 
This patient was enrolled in the study presented in Chapter 4, and she with her mother was 
presented in Chapter 2. 
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Family 0034, Patient 0034_1 
Hispanic family of 5 with single affected female and a brother and an unaffected sister. Clinical 
diagnosis at time of enrollment was Aicardi Syndrome.  
Prenatal ultrasound was suggestive of ventriculomegaly, and possible agenesis of corpus 
callosum. At birth diagnosed with asymmetric ventriculomegaly, agenesis of the corpus callosum, 
and L microphthalmia with optic nerve dysplasia. She smiled at 2 months of age. Myoclonic 
seizures and infantile spasms in clusters presented at 3.5 months. Seizures were controlled with 
vigabatrin and valproate. Ophthalmology exam showed microphthalmia, bilateral optic nerve 
colombomas with variable size, choreoretinal lacunae surrounding optic nerves in both eyes, 
sparing fovea. Combination of infantile spasms with agenesis of corpus callosum and optic nerve 
coloboma/choreoretinal lacunae led to diagnosis of Aicardi Syndrome. 
MRI scan: MRI showed dilation of posterior portion of ventricles, left more than right; third 
ventricle was elevated. CT scan showed features of agenesis of corpus callosum, and 
colpocephaly. EEGs showed slowing and bursts of epileptiform activity, primarily from left 
hemisphere. 
Molecular tests: not available  
Genetic tests: not available  
This patient was enrolled in the study presented in Chapter 4, and she with her mother was 
presented in Chapter 2. 
Family 0046, Patient 0046_1 
African American family of 5 with single affected female and two half-sisters unaffected. Clinical 
diagnosis at time of enrollment was Aicardi Syndrome. Pregnancy was normal, prenatal 
ultrasound suggested agenesis of corpus callosum. Prenatal MRI showed partial agenesis of 
corpus callosum MRI at birth partial agenesis of corpus callosum. Seizures were noted at 6 
weeks of age; ophtho exam at 3 months of age showed retinal lacunae and consequently was 
diagnosed with Aicardi syndrome. She has intractable epilepsy and spams like seizures.  
MRI scan: Brain MRI at 3 months of age also showed cortical dysplasia in left frontal lobe and 
partial agenesis of corpus callosum with preserved genu and anterior body of corpus callosum. 
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Molecular tests: not available 
Genetic tests: not available 
This patient was enrolled in the study presented in Chapter 2. 
Family 0047, Patient 0047_1 
Caucasian family of five with single affected female. Clinical diagnosis at time of enrollment was 
Aicardi Syndrome. She is a high functioning Aicardi patient. She walked at 2.5 years and uses a 
few single words; finger feeds, and is able to use the toilet. Normal birth. She showed infantile 
spasms and retinal lesions at 3 months of age. She has seizures. 
MRI scan: MRI showed only a small remnant of the splenium of corpus callosum; posterior fossa 
arachnoid cyst requiring shunting;  
Molecular tests: not available 
Genetic tests: not available 
This patient was enrolled in the study presented in Chapter 4, and she with her mother was 
presented in Chapter 2. 
Family 0048, Patient 0048_1 
Caucasian/Filipino family with a single affected female. Clinical diagnosis at time of enrollment 
was Aicardi Syndrome. She had infantile spasms and seizures starting at 10 weeks of age. 
She has global developmental delay, failure to thrive, trunkal hypotonia, scoliosis with trunkal 
curvature. She has the Aicardi characteristic of lacunae 
MRI scan: MRI showed absent corpus callosum, heterotopic gray matter in frontal lobes, 
intracranial cysts, ventricular dilatation ex vacuo, and abnormal sulcation patter.  
Molecular tests: not available 
Genetic tests: not available 
This patient was enrolled in the study presented in Chapter 4, and she with her mother was 
presented in Chapter 2. 
Family 0049, Patient 0049_1 
Caucasian family of five with single affected female. Clinical diagnosis at enrollment was 
Cockayne syndrome or Cerebro-Oculo-Facio-Skeletal Syndrome (COFS type 2). 
  159 
She presents severe delay in motor and cognitive development. 
She has intrauterine growth retardation, congenital cataracts, congenital nystagmus, specifically 
continuous rotary and horizontal nystagmus. She has microcephaly, developmental delay, 
hypotonia and dystonia. She has Dysphagia, failure to thrive, and scoliosis. 
MRI scan: MRI shows diffuse T2 hyperintensities in the entire white matter indicative of 
leukoencephalopathy. 
Molecular tests: Plasma amino acids, urine organic acids, extended newborn screen all 
negative. 
Lysosomal enzymes, very long chain fatty acids are negative. 
Genetic tests: Congenital disease of glycosylation screen is negative. 3. FISH for Prader-Willi 
syndrome was negative. 
This patient was enrolled in the study presented in Chapter 4, and she with her mother were 
presented in Chapter 2. 
Family 0059, Patient 0059_1 
Caucasian family with single affected female. Her clinical diagnosis at enrollment without a 
suspected causal gene is Aicardi Syndrome. She presented seizures at 3 months of age. She 
has a cyst in the brain and is getting smaller. She has preserved, almost entire corpus callosum 
She has lacunae in one eye and her vision is improving. 
MRI scan: not available 
Molecular tests: not available 
Genetic tests: not available 
This patient was enrolled in the study presented in Chapter 4, and she with her mother was 
presented in Chapter 2. 
Family 0091, Patient 0091_1 
Caucasian family of four with single affected male and unaffected female sibling. Clinical 
diagnosis at enrollment was Schizophrenia, which was diagnosed at age 7. He has language 
difficulties and did not start to speak until age 4. He is also presenting symptoms characteristics 
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of Bipolar disorder. He has a propensity for violence and aggression. He has commanding 
auditory and visual hallucinations. EEG was normal. 
Maternal grandmother and her sister as well as maternal great-grandmother diagnosed with 
schizophrenia. Asperger's runs on father's side of family.  
MRI scan: not available 
Molecular tests: not available 
Genetic tests: not available 
This patient was enrolled in the study presented in Chapter 4, and his mother and grandmother 
presented in Chapter 2. 
Family 0103, Patient 0103_1 and 0103_2 
Clinical description can be found in Chapter 2. These patients were enrolled in the study 
presented in Chapter 2 and 3. 
Family 0117, Patient 0117 
Caucasian family of three with single affected male. Clinical diagnosis at enrollment was 
Pelizaeus–Merzbacher-like disease (leukodystrophy) with no candidate genes identified. 
Patient present nystagmus, hypotonia, delayed development. Limited speech, can only say about 
5 words, but can use signs. 
MRI shows diffuse lack of myelination of subcortical white matter, but with time some 
improvement, especially in the genu of corpus callosum; atrophy of splenium of corpus callosum 
Molecular tests: urine organic acids negative.  
Genetic tests: PLP1, GJA12, CDG screening is negative. 
CT scan negative for calcifications. 
This patient was enrolled in the study presented in Chapter 4, and his mother presented in 
Chapter 2. 
Family 0118, Patient 0018_1 
Caucasian family with single affected female. Clinical diagnosis at enrollment was Aicardi 
Syndrome. 
MRI scan: not available 
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Molecular tests: not available 
Genetic tests: not available 
This patient and her mother were enrolled in the study presented in Chapter 2. 
Family 0139, Patient 0139_1 
Caucasian family of three with single affected male. Clinical diagnosis at enrollment was not 
available. Self reported case. Patient has very small stature and features. Total situs inversus, 
wide set eyes, small low set ears, developmental and speech delays. 
Patient is unable to feed through mouth, VP shunt and g-tube and fundo. 
He has chronic lung disease, immotile cilia syndrome. 
MRI scan: not available 
Molecular tests: not available 
Genetic tests: not available 
This patient was enrolled in the study presented in Chapter 4, and his mother presented in 
Chapter 2. 
Family 0140, Patient 0140_1 
This is an adopted, Caucasian female patient. Clinical diagnosis at enrollment was suspected 
Dystonia. 
She has abnormal gait and posture that fluctuates without weakness; left leg with choreoathetotic 
or dystonic posture; can walk one minute and then is crawling the next because she cannot walk 
She was evaluated for Torticollis. She has low set ears flat nasal bridge. 
MRI scan: MRI showed stable very small 2.2mm syrinx at T12-L1. EMG was normal. 
Molecular tests: CSF was normal. 
Genetic tests: DYT1 mutation was negative. Array cGH for insertions deletions was negative. 
This patient was enrolled in the study presented in Chapter 2. 
Family 0152, Patient 0152_1 
Caucasian family with single affected male. Clinical diagnosis at enrollment was Leigh’s 
Syndrome with suspected causal mechanism. This is and old Amish family. Patient can crawl, sit 
without support, pull to stand, and cruise. He can say about 12 words and continues to expand. 
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MRI scan: MRI showed bilateral signal intensity alterations involving the anterior aspect of the 
subthalamic regions and the substantia nigra and pars reticularis of the mid brain. CT scan was 
normal 
Molecular tests: spectroscopy suggested subtle alterations in the lactate profile. 
Genetic tests: indicated that the child had a regions of homozygosity (ROH) across 9 
chromosomes. Genes associated with Mitochondrial complex I deficiency/Leigh’s syndrome are 
in these regions (NDUFAF2 and NDUFS3). 
This patient was enrolled in the study presented in Chapter 4 and her mother was enrolled in a 
study presented in Chapter 2. 
Family 0157, Patient 0157_1 
Caucasian family with affected female. Clinical diagnosis at enrollment was not available. Patient 
presents delayed development, Autism Spectrum behavior. She has normal skin. 
MRI scan: MRI showed non-specific symmetric prominence of T2-weighted high signal within the 
eperitrigonal white matter; delay in myelination or dysmyelination. 
Molecular tests: patient has borderline low levels of vitamin A level and undetectable DHEAS 
level. 
Genetic tests: FISH study showed a de novo 1.6 Mb deletion at Xp 22.31 (6,456,510-8,077,333)  
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       PCT target bases covered 
ID 
Study 
Chapter 
Gend
er 
Capture 
assay 
HQ 
Read 
(M) 
PCT 
Aligned 
reads 
Mean 
target 
coverage 
2X 10X 20X 30 X 
0001_1 Ch2|Ch4 F TruSeq 39.22 0.840 19.4 0.8
15 
0.59
0 
0.39
8 
0.23
1 
0001_3 Ch2|Ch4 M TruSeq 127.96 0.842 54.8 0.9
62 
0.91
1 
0.82
7 
0.71
1 
0001_2 Ch2|Ch4 F TruSeq 128.11 0.835 55.4 0.9
62 
0.91
2 
0.82
8 
0.71
1 
0001_4 Ch2 F TruSeq 129.77 0.895 91.8 0.9
74 
0.95
1 
0.92
4 
0.88
8 
0001_5 Ch4 F TruSeq 131.60 0.899 94.9 0.9
73 
0.95
0 
0.92
4 
0.89
2 
0001_6 Ch4 F TruSeq 147.49 0.899 104.5 0.9
74 
0.95
3 
0.93
1 
0.90
3 
0002_5 Ch2|Ch4 M TruSeq 193.32 0.872 124.4 0.9
76 
0.95
2 
0.92
6 
0.89
4 
0002_2 Ch2|Ch4 F TruSeq 135.25 0.877 87.3 0.9
71 
0.93
8 
0.89
5 
0.84
3 
0002_4 Ch2|Ch4 M TruSeq 125.71 0.872 80.3 0.9
71 
0.93
4 
0.88
4 
0.82
1 
0002_1 Ch2|Ch4 F TruSeq 138.80 0.884 85.2 0.9
66 
0.92
6 
0.87
9 
0.82
3 
0002_6 Ch4 M TruSeq 114.83 0.884 71.6 0.9
63 
0.91
4 
0.84
9 
0.77
0 
0002_3 Ch2|Ch4 F TruSeq 123.56 0.884 77.4 0.9
64 
0.92
0 
0.86
3 
0.79
6 
0008_1 Ch2|Ch4 F TruSeq 152.24 0.880 100.0 0.9
72 
0.94
2 
0.90
7 
0.86
4 
0008_3 Ch4 M TruSeq 141.72 0.876 94.8 0.9
73 
0.94
2 
0.90
3 
0.85
4 
0008_2 Ch2|Ch4 F TruSeq 129.64 0.883 84.9 0.9
71 
0.93
5 
0.89
0 
0.83
5 
0008_4 Ch4 F TruSeq 133.06 0.883 87.7 0.9
72 
0.93
9 
0.89
6 
0.84
4 
0012_3 Ch4 M TruSeq 92.04 0.878 54.3 0.9
60 
0.90
9 
0.82
8 
0.72
0 
0012_2 Ch4 F TruSeq 94.63 0.876 56.5 0.9
58 
0.91
0 
0.83
5 
0.73
4 
0016_1 Ch4 M TruSeq 62.47 0.868 30.0 0.9
43 
0.82
1 
0.64
0 
0.45
2 
0016_3 Ch4 M TruSeq 142.58 0.895 101.2 0.9
75 
0.95
4 
0.93
0 
0.89
9 
0016_2 Ch2|Ch4 F TruSeq 146.68 0.898 101.6 0.9
75 
0.95
2 
0.92
9 
0.90
0 
0018_1 Ch2|Ch3|Ch
4 
F TruSeq 138.58 0.883 81.7 0.9
61 
0.91
7 
0.86
2 
0.79
6 
0018_3 Ch2|Ch3|Ch
4 
M TruSeq 133.88 0.878 77.8 0.9
62 
0.91
3 
0.85
0 
0.77
6 
0018_2 Ch2|Ch3|Ch
4 
F TruSeq 145.77 0.882 84.9 0.9
62 
0.92
1 
0.87
0 
0.80
7 
0019_1 Ch2|Ch4 F TruSeq 90.53 0.873 54.6 0.9
58 
0.91
0 
0.83
5 
0.72
9 
0019_4 Ch4 F TruSeq 105.24 0.875 68.2 2.2
24 
0.96
2 
0.92
0 
0.85
8 
0019_5 Ch4 M TruSeq 134.00 0.872 83.4 0.9
69 
0.93
9 
0.90
0 
0.84
6 
0019_3 Ch4 M TruSeq 91.15 0.873 53.3 0.9
61 
0.91
2 
0.83
2 
0.71
9 
0019_2 Ch2|Ch4 F TruSeq 94.00 0.871 57.4 0.9
58 
0.91
1 
0.84
0 
0.74
0 
0019_6 Ch4 F TruSeq 99.06 0.871 60.3 0.9
60 
0.91
6 
0.85
1 
0.76
0 
0023_1 Ch2|Ch3 F TruSeq 134.41 0.884 74.9 0.9
64 
0.91
5 
0.85
4 
0.78
2 
0023_3 Ch2|Ch3 F TruSeq 164.02 0.882 94.1 0.9
67 
0.92
7 
0.87
9 
0.82
6 
0023_2 Ch2|Ch3 M TruSeq 152.04 0.876 82.4 0.9
65 
0.91
8 
0.86
4 
0.80
2 
0024_1 Ch2|Ch4 F TruSeq 120.12 0.881 76.7 0.9
65 
0.91
9 
0.86
0 
0.79
0 
0024_3 Ch4 M TruSeq 112.98 0.885 71.5 0.9
62 
0.91
0 
0.84
0 
0.75
6 
0024_2 Ch2|Ch4 F TruSeq 130.30 0.891 83.2 0.9
65 
0.92
1 
0.86
7 
0.80
2 
0025_1 Ch2|Ch4 F TruSeq 156.44 0.882 92.3 0.9
65 
0.92
6 
0.87
8 
0.82
3 
0025_3 Ch4 M TruSeq 147.60 0.878 86.8 0.9
65 
0.92
1 
0.86
7 
0.80
5 
0025_2 Ch2|Ch4 F TruSeq 176.04 0.869 102.9 0.9
66 
0.93
0 
0.89
0 
0.84
5 
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0025_4 Ch4 F Agilent 129.23 0.978 140.1 0.9
92 
0.98
6 
0.97
3 
0.95
2 
0025_5 Ch4 M Agilent 134.79 0.970 147.1 0.9
93 
0.98
6 
0.97
4 
0.95
4 
0029_1 Ch2 M TruSeq 115.83 0.888 82.9 0.9
55 
0.91
7 
0.87
5 
0.82
3 
0029_2 Ch2 F TruSeq 104.61 0.881 73.1 0.9
49 
0.89
2 
0.82
3 
0.75
0 
0029_3 Ch2 M TruSeq 144.50 0.871 102.5 0.9
61 
0.93
2 
0.90
3 
0.86
9 
0029_4 Ch2 F TruSeq 124.04 0.877 87.9 0.9
60 
0.92
9 
0.89
6 
0.85
3 
0029_5 Ch2 M TruSeq 151.58 0.840 43.5 0.9
62 
0.89
5 
0.76
4 
0.60
5 
0033_1 Ch2|Ch4 F TruSeq 139.65 0.900 100.2 0.9
73 
0.95
1 
0.92
8 
0.89
9 
0033_3 Ch2|Ch4 M TruSeq 145.74 0.894 102.5 0.9
76 
0.95
3 
0.93
0 
0.89
9 
0033_2 Ch2|Ch4 F TruSeq 146.21 0.896 104.4 0.9
74 
0.95
3 
0.93
1 
0.90
3 
0034_1 Ch2|Ch3|Ch
4 
F TruSeq 134.89 0.899 97.8 0.9
72 
0.95
0 
0.92
6 
0.89
6 
0034_3 Ch2|Ch3|Ch
4 
M TruSeq 121.93 0.897 87.7 0.9
72 
0.94
7 
0.92
0 
0.88
3 
0034_2 Ch2|Ch3|Ch
4 
F TruSeq 121.11 0.900 81.4 0.9
73 
0.94
6 
0.91
4 
0.87
0 
0046_1 Ch2 F TruSeq 112.76 0.874 45.4 0.9
54 
0.88
0 
0.76
6 
0.63
8 
0046_2 Ch2 F TruSeq 149.68 0.886 79.5 0.9
64 
0.92
1 
0.86
7 
0.79
9 
0047_1 Ch2|Ch4 F TruSeq 96.12 0.875 58.4 0.9
61 
0.91
5 
0.84
5 
0.74
8 
0047_3 Ch2|Ch4 M TruSeq 98.56 0.872 61.4 0.9
63 
0.91
9 
0.85
5 
0.76
6 
0047_2 Ch2|Ch4 F TruSeq 119.45 0.877 73.4 0.9
64 
0.92
8 
0.88
0 
0.81
5 
0048_1 Ch2|Ch4 F TruSeq 96.96 0.871 58.3 0.9
60 
0.91
5 
0.84
7 
0.75
4 
0048_3 Ch2|Ch4 M TruSeq 93.18 0.873 55.6 0.9
61 
0.91
3 
0.83
9 
0.73
7 
0048_2 Ch2|Ch4 F TruSeq 106.08 0.869 61.3 0.9
61 
0.91
8 
0.85
6 
0.77
1 
0049_1 Ch2|Ch4 F TruSeq 140.43 0.877 71.4 0.9
65 
0.91
6 
0.85
2 
0.77
8 
0049_3 Ch4 M TruSeq 134.70 0.873 68.5 0.9
66 
0.91
4 
0.84
6 
0.76
9 
0049_2 Ch2|Ch4 F TruSeq 125.76 0.878 65.0 0.9
63 
0.90
7 
0.83
4 
0.74
9 
0059_1 Ch2|Ch4 F TruSeq 143.69 0.879 103.1 0.9
68 
0.94
4 
0.92
0 
0.89
0 
0059_3 Ch4 M TruSeq 152.70 0.875 110.6 0.9
70 
0.94
6 
0.92
4 
0.89
6 
0059_2 Ch2|Ch4 F TruSeq 151.30 0.883 108.4 0.9
69 
0.94
5 
0.92
3 
0.89
6 
0091_1 Ch2|Ch4 F TruSeq 125.67 0.876 78.5 0.9
69 
0.93
8 
0.89
1 
0.81
5 
0091_3 Ch4 M TruSeq 170.94 0.872 105.6 0.9
72 
0.94
8 
0.92
0 
0.87
8 
0091_5 Ch2 F Agilent 143.42 0.978 154.3 0.9
92 
0.98
6 
0.97
4 
0.95
7 
0091_2 Ch2|Ch4 F TruSeq 130.68 0.882 83.3 0.9
69 
0.94
0 
0.90
1 
0.83
7 
0091_4 Ch2 F TruSeq 158.58 0.873 100.2 0.9
71 
0.94
8 
0.91
6 
0.86
4 
0103_1 Ch2|Ch4 M TruSeq 144.44 0.891 109.0 0.9
66 
0.93
9 
0.91
0 
0.87
6 
0103_2 Ch2|Ch4 F TruSeq 123.90 0.891 91.5 0.9
64 
0.93
3 
0.89
8 
0.85
6 
0103_4 Ch2|Ch4 M TruSeq 143.73 0.889 106.4 0.9
66 
0.93
8 
0.90
9 
0.87
4 
0103_3 Ch2|Ch4 F TruSeq 140.95 0.885 104.7 0.9
65 
0.93
6 
0.90
6 
0.87
2 
0117_1 Ch4 M TruSeq 135.07 0.884 95.9 0.9
67 
0.94
1 
0.91
0 
0.86
8 
0117_3 Ch4 M TruSeq 126.66 0.882 92.0 0.9
66 
0.93
8 
0.90
5 
0.86
2 
0117_2 Ch2|Ch4 F TruSeq 127.41 0.889 91.7 0.9
66 
0.93
8 
0.90
7 
0.86
5 
0118_1 Ch2 F TruSeq 135.49 0.887 98.1 0.9
66 
0.93
8 
0.90
8 
0.87
1 
0118_2 Ch2 F TruSeq 142.71 0.886 102.9 0.9
66 
0.94
1 
0.91
3 
0.87
8 
0139_1 Ch4 M TruSeq 161.13 0.873 86.0 0.9
72 
0.94
4 
0.91
2 
0.87
3 
0139_3 Ch4 M TruSeq 103.65 0.880 58.1 0.9
65 
0.92
8 
0.87
4 
0.79
4 
0139_2 Ch2|Ch4 F TruSeq 136.84 0.877 73.3 0.9
68 
0.93
7 
0.90
1 
0.85
4 
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0140_1 Ch2 F TruSeq 151.16 0.877 80.8 0.9
69 
0.94
1 
0.90
9 
0.86
8 
0152_1 Ch2|Ch4 M Agilent 84.85 0.961 96.8 0.9
93 
0.98
1 
0.95
4 
0.90
6 
0152_3 Ch4 M Agilent 66.82 0.978 78.0 0.9
92 
0.97
7 
0.93
4 
0.86
2 
0152_2 Ch2|Ch4 F Agilent 93.09 0.979 109.0 0.9
92 
0.98
3 
0.96
3 
0.92
9 
0157_1 Ch2|Ch4 F Agilent 110.45 0.978 122.7 0.9
92 
0.98
5 
0.96
9 
0.94
3 
0157_3 Ch4 M Agilent 112.65 0.980 128.9 0.9
93 
0.98
7 
0.97
2 
0.94
7 
0157_2 Ch2|Ch4 F Agilent 103.48 0.979 116.9 0.9
92 
0.98
5 
0.96
8 
0.93
8  
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Id Study Chapter 
Gend
er RIN 
Read
s HQ 
(M) 
HQ 
Base
s 
(Gb) 
Bases 
mapp
ed 
(Gb) 
Median 
CV 
Covera
ge 
5’-3’ 
Bias 
0001_4 Ch2 F 7.8 154.7 13.1 12.8 0.39 0.65 
0001_1 Ch2|Ch4 F 8.6 119.6 10.0 9.6 0.37 0.74 
0001_3 Ch2|Ch4 M 8.6 117.1 9.3 9.0 0.37 0.76 
0001_2 Ch2|Ch4 F 8.8 82.2 7.4 7.1 0.38 0.77 
0002_1 Ch2|Ch4 F 8.9 108.3 9.1 8.8 0.38 0.75 
0002_2 Ch2|Ch4 F 8.9 152.5 12.7 12.3 0.38 0.75 
0002_3 Ch2|Ch4 F 8.9 125.9 10.4 10.0 0.37 0.72 
0002_4 Ch2|Ch4 M 9.4 106.0 9.2 8.9 0.37 0.74 
0002_5 Ch2|Ch4 M 8.9 127.3 9.6 9.3 0.38 0.81 
0002_6 Ch4 M 9 162.1 12.8 12.4 0.38 0.71 
0004_1 Ch4 M 8.2 128.3 8.2 8.0 0.41 0.67 
0004_2 Ch2|Ch4 F 7.5 230.6 14.5 14.0 0.42 0.67 
0004_3 Ch4 M 4.8 184.8 10.3 10.0 0.50 0.48 
0005_1 Ch4 M 9.1 117.4 9.8 9.5 0.38 0.74 
0005_3 Ch4 M 8.9 164.8 12.0 11.6 0.39 0.71 
0005_2 Ch4 F 8.4 126.3 11.4 11.0 0.39 0.73 
0006_1 Ch4 F 8.5 111.5 9.4 9.1 0.37 0.73 
0006_3 Ch4 M 8.7 98.8 7.1 6.9 0.38 0.76 
0006_2 Ch4 F 8.8 109.9 8.9 8.6 0.37 0.77 
0008_1 Ch2|Ch4 F 7.7 116.7 9.0 8.7 0.45 0.57 
0008_3 Ch4 M 7.3 134.2 10.5 10.2 0.42 0.63 
0008_2 Ch2|Ch4 F 7.3 166.3 11.0 10.6 0.44 0.58 
0011_2 Ch2|Ch3|Ch4 F 7.1 128.3 8.7 8.4 0.41 0.69 
0011_3 Ch3|Ch4 M 5.9 142.1 9.4 9.2 0.45 0.59 
0011_1 Ch2|Ch3|Ch4 F 8.8 126.9 9.1 9.1 0.38 0.74 
0012_1 Ch2 F 8.1 135.5 10.1 9.7 0.39 0.72 
0014_2 Ch2|Ch3|Ch4 F 8.6 132.9 10.5 10.1 0.41 0.71 
0014_3 Ch3|Ch4 M 8.3 141.2 10.0 9.6 0.40 0.69 
0014_1 Ch2|Ch3|Ch4 F 8.5 135.5 9.6 9.5 0.39 0.70 
0016_1 Ch4 M 8.5 120.6 10.0 9.7 0.38 0.71 
0016_2 Ch2|Ch4 F 8.5 159.1 11.1 10.7 0.38 0.70 
0016_3 Ch4 M 8.7 102.4 8.5 8.2 0.40 0.74 
0018_1 Ch2|Ch3|Ch4 F 7.5 109.3 8.6 8.4 0.39 0.74 
0018_2 Ch2|Ch3|Ch4 F 8 174.8 14.5 14.1 0.39 0.74 
0018_3 Ch2|Ch3|Ch4 M 7.9 111.0 9.5 9.2 0.39 0.73 
0019_1 Ch2|Ch4 F 8.1 177.1 12.6 12.2 0.40 0.72 
0019_2 Ch2|Ch4 F 8.8 152.2 9.9 9.5 0.38 0.73 
0019_3 Ch4 M 7.3 124.3 9.8 9.5 0.43 0.65 
0020_1 Ch2 F 8.5 122.0 10.1 9.7 0.37 0.72 
0023_1 Ch2|Ch3 F 8 151.7 10.3 10.0 0.39 0.72 
0024_1 Ch2|Ch4 F 7.4 145.9 11.3 10.9 0.39 0.74 
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0024_2 Ch2|Ch4 F 7.5 116.6 9.5 9.2 0.39 0.73 
0024_3 Ch4 M 8.1 104.8 8.9 8.7 0.40 0.69 
0025_1 Ch2|Ch4 F 5.1 239.8 14.7 14.0 0.49 0.56 
0025_3 Ch4 M 5.9 130.8 8.5 8.2 0.46 0.65 
0025_2 Ch2|Ch4 F 6 198.7 12.0 11.4 0.46 0.62 
0033_2 Ch2|Ch4 F 6.3 123.1 10.0 9.9 0.43 0.72 
0033_3 Ch2|Ch4 M 6.4 111.2 8.0 7.9 0.45 0.71 
0033_1 Ch2|Ch4 F 8.7 110.1 9.3 9.2 0.43 0.68 
0034_2 Ch2|Ch3|Ch4 F 8.6 104.9 9.0 8.9 0.41 0.80 
0034_3 Ch2|Ch3|Ch4 M 7.9 118.8 9.4 9.3 0.42 0.77 
0034_1 Ch2|Ch3|Ch4 F 9 112.7 9.9 9.9 0.39 0.75 
0046_1 Ch2  8.8 102.3 8.7 8.3 0.37 0.76 
0047_3 Ch2|Ch4 M 7.8 108.8 9.0 8.9 0.38 0.75 
0047_2 Ch2|Ch4 F 7.5 114.2 9.2 9.1 0.41 0.65 
0047_1 Ch2|Ch4 F 8.8 120.5 8.7 8.6 0.38 0.76 
0048_2 Ch2|Ch4 F 6 109.8 8.2 8.1 0.45 0.60 
0048_3 Ch2|Ch4 M 6.1 165.9 10.4 10.3 0.44 0.62 
0048_1 Ch2|Ch4 F 6.9 135.0 8.8 8.7 0.43 0.65 
0049_1 Ch2|Ch4 F 7.5 149.7 10.8 10.7 0.40 0.70 
0049_2 Ch2|Ch4 F 7 124.3 9.2 9.1 0.41 0.61 
0049_3 Ch4 M 6.8 110.8 9.0 8.9 0.42 0.69 
0059_1 Ch2|Ch4 F 7.3 64.6 5.3 5.3 0.43 0.63 
0059_2 Ch2|Ch4 F 7 148.4 10.8 10.7 0.41 0.69 
0059_3 Ch4 M 7.7 137.0 9.8 9.7 0.40 0.71 
0091_1 Ch2|Ch4 F 7.3 116.5 9.4 9.4 0.43 0.66 
0091_2 Ch2|Ch4 F 7.1 127.8 9.5 9.4 0.43 0.63 
0091_3 Ch4 M 7.6 132.0 9.1 9.0 0.43 0.66 
0091_4 Ch2 F 7.1 102.0 7.9 7.8 0.43 0.72 
0091_5 Ch2 F 5.6 194.5 12.1 11.4 0.39 0.68 
0103_4 Ch2|Ch4 M 6.9 128.1 10.9 7.4 0.46 0.63 
0103_3 Ch2|Ch4 F 8.9 45.2 3.6 2.4 0.47 0.67 
0103_2 Ch2|Ch4 F 7 76.0 9.6 6.4 0.45 0.66 
0103_1 Ch2|Ch4 M 6.9 26.8 2.8 2.0 0.44 0.70 
0103_2 Ch2|Ch4 F 7 76.0 9.6 6.4 0.45 0.66 
0103_3 Ch2|Ch4 F 8.9 45.2 3.6 2.4 0.47 0.67 
0103_4 Ch2|Ch4 M 6.9 128.1 10.9 7.4 0.46 0.63 
0117_1 Ch4 M 8.4 101.8 7.3 7.2 0.40 0.69 
0117_2 Ch2|Ch4 F 7.9 185.3 13.2 13.1 0.41 0.69 
0117_3 Ch4 M 8.5 88.1 6.4 6.4 0.44 0.64 
0118_1 Ch2 F 8.1 137.8 9.8 9.7 0.39 0.76 
0118_2 Ch2 F 8.4 116.6 9.3 9.2 0.39 0.71 
0139_1 Ch4 M 9.6 202.8 13.4 12.8 0.37 0.79 
0139_3 Ch4 M 5.2 200.6 13.5 13.0 0.40 0.71 
0139_2 Ch2|Ch4 F 7.7 183.7 11.9 11.4 0.53 0.59 
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0140_1 Ch2 F 7.7 235.2 16.1 15.5 0.39 0.79 
0152_1 Ch4 M 8.1 163.3 13.4 12.2 0.40 0.73 
0152_3 Ch4 M 7.4 231.4 15.5 14.7 0.40 0.73 
0152_2 Ch2|Ch4 F 8.1 99.6 8.3 7.4 0.40 0.71 
0157_1 Ch2|Ch4 F 7.1 199.1 13.1 12.2 0.43 0.69 
0157_3 Ch4 M 7 181.2 12.1 11.3 0.41 0.71 
0157_2 Ch2|Ch4 F 7.6 174.6 12.4 11.5 0.42 0.71 
 
  
 
 
 
 
 
 
 
 
 
